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ABSTRACT
Anticancer drug resistance occurs as a result of altered response to cytotoxic insult, via 
inhibition or inactivation of apoptosis (programmed cell death type I, PCDI), which plays 
a major role in tumour development and progression. An alternative form of cell death -  
non-apoptotic, or autophagic cell deatli (PCD II) has recently emerged as a factor 
contributing to the cytotoxic response of cancer cells. We studied in vitro cell death in a 
drug resistant model MCF-7 human breast cancer cells with acquired resistance (c, 10- 20 
fold) to paclitaxel, termed MCF-7TaxR. It has been reported tliat the absence of caspase-3 
in parental MCF-7 cells (due to chromosome deletion) may explain why they recruit 
apoptotic and autophagic cell death following cytotoxic insult. We investigated the 
induction of apoptosis response to staurosporine and Z-VAD (pan-caspase inhibitor) using 
the Annexin V-FITC/PI assay and studied die effect of anti-Fas on MCF-7TaxR. Results 
demonstrated the lack of apoptosis induction in paclitaxel resistant breast cancer cells. The 
oligo GEAiTay® human apoptosis microarray and qPCR analysis confirmed the absence 
of caspase-7 and caspase~9 genes and many other apoptosis genes in MCF-7TaxR cells 
and their presence in MCF-7 cells. Western blot analysis also confirmed these results. 
Therefore, we investigated the presence of autophagic cell death in our MCF-7TaxR 
model. Flow cytometry using Acridine Orange assay, Beclin 1 and LC-3 protein detection, 
confocal microscopy and detection of Akt/mTOR expression. Data showed evidence of 
autophagic cell death in MCF-7TaxR cells in tlie absence of an apoptotic response. 
Collectively, these findings indicate the lack of involvement of caspase mediated cell 
death in a paclitaxel dmg-resistant cancer cell line MCF-7TaxR, and presence of 
autophagic cell death as an alternative cell death mechanism.
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CHAPTER 1
GENERAL INTRODUCTION
CHAPTER 1
1 General Introduction
1.1 Overview of breast cancer
Breast cancer is the most commonly diagnosed invasive malignancy in women and is the 
second leading cause of cancer-related deaths among females in most industrialized 
countries (Nkondjock and Ghadiiian 2004). Globally, the number of women diagnosed with 
breast cancer is more than one million per year (Cancer-ResearchUK 2008). The incidence 
of breast cancer is highest in Northern and Western Europe and North America, with
decreased rates in Northern, Eastem and Central African countries and Asia (Cancer-
ResearchUK 2008). In the UK, breast cancer is the most common cancer in women 
(Cancer-Reseai’chUK 2008), and 45,500 women were diagnosed with the disease in 2005. 
This number means that approximately 125 women per day were diagnosed with breast 
cancer (Cancer-ReseaichUK 2008). The incidence of breast cancer has increased by 50% 
over tlie last 25 years (Cancer-ResearchUK 2008). Moreover in the past 10 years alone in 
the UK, the incidence of breast cancer has increased by 13% (Cancer-ResearchUK 2008).
The occurrence of breast cancer is associated with different risk factors, including age, 
family histoiy or genetic background, age at first pregnancy, age at menarche and at 
menopause, use of oral contraceptives, and lifestyle (McPherson et al. 2000). The incidence 
and mortality rate for breast cancer increases with age, doubling approximately every 10 
years (McPherson et al. 2000; Lester 2005). Neaidy 70% of breast cancer cases occur in 
women over the age of 50 (McPherson et al. 2000; Lester 2005). Women who start 
menstmating eaily (under 11 years of age), or who have a late menopause, have an 
increased risk for developing breast cancer (McPherson et al. 2000; Lester 2005). Women
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who have stopped taking oral contraceptive agents after using them for a period of 10 years 
have a small increase in risk of developing breast cancer (McPherson et al. 2000; Lester 
2005). Moreover, women who began taking birth control pills before the age of 20 appear 
to have a higher relative risk than women who began taking oral contraceptives when they 
were older (McPherson et al. 2000). Lifestyle is another factor considered in the occurrence 
of breast cancer (McPherson et al. 2000). Obesity may increase the risk of breast cancer by 
two-fold in postmenopausal women (McPherson et al. 2000). Alcohol intake is also 
correlated with the incidence of breast cancer (McPherson et al. 2000).
Family history or genetic background is a vital factor that affects the incidence of breast 
cancer, but less than 10% of breast cancer cases in Western countries are due to genetic 
background (McPherson et al. 2000; Schulz 2007). A certain number of women have a 
higher risk of breast cancer due to the presence of mutations in two breast cancer genes, 
BRCAl and BRCA2 (McPherson et al. 2000). These two genes are located on chromosome 
17 and 13, respectively (McPherson et al. 2000). Both genes are very large and mutations 
can occur at any position, therefore molecular screening should be used to detect the 
mutation in individuals if a family history of breast cancer exists (McPherson et al. 2000). 
BRCAl and BRCA2 encode prxrteins involved in DNA repair and the control of genomic 
integrity (Schulz 2007). These genes act as classical tumour suppressors hr many familial 
cases of breast cancer, with one defective copy inherited and the second copy inactivated by 
mutation, recombination, deletion, or epigenetic inactivation in the tumour (Schulz 2007). 
Thus, blocking the inactivation of these genes reduces susceptibility to breast and ovarian 
cancers (Nkondjock and Ghadirian 2004). Mutation of BRCAl and/or BRCA2 is commonly 
found in women who have a family history of breast and ovarian cancer occurrence (Ford et
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al. 1994). In addition, the PTEN g&iiG, located on chromosome 10, encodes a phospholipid 
and protein phosphatase which controls the activity of the PI3K pathway (Schulz 2007). 
Mutation in this gene increases the risk of breast cancer (Schulz 2007).
1.2 Classification of breast cancer
Different systems have been developed to classify breast cancers (Schulz 2007). Breast 
cancer tumours are adenocarcinomas and are classified as in situ carcinomas or invasive 
carcinomas (Robbins 1999). Carcinoma in situ is a cancer that has not spread beyond tire 
area where it began. In situ breast cancers are confined within the ducts (ductal carcinoma 
in situ or DCIS) or the lobules (lobular carcinoma in situ, or LCIS) of the mammary tissues 
and have not invaded die basement membrane (Lester 2005). The majority of these tumours 
will not spread to lymph nodes and blood vessels and will not progress to become invasive 
tumours (Lester 2005). Cai'cinoma in situ is an early stage of cancer and nearly all of these 
cancers can be cured (Lester 2005). However, LCIS can be a marker for an increased risk of 
developing an invasive cancer in the future (Robbins 1999; Lester 2005). Invasive breast 
carcinoma is a condition whereby a cancer that started in tlie ducts or lobules of the breast 
infiltrates the basement membranes, duct or gland walls and, subsequently, invades the 
lymph nodes and sunounding fatty tissue of the breast to become metastatic (Lester 2005).
Moleculai' markers have been used in the classification of breast cancers (Schulz 2007). 
Several proteins, the estrogen receptor (ER), progesterone receptor (PR), and HER2, have 
been used as breast cancer markers (Lester 2005). Testing for expression of these proteins is 
cai'ried out by immuno-histochemistry techniques (Lester 2005). The profile of the tumour 
influences the prognosis and helps the oncologist to select the appropriate treatment for the
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patient (Lester 2005). The ER is expressed in about 80% of all breast cancers and ER 
positive cancers generally have a better prognosis and often respond to hormonal therapy 
(Lester 2005). However, ER negative breast cancers are more aggressive and unresponsive 
to anti-estrogens (Lester 2005).
Grading and staging of the breast cancer tumour uses a histopathology classification 
scheme and is very important in deteimining tlie prognosis of the disease (Schulz 2007). 
When the tumour is well differentiated and similar to normal tissue, it is low grade (Lester 
2005; Schulz 2007). If the tumour is poorly differentiated and consists of disorganized cells 
with abnormal neuropathy, it is described as high grade (Lester 2005; Schulz 2007). 
Moderately differentiated tumours (intermediate grade) exhibit a morphology intennediate 
to that of the low and high grade tumours (Lester 2005). The staging method of classifying 
tumours is an important determinant in prognosis of the disease (Schulz 2007). The 
accepted clinical method for breast cancer staging is the tumour lymph node métastasés 
(TNM) classification system (Mammen 2005). Staging involves the size of the tumour 
itself, whether it has reached lymph nodes, and whether there are any distant métastasés to 
organs other tlian the breast and lymph nodes (Mammen 2005). Table 1-1 shows a summary 
of breast cancer staging.
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Breast cancer staging Description of staging
Stage 0 Ductal carcinoma in situ (DCIS)
Stage I (T) not involving (N)
Stage HA (T) size 2-5 cm, but (N) negative
Stage IIB (T) size >5 cm and (N) negative, or (T) size 2-5 cm 
and (N) positive (size <4cm in axillary nodes)
Stage IIIA (T) size 5 cm and, (N) positive, or (T) 2-5 cm with 
involvement of 4 or more axillary nodes.
Stage IIIB Tumour has spread to chest wall or skin and may 
have spread to more than 10 axillary lymph nodes
Stage m e Tumour has spread to more than 10 lymph nodes, 
one or more supraclavicular or infraclavicular nodes, 
or spread to internal mammary nodes.
Stage IV Distant metastasis.
Table 1-1: A summary of breast cancer staging.
(T) tumour, (N) axillaiy lymph node. Adapted from (Mammen 2005).
1.3 Breast cancer treatments
When a breast tumour is localized treatment with surgery is the primaiy treatment protocol. 
Other treatments, depending on tumour staging, include potential adjuvant chemotherapy 
and hormonal therapy (chemotherapy after operation) or neoadjuvant chemotherapy 
(chemotherapy prior to operation) and/or radiotlierapy and, less frequently, immunotherapy.
1.3.1 Surgery and radiotherapy
Surgery and radiotherapy are the local regional treatments for breast cancer. Surgery in 
breast cancer is the main and essential standard freatment (Kauftnann et al. 2007). The 
surgical management of the breast is performed according to the breast surgeiy guidelines 
prior to systemic chemotlierapy (Kauftnann et a l 2007). Different factors are considered 
and can affect successful breast cancer surgery (Chen et a l 2005). These factors include 
tumour size, lymphatic invasion and nodal status, or spread of microcalcifications (Chen et
6
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a l 2005). Lumpectomy, wide excision and quadrantectomy aie breast surgery conservation 
techniques (Spear et a l 1998). Another option in surgical tieatment is subcutaneous 
mastectomy, which is the removal of breast tissues only, sparing die nipple-areola complex, 
skin and nodes (Mammen 2005). Simple mastectomy, which is tlie total removal of the 
breast (removing the breast tissue, nipple-areola complex and skin) without axillaiy node 
dissection, is one type of surgical management for metastatic breast cancer (Mammen 
2005). Another type of mastectomy is the modified radical mastectomy (MRM) which 
involves the removal of breast tissue, pectoralis fascia, nipple-areola complex, skin and 
axillary lymph nodes (Mammen 2005).
In the majority of breast cancer patients who aie recommended for mastectomy, 
radiotherapy after mastectomy is recommended in most cases (Kauftnann et a l 2007). A 
recommendation for radiotlierapy in patients who have had a mastectomy with a stage I 
cancer, or a stage II cancer with one to three positive lymph nodes, is not always made due 
to the reduced 5 yeai* risk of local/regional recurrence in these patients (Gai'g et a l 2004; 
Kauftnann et a l 2007). However, radiotherapy for patients with stage III and stage IV 
breast cancer is strongly recommended (Huang et a l 2004).
1.3.2 Adjuvant and neo-adjuvant chemotherapies
In women with metastatic breast cancer, systemic treatments are still the most effective and 
reduce the risk of breast cancer deatli (Mamounas 2005). In tlie last 20 years, adjuvant 
therapy has been shown to have a major impact on treatment of breast cancer patients with 
eitlier node-negative or node-positive disease (Mamounas 2005). Adjuvant chemotherapy 
was first established in the 1950s in response to concerns that the cancer might be spread
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during surgery, resulting in a recurrence of the disease, as well as the possibility of death 
from most metastatic cancers (Robin Stuart-Hairis 2005). Chemotherapy used in the pre­
operative period, referred to as neo-adjuvant chemotherapy, in the first clinical trials in 
1958, but no differences were found in survival or recuirence of the disease (Fisher et al. 
1968). A subsequent study of post-operative administration of Thiotepa or placebo for 2 
days in a randomized tiial with 826 premenopausal women, with a least four positive nodes, 
showed a considerably better incidence of survival at 5 years (Fisher et al. 1968). 
Therefore, post-operative adjuvant chemotherapy was highly recommended and most 
chemotlierapeutic administration has been post-operative since the 1960s (Fisher et al. 
1975). Also, a number of clinical trials were carried out using a post-operative combination 
of chemotherapy agents instead of single agent (Fisher et al. 1975; Fisher et al. 1986; 
Group 1992). The results showed that a combination of chemotherapies was more effective 
than long-term administration of a single chemotlierapeutic agent (Fisher et al. 1975; Fisher 
et al. 1986; Group 1992).
The adjuvant chemotherapy cunently used to treat metastatic breast cancer consists of the 
alkylating agent cyclophosphamide and two anti-metabolites, methotrexate and 5- 
fluorouracil, (the CMF mgimen). The CMF regimen is correlated with a reduction in breast 
cancer deaths (Mamounas 2005; Ring and Ellis 2005). The use of CMF was established in 
the 1970s and used for 20 years (Bonadonna et al. 1976). More recently, anthracycline 
containing regimens (doxombicin or epirubicin) have reduced the levels of death and 
recurrence, more effectively than the CMF regimen (Robin Stuait-Hanis 2005). The Early 
Breast Cancer Trialists Collaborative Group (EBCTCG) evaluated the effect of the 
anthracycline regimens in 1998 in over 11 randomized studies comparing anthracycline
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containing regimens to CMF (Robin Stuart-Harris 2005). The results showed that 
anthracycline containing regimens produced a reduction in recunence (12%) and death 
(11%) equivalent to CMF (Robin Stuait-Harris 2005). Anthracycline treatment has not 
always show a benefit similai' to CMF in clinical trials (Robin Stuart-Harris 2005). The 
advantages of anthracycline containing regimens compared to the CMF chemotherapy is 
that they are suitable for newly diagnosed breast cancer patients, premenopausal patients 
aged <50, and postmenopausal patients aged 50-69, both ER negative and positive, and 
both node negative and node positive patients (Gluck 2005). There have been some adverse 
side effects resulting from treatment with high doses of anthracycline (Bemard-Marty et a l 
2003). In one of the trials, an analysis was cairied out that noted tlie subsequent 
development of secondary malignancies in 16 patients administered a high dose of 
epirubicin compared witli epirubicin at an intermediate dose (Bemard-Marty et a l 2003).
Taxanes aie one of the most effective groups of anticancer drags that have been 
incorporated into the treatment of metastatic breast cancer (Robin Stuart-Hanis 2005). Most 
clinical trials of taxane containing regimens, in early breast cancer cases, showed greater 
efficacy than CMF (Robin Stuart-Harris 2005). The first strategy involved sequential 
therapy with anthracycline tieatment followed by taxane tieatment (Mamounas 2005). In 
four clinical trials (CALGB 9344, NSAB B-28, [PACS] 01, and NSBP B-27), paclitaxel or 
docetaxel were used in patients who had previously undergone anthracycline therapy 
(Mamounas 2005). These trials demonstrated a significant increase in disease- free survival 
of approximately 14-17% (Mamounas 2005). In two of the clinical trials (CALGB 9344 and 
PACS 01), results indicated a significant reduction in breast cancer mortality of 
approximately 18-23%, in patients treated wititi regimens including taxanes (Mamounas
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2005). An alternative approach is to integrate taxanes into adjuvant regimens and to 
administer them simultaneously with the anthracycline (Ring and Ellis 2005). This 
approach enables a shorter treatment duration, but potentially increases toxicity (Ring and 
Ellis 2005). The BCIRG 001 clinical study randomized 1491 women who had lymph node 
positive breast cancer and completed regional treatment (Ring and Ellis 2005). These 
patients were treated with docetaxel, doxombicin and cyclophosphamide (TAG), or with 5- 
fluomracil, doxorubicin and cyclophosphamide (FAC) (Ring and Ellis 2005). There were 
significant improvements with TAG compared with FAG in disease-free survival (5 years 
DFS 75% vs. 68%) (Ring and Ellis 2005). However, the benefits of TAG over FAG were 
only significant in those with 1-2 positive lymph nodes (Ring and Ellis 2005). In several 
cases of breast cancer, the use of taxanes rather tlian anthracyclines is preferable in order to 
prevent anthracycline-induced caidiotoxicity (Mamounas 2005). Taxanes have also been 
used with trastuzumab (Herceptin®) containing regimens, which is one of the most recent 
advances in adjuvant tieatments for breast cancer (Mamounas 2005).
However, the benefit of specific treatments to individual breast cancer patients and the 
adverse effects they experience varies considerably (Steams et al. 2004). The efficacy and 
safety of anticancer therapies may depend on the tumour, the treatment and the individual 
patient’s characteristics (Steams et al. 2004). The antitumor activity or safety of specific 
agents may depend not only on dmg dose and timing but also on functional targets, dmg 
metabolizing enzymes and tiansporters (Steams et al. 2004).
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1.3.3 Molecular mechanism of chemotherapies and hormonal 
therapy
There are different types of anticancer drugs, some of which target cell cycle components, 
cause cell cycle inhibition, and induce apoptosis (Steams et al. 2004; McGrogan et al. 
2008). In general, chemotherapy can be described as DNA damaging and includes a number 
of different classes of agent (Steams et al. 2004). Chemotherapies include alkylating agents 
and antimetabolites, as well as microtubule and topoisomerase inhibitors (Figure 1-1). 
Hormonal targeted therapy includes agents such as tamoxifen and aromatase inhibitors and 
a new, targeted therapy for breast cancer, which includes human epidermal growth factor 
HER2 targeted therapy such as lapatinib and trastuzumab.
Microtubule Inhibitors
(paclitaxel, docetaxel). 
Epothilones 
Vinca alkaloids 
(vinblastine, vincristine, 
vinorelbine). j
Alkylating agents
(Cyclophosphamide). 
Anthracyclines 
(Doxorubicin, epirubicin). 
Platinum agents 
(cisplatin, carboplatin) 
HER2 (trastuzumab)
I N T E R P H A S E #
Antimetabolites
(5-fluorouracil, 
methotrexate, 
capecitabine, gemcitabine). 
Topoisomerase Inhibitors
(etoposide).
Figure 1-1: The action of anticancer drugs on different targets in the cell cycle
(McGrogan et al. 2008).
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1.3.3.1 Cyclophosphamide
Cyclophosphamide is one of the main alkylating anticancer drugs and has been used in the 
treatment of breast cancer for more than 30 years (Steams et aL 2004). Cyclophosphamide 
(Cytoxan™) is used in combination with other anticancer dmgs, such as adjuvant 
chemotherapy CMF reghnens, or can be given as single high dose chemotherapy (Steams et 
a l 2004). Cyclophosphamide is a mechlorethamine-analog, which possesses potent, broad- 
spectmm anticancer activity (Steams et a l 2004). Cyclophosphamide bio-activation 
involves enzymatic conversion by cytochrome P450 enzymes in the liver to yield 
phosphoramide mustard (Figure 1-2) following the initial reaction producing 4-hydroxy- 
cyclophosphamide (Mahoney et a l 2003). Phosphoramide mustard is the active compound 
generated from cyclophosphamide; it is the active DNA alkylating metabolite which causes 
both single-stranded DNA breaks and DNA cross-links in dividing cells QVlalroney et a l  
2003).
The toxicities commonly associated with cyclophosphamide treatment of breast cancer are 
rnyelosuppression such as leukopenia, nausea and vomiting, in addition to skin and nail 
hyper-pigmentation and gonadal dysftmction (Stearns et a l 2004). Administration of a high 
dose of cyclophosphamide may cause haemorihagic cystitis or secondary leukaemia 
(Steams et a l 2004).
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Cyclophosphamide
Liver P450 enzymatic 
activation
4-hydroxy-cyclophosphamlde
Aldophosphamlde
PHOSPHORAMIDE
MUSTARD ACROLEIN
I
Active DNA alkylating 
metabolite
Toxic compound causes 
hemorrhagic cystitis
Figure 1-2: Summary of metabolic activation of cyclophosphamide in treating human 
cancer (Steams et al. 2004).
1.3.3.2 Methotrexate
Methotrexate is one of the oldest antimetabolite dmgs used as part of the CMF regimen for 
breast cancer treatment (Mamounas 2005; Ring and Ellis 2005). Many women tolerate 
methotrexate comparatively well (Steams et al. 2004). However, a small number of women 
experience severe myelosuppression (Steams el al. 2004). Methotrexate is a stmctural 
analogue of folic acid and antagonizes the functions of this vitamin by suppressing 
dihydrofolate reductase (DHFR) activity (Mycek et al. 2000). Folic acid is important in 
nucleic acid and protein synthesis (Mycek et al. 2000). Methotrexate regimens act through 
regulating the level of intracellular folate by inhibiting DHFR, resulting in a depletion in 
nucleic acid synthesis and, ultimately, inducing cell death (Figure 1-3) (Mycek et al. 2000; 
Steams et al. 2004).
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Folate from diet 
or intestinal flora Methotrexate
Folate
Di hydrofolate 
reductaset ©
FH,
Inhibition of ■  
folate metabolism
Folate
metabolism
Methotrexate
Decrease in synthesis 
^  of thymidylic acid, 
methionine, serine and 
the purines (adenine 
and guanine)
Nucleic acid and ^ ^ C e l l  Depletion DNA
protein synthesis and RNA synthesis
Target Cell
Figure 1-3; The action of methotrexate on folic acid metaholism inducing cell death in 
cancer cells (Mycek et a i 2000; Steams et al. 2004).
1.3.3.3 Fluoropyrimidines
Fluoropyrimidines such as 5-fluorouracil and capecitabine are antimetabolite dmgs which 
have been used in the treatment of a number of solid tumours, such as breast cancers, for 
many years (Mycek et al. 2000; Steams et al. 2004). The 5-fluorouracil analogue is a uracil 
ring that contains a stable fluorine atom (Mycek et al. 2000). In normal cells, deoxyuridylic 
acid is converted to thymidylic acid, which is an important precursor for DNA synthesis 
(Mycek et al. 2000). This process is inhibited by the presence of the fluorine containing 
ring of 5-fluorouracil, thus depriving the cell of one of the essential precursors for DNA 
synthesis (Figure 1-4) (Mycek et al. 2000). The dmg targets thymidylate synthase (TS), 
which affects cell proliferation and cell death (Liu et al. 2002). However, 5-fluorouracil is
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severely toxic to the gastrointestinal tract, and also causes myelosuppression, nausea and 
vomiting, diarrhoea, hand foot syndrome, and, less frequently, ocular and neurological 
toxicity (Steams et al. 2004).
5-fluorouracil [^u ]
Deoxyuridylic acid 
mono-phosphate
FH,
Thymidylate 
synthetase
Thym
mono
5-fluorouracil
Ns,N,0-Methylene FH^
6cid 
\}haXe
DNAlOOOOOOt
Deo etion in DNApi i u
Ceil Death
Target Cell
Figure 1-4: Mechanism of cytotoxic activity of the anti-metaholite 5-fluorouracil (5- 
FU) in cancer cells (Mycek et al. 2000).
Capecitabine is a 5-fluorouracil pro-drug. This drug requires three enzymatic reactions to be 
activated (Hamilton and Hortobagyi 2005). Capecitabine as an oral formulation (Xeloda) is 
widely used in breast cancer treatment (Steams et al. 2004). The action of capecitabine is 
the same as 5-fluorouracil, but involves bio-activation via thymidine phosphorylase 
(Steams et al. 2004; Hamilton and Hortobagyi 2005). Since thymidine phosphorylase is 
over-expressed in cancer cells, a degree of target selectivity is achieved (Hamilton and 
Hortobagyi 2005). The pro-drug prevents exposure of normal cells and tissue to the active 
drug and, thus, offers protection from its toxic effects (Hamilton and Hortobagyi 2005).
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Unlike other chemotherapies, which are taken intravenously, capecitabine is talcen orally for 
14 days in a 3-week cycle (Blum et al. 1999). Capecitabine was registered in die US after it 
showed a 20% improvement in response rate in treating breast cancer patients (Blum et al.
1999).
1.3.3.4 Taxanes
Paclitaxel is an effective chemotherapy tliat has recently been introduced for breast cancer 
treatments (Braakhuis et al. 1994). Paclitaxel is a micro tubule binding agent and a natural 
product extracted from the Pacific Yew Taxus brevifolia (Schiff and Horwitz 1980). The 
US Food and Drug administration (FDA) were the first to approve paclitaxel for treating 
ovarian cancer in 1992 and subsequently for the treatment of metastatic breast cancer in 
1994 (Gueritte 2001). The hydrophobic nature of paclitaxel requires that it be administered 
in a solution containing alcohol and Cremophor® EL (polyoxyethylated castor oil) to 
enhance delivery (Roy and Perez 2006). Therefore, treatment with dexamethasone prior to 
paclitaxel treatment is recommended due to hypersensitivity reactions resulting from 
Cremophor® EL (Roy and Perez 2006). Docetaxel is a second generation taxane, taken 
intravenously as standard three week management therapy (Martin et al. 2005). However, 
docetaxel is poorly tolerated clinically and less effective fit an paclitaxel and is, therefore, 
used less frequently (Mackey et al. 2004; Mar tin et al. 2005)
Intracellularly, paclitaxel binds to p-tubulin (the taxane target site) in the mitotic spindle 
(Figure 1-5) (McGrogan et al. 2008). Paclitaxel stabilizes microtubules, inhibiting their 
depolymerisation and interfering with kinetochore attachment (Kelling et al. 2003; Jordan 
and Wilson 2004; Kienitz et al. 2005). The net result is to change the tension through the
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kinetochores in mitosis, thus disrupting mitosis and inducing apoptosis (Kelling et al. 2003; 
Jordan and Wilson 2004; Kienitz et al. 2005). Docetaxel shares the same target as 
paclitaxel, the micro tubule (Gligorov and Lotz 2004). Docetaxel interrupts centromere 
organization and, thus, affects the late stage of S phase, as well as the G2 and M phases, 
resulting in defects in mitosis and increased numbers of cells in the G2 and M phase, 
ultimately resulting in cell death (Gligorov and Lotz 2004). The major toxic effects 
associated with paclitaxel treatment are myelosuppression (leukopenia, myalgias), 
arthralgias, sensory peripheral neuropathy, and sporadic anaphylactoid reactions (reversed 
by corticosteroid treatment) (Steams et al. 2004). Accumulation of docetaxel results in 
toxic effects including edema and nail changes (Steams et al. 2004).
I N T P R P H A R F
MITOSIS
MIcrotubule
—Centrosome
/
PACLITAXEL
Prophase
Metaphase
Anaphase
Telophasel
Cytokinesis
Kinetochore
INTERPHA Sa
inhibition of m icrotubuie 
dynam ics by paclitaxel cau sin g  
stabilising  of the  m icrotubuies
Cell Death
RESULTING IN INCOMPLETE MITOSIS
Figure 1-5: Paclitaxel mediated disruption of the mitotic phase of the cell cycle 
resulting cancer cell death (McGrogan et al. 2008).
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Microtubuie targeting drugs can be divided into two groups. The first group are 
microtubule-stabilizing agents such as die taxanes, epothilones A and B, discodermolide 
and eleutherobin (Jordan and Wilson 2004). These agents stabilize microtubuies by binding 
to tubulin polymers and preventing microtubuie disassembly (Zhou and Giannakakou
2005). The second group are the microtubuie destabilizing agents including the vinca 
alkaloids (Vincristine, Vinblastine) (Jordan and Wilson 2004). These agents destabilize 
microtubuies, thus preventing microtubuie attachment to kinetochores and suppressing 
microtubuie assembly (Orr et al. 2003).
1.3.3.5 Anthracyclines
Doxorubicin and epirubicin are antibiotic anthracyclines, and are tlie most common 
chemotherapeutic agents used in breast cancer treatment (Steams et al. 2004). 
Anthracyclines are generally used in combination with other anticancer regimens such as 
cyclophosphamide and 5-fluorouracil, for treatment of eaiiy breast cancers (Hamilton and 
Hortobagyi 2005). Doxombicin is isolated from Streptomyces peucetius var. caesius 
(Arcamone et al. 1969). Doxombicin intercalates between DNA base pairs, producing a 
local uncoiling in the DNA through non-specific binding to the sugar phosphate backbone 
(Painter 1978; Mycek et al. 2000). The intercalation results in blocking of DNA and RNA 
synthesis (Painter 1978; Mycek et al. 2000). In addition, this intercalation can interfere with 
topoisomerase II, which mediates breakage repair of DNA strands (Figure 1-6) (Mycek et 
al. 2000). Doxorubicin is also a topoisomerase type II inhibitor (Mycek et al. 2000). 
Anthracycline cytotoxicity is largely dependent on the inhibition of topoisomerase II 
activity, resulting in DNA strand breaks (Mycek etal. 2000).
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Figure 1-6: Anthracycline (doxorubicin) mechanism of action in cancer cells (Mycek et 
al. 2000).
Epirubicin is the 4’ isomer of doxombicin but its action in the liver is slightly different from 
that of doxombicin (Mycek et al. 2000). The common toxic effects of both anthracyclines 
are cardiotoxicity which is caused by the production of free radicals in the cell (Steams et 
al. 2004), although epimbicin is much less cardiotoxic (Steams et al. 2004). Other side 
effects include myelosuppression, commonly leukopenia, acute and delayed nausea and 
vomiting, mucositis, and skin and nail hyperpigmentation (Steams etal. 2004).
1.3.3.6 Tamoxifen
Breast cancers are routinely screened for the presence of estrogen or progesterone receptors 
(Steams et al. 2004). Approximately 50% of women presenting primary breast cancers 
express the estrogen receptor (ER+) and or progesterone receptor (PR+), and, thus, should 
be offered some form of hormonal adjuvant therapy, for example, tamoxifen (Steams et al. 
2004). Tamoxifen is one of the most commonly used hormonal therapies (Mocanu and 
Harrison 2004). It is a non-steroidal synthetic anti-estrogen and belongs to the selective
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estrogen receptor modulator (SERM) family (Mocanu and Harrison 2004). In 1973, 
tamoxifen was approved in the UK; in 1977, it was approved by the FDA in the US for use 
in adjuvant chemotherapy for postmenopausal, node positive breast cancer patients (Cole et 
al. 1971). Most hormones mediate their effects by activating cell surface receptors (Mocanu 
and Harrison 2004). However, steroid hormones have a different mechanism of action, first 
entering the cell and then binding to a nuclear receptor (Mocanu and Harrison 2004). 
Therefore, tamoxifen enters the cell, and binds to the nuclear receptor (ER) in place of 
estrogen (Nilsson et al. 2001). The hormone receptor complex normally binds to a specific 
site on the DNA, the estrogen response element (ERE) (Figure 1-7) (Mocanu and Harrison 
2004). These sites regulate the genomic responses in all cells expressing ER (Mocanu and 
Harrison 2004).
Tamoxifen
CytoplasmEstrogen
Nucleus
Figure 1-7: The action of tamoxifen on the estrogen receptor in the nucleus (Mocanu 
and Harrison 2004).
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Tamoxifen reduces the risk of breast cancer recunence in hormone receptor positive 
women by 50% and reduces the incidence of newly diagnosed breast cancer in women at 
high risk for the disease (Group. 1998; Steams et a l  2004). Tamoxifen is well tolerated and 
has short term side effects that are similar to menopause (Group. 1998; Steams et a l 2004).
The adverse effects of tamoxifen are hot flushes, skin rash, vaginal bleeding and discharge 
(Clemons et a l 2002). Another side effect of long term tamoxifen treatment is an increased 
risk of endometrial cancer (Clemons et a l 2002).
1.3.3.7 Aromatase Inhibitors
Aiomatase inhibitor therapy is recommended for postmenopausal women (Stearns et a l
2004). The most commonly used aromatase inhibitor is anastrozole (Carpenter 2008), 
which inhibits the synthesis of estrogen from androgens by inhibiting aromatase (Steams et 
a l 2004; Carpenter 2008). There are a number of reports tliat describe aromatase inhibitors 
used as first line treatment in metastatic breast cancer over tamoxifen, with data showing a 
lower recurrence of breast cancer (Smith and Dowsett 2003). However, the advantage of 
aiomatase inhibitors is not apparent for all hormone receptor positive breast cancers 
(Steams et a l 2004). Aromatase inhibitor side effects include a decrease in circulating 
estrogens, resulting in bone demineralisation, arthralgias/myalgias and hot flushes (Steams 
et a l 2004).
1.3.3.8 Trastuzumab
Human epidermal growth factor receptor 2 (HER2/neu) targeted therapy has recently
become one of the most vital components of breast cancer treatment (Gluck 2005).
Trastuzumab (Herceptin®) was approved in 1998 as a first line adjuvant therapy treatment j
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to be administered with paclitaxel for metastatic breast cancer patients positive for HER2 
expression (Slamon et al. 2001). Trastuzumab is a human monoclonal antibody that binds 
specifically to the human epidermal growth factor receptor on the cell surface (HER2) 
(Gluck 2005). hr normal cells, the function of HER2 is to promote growth and division 
(Gluck 2005; Hamilton and Hortobagyi 2005). hr cancer cells, HER2 is over-expressed and 
promotes abnormal cell proliferation and tumour growth (Gluck 2005). Trastuzumab binds 
to the HER2 receptor and suppresses its fiinction (Gluck 2005; Hamilton and Hortobagyi
2005). Trastuzumab reduces HER2 signalling through the phosphatidylinositol 3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) cascades (Nahta and Esteva 2006). 
The decrease in downstream signalling through these pathways induces expression of the 
cyclin-dependent kinase inhibitor p27’^‘^ \ which promotes cell cycle arrest and apoptosis 
(Sliwkowski et al. 1999; Baselga et al. 2001).
A number of randomized clinical trials have been carried out investigating the effect of 
trastuzumab as an adjuvant therapy, in high risk, early stage breast cancer patients with 
HER2-positive disease (Slamon et al. 2001; Gluck 2005). In these trials, trastuzumab 
exhibited significant tJierapeutic advantages over anthracyclines and taxanes (Gluck 2005). 
The NSABP B31 and the North Central Cancer Treatment Group (NCCTG) N9831 clinical 
trials for breast cancer treatment used adjuvant chemotherapy consisting of an anthracycline 
as a first line treatment, followed by paclitaxel plus trastuzumab (Gluck 2005). The results 
of these clinical trials were significant (Gluck 2005). The addition of trastuzumab to 
antliracycline-based chemotherapy either with or without taxanes produced a reduction in 
the recurrence risk by approximately 50% in patients over-expressing the HER2 receptor 
compared with patients who were HER2-negative (Gluck 2005; Romond et al. 2005).
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1.4 Development of chemoresistance In breast cancer
There are several problems that may develop in breast cancer patients undergoing 
chemotherapy leading to a failure of treatment associated with chemoresistance (Gottesman
2002). These problems involve poor patient tolerance to anticancer drugs, as well as genetic 
or epigenetic changes within the cancer cell (Gottesman 2002). Factors that can give rise to 
clinical problems are the rapid metabolism or excretion of the anticancer drug and limited 
absorption of the dmg (common in elderly patients), which reduces the dmg dose below 
optimal levels (Pluen et a l 2001). There may also be a failure to distribute the drug to the 
tumour location, particularly in bulky tumours (Pluen et a l 2001). Genetic alterations in the 
cancer cells involve changes in the molecular components of the cell, such as a lack of cell 
surface receptors, or efflux transport of the dmg, or mutation of the drug target (Gottesman 
2002; Gottesman et al. 2002; Leonard et al. 2003; Leonessa and Clarke 2003). There may 
also be defects in apoptotic mechanisms, alterations in protein expression related to tumour 
resistance, and changes in DNA repair mechanisms after dmg-induced damage (Figure 1-8) 
(Gottesman 2002; Gottesman et al. 2002; Leonard et al. 2003; Leonessa and Clarke 2003).
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Figure 1-8: Different molecular mechanisms of drug resistance in cancer cells
(Gottesman 2002; Coley 2008).
Metastatic breast cancers treated with first line chemotherapies containing anthracyclines or 
taxanes have a response rate ranging from 30-70% (Bonneterre et al. 2004; Ishikawa et al. 
2004; Vassilomanolakis et al. 2005). When metastatic breast cancers continue to progress 
following first line therapies, response rates are reduced to 20-30% with use of either a 
single agent or a combination of anticancer drugs (Porkka et al. 1994). More than 90% of 
the failures in breast cancer treatment are due to the development of chemoresistance 
(Longley and Johnston 2005). The development of drug resistance following the exposure 
of cancer cells to chemotherapeutic agents is referred to as “acquired resistance” (Coley 
2008). When tumour cells become resistant to one chemotherapeutic agent, they may also 
show resistance to other stmcturally different anticancer drugs, a process referred to as 
cross-resistance or multi-drug resistance (MDR) (Coley 2008). However, in some cancers,
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dmg resistance occurs without prior exposure to chemotherapy; this type of multi-drug 
resistance is referred to as intrinsic resistance (Gottesman 2002; Coley 2008).
The standard chemotherapy treatment for breast cancer, a regimen containing 
anthracyclines plus taxanes, showed improved activity in patients who had developed 
resistance to treatment with a single anthracycline (Fisher et a l 1990; Lister-Sharp et a l
2000). In their meta-analysis, Jones and Smith suggested that the inclusion of taxanes and 
anthracycline in treatment is more effective tlian antliracyclines alone or in combination 
with cyclophosphamide, 5-flurouracil and or vincristine [Gensia Sicor Pharmaceuticals Inc., 
Ii-vine, CA] (Jones and Smitli 2006; Coley 2008). In cases in which a metastatic breast 
tumour is resistant to both anthracycline and taxanes, another option is Hie administration of 
capecitabine (Coley 2008). If chemoresistance to taxanes, anthracyclines and capecitabine 
develops in tumour cells, metastatic breast cancer patients cunently have no other treatment 
options (Coley 2008).
The most common cellular mechanism connected to tumour resistance is the drug efflux 
mechanism mediated by members of the ATP binding cassette (ABC) transporter family, 
particularly P-glycoprotein (P-gp), multidrug resistant protein 1 (MRPl), and the breast 
cancer resistance protein (BCRP) (Table 1-2) (Coley 2008). The function of these 
transporters in normal cells is clearance and protection against unnecessary extiacellular 
and intracellulai’ xenobiotics and toxins (Borst et a l 2000; Leonard et a l 2003). Hence, in 
the case of cancer cells, ABC transporters effectively block tlie accumulation of adequate 
amounts of cytotoxic agents (e.g. doxombicin) intiacellulaiiy (Coley 2008). Low levels of 
the dmgs are insufficient to provoke cell death (Coley 2008). These ABC transporters are
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found primarily in the plasma membrane of the cell (Coley 2008).
P-gp (MDRl) MRPl BCRP
Anthracyclines Antlnracyclines Anthracyclines
Topoisomerase inhibitors Topoisomerase inhibitors Topoisomerase inhibitors
Vinca alkaloids Vinca alkaloids
Alkaloids
Taxanes
Antitumor antibiotics Antitumor antibiotics
Antimetabolites Antimetabolites Antimetabolites
Table 1-2: Drug efflux transporters and associated anticancer drug substrates.
(P-gp) P-glycoprotein, (MRP) multidrug resistance protein, (BCRP) breast cancer 
resistance protein. Adapted from (Coley 2008).
The classical drug efflux transporter is P-glycoprotein (molecular weight 170 kDa) (Chen et
a l 1986; Sauna et a l 2001; Gottesman et a l 2002), which is encoded by the MDRl gene,
and consists of 12 transmembrane domains attached to an ATPase domain (Chen et a l
1986). ATP is hydrolysed when a substrate binds to the transporter, resulting in a
conformational change that releases the substrate into the extracellular compartment (Sauna
et a l 2001; Gottesman et a l 2002). P-gp is expressed in approximately 40-50% of primaiy
breast cancers (Leonessa and Clarke 2003). Small tumours, < 2 cm in size, showed lower P-
gp expression than tumours > 2 cm in size (Leonessa and Clarke 2003). Over-expression of
P-gp in breast cancer patients increases following chemotherapy, from 40-50% to 60-70%
(Chevillard et a l 1997; Vaigas-Roig et a l  1999). The otlier type of drug efflux proteins
involved in anticancer dmg resistance are the multidmg resistance protein (MRP) family
members, M RPl-9 (Coley 2008). MRPl is a 190 kDa protein, which is composed of 17
transmembrane domains and has a central region similai' to P-gp (Cole et a l 1992; Borst et
a l 2000; Gottesman et a l 2002). Substrates for the MRPl transporter include
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anthracyclines, antifolates, and vinca alkaloids (Cole et al. 1994; Hooijberg et al. 1999; 
Borst et al. 2000; Leonessa and Clarke 2003). However, taxanes and cisplatin are not 
substrates for MRPl (Cole et al. 1994; Hooijberg et al. 1999; Borst et al. 2000; Leonessa 
and Clarke 2003). The size of the tumour, lymph node grade and histological stage are not 
correlated to MRPl expression (Leonessa and Clarke 2003). The incidence of MRPl 
expression in breast cancers, 62% of cases before chemotherapy, increases following 
chemoüierapy to about 88% (Sauna et al. 2001). The breast cancer resistance protein 
transporter BCRP (ABCG2) is a dmg efflux protein (molecular weight 72 kDa) consisting 
of six transmembrane domains plus an N-terminal domain with an ATP binding site (Coley 
2008). Cultured MCF-7 human breast cancer cells express BCRP constitutively (Coley 
2008).
The alterations in proteins and enzymes in cancer is associated with anticancer dmg 
resistance (Coley 2008). The topoisomerase enzymes change as a consequence of 
anthracycline resistance (Coley 2008). However, studies on Hie MD-MB-231 breast cancer 
cell line with acquired resistance to etoposide showed a lack of P-gp and MRP over­
expression and a reduction in topoisomerase II alpha and beta (Lewis et al. 2007). The p53 
gene codes for a vital tumour suppressor which has a role in the apoptotic response to DNA 
damage (O'Connor et al. 1997). p53 is mutated at a high frequency in cancers (O'Connor et 
a l 1997). In one study, approximately 50% of all tumours and 25% of breast cancers 
exliibited deletions and point mutations in the p53 gene (Gasco et a l 2003). Resistance to 
doxombicin is associated with p53 mutation and eaiiy recuiTence in breast cancer patients 
(Aas et a l 1996). In addition, dysfunction of the cell cycle in breast cancer cells is strongly 
linked to the loss of p53 activity (Coley 2008). DNA repair processes are correlated to
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tumour resistance in breast cancer (Coley 2008). Mutations in the breast cancer 
susceptibility gene 1 (BRCAl) result in a deficiency of homologous recombination repair 
(HHR) of DNA double stiand break repair and cross-links, thus producing unstable DNA 
(Bernstein et a l 2002). Furthermore, defects in the mismatch repair mechanism (MMR) in 
breast cancer are associated with the development of anti-cancer drug resistance (Coley 
2008). Genes involved in MMR {hMLHl and hMSH2) can be subject to epigenetic 
silencing and are associated with low sensitivity to cyclophosphamide, methotrexate and 
fluorouracil in breast cancer (Son et a l 2004). The cell death response is also correlated 
with anticancer drug resistance (Coley 2008). The cell death mechanism known as 
apoptosis may act via two main routes, mitochondrial (intrinsic) and cell surface receptor 
(Fas) mediated (extrinsic) pathways (Coley 2008). A number of studies found that drug 
resistance was associated with the intrinsic pathway rather than the extrinsic pathway 
(Coley 2008). However, many breast cancer cell lines are Fas-resistant, and the Fas receptor 
is downregulated in many breast cancers (Keane et a l 1996).
1.5 Types of cell death
There are several classes of cell death: apoptosis, autophagy, necrosis, and mitotic 
catastrophe (Table 1-3). The classification of cell death is often based on biochemical and 
morphological features (Kerr et a l 1972; Kerr 2002). Apoptosis and autophagy are 
programmed cell death mechanisms (Kerr et a l  1972; Kerr 2002).
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Cell death types Nucleus and 
cytoplasm changes
Cell membrane 
changes
Biochemical features
Apoptosis Nuclear fragmentation, 
chromatin condensation 
and formation of 
apoptotic bodies
Blebbing Caspase dependent
Autophagy Partial chromatin 
condensation and 
increased number of 
autophagic vesicles
Blebbing Non-caspase dependent
Necrosis Clumping and random 
degradation of nuclear 
DNA and increased 
mitochondrial swelling 
and organelle 
degeneration
Swelling and 
rupture
Mitotic catastrophe Multiple micronuclei 
nuclear fragmentation
Caspase independent at 
early stages, abnormal 
CDKl/CyclinB 
activation
Table 1-3: Features of different cell death mechanisms (Okada and Mak 2004).
Apoptosis, or programmed cell death I (PCD I), is cell suicide by physiological means 
(Kerr et a l 1972). Apoptosis is important for embryonic development, immune system 
function, and maintenance of tissue homeostasis (Kerr et a l 1972; Ellis et a l 1991; 
Jacobson et a l 1997). Defects in apoptosis may be associated with pathological states such 
as neurodegenerative disease, autoimmunity, and cancer (Okada and Mak 2004). Apoptosis 
involves the breakdown of cellular components and their engulfment by neaihy cells 
(Okada and Mak 2004). Morphological features of apoptosis include condensation and 
fragmentation of the nuclei, membrane blebbing and apoptotic body formation (Kerr 2002; 
Okada and Mak 2004). Under normal conditions, apoptotic cells will be engulfed by 
macrophages or nearby cells (Ricci and Zong 2006). Many chemotherapeutic agents kill 
tumour cells by apoptosis and this is an active area of research allied to the discovery and
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design of new, more effective anticancer drugs (Ricci and Zong 2006).
Autophagic cell death, or programmed cell death II (PCD II), is a non-apoptotic form of cell 
deatli (Okada and Mak 2004). Unwanted proteins in normal cells are degraded by two 
independent mechanisms: ubiquitin-mediated proteolysis and autophagy (Okada and Mak 
2004). Activation of autophagic cell death is triggered as a response to nutrient depletion, 
developmental triggers, and metabolic stresses, and involves degradation of intracellular 
proteins and organelles (Shintani and Klionsky 2004; Lum et al. 2005). Excessive 
autophagy in cells tends to induce PCD H, and dysregulation of autophagy is associated 
with pathological conditions such as neurodegenerative diseases, cardiomyopathy, and 
cancer (Kalimo et al. 1988; Schwartz et al. 1993; Anglade et al. 1997; Bursch et al. 2000; 
Tanaka et al. 2000). The main morphological features of autophagic cell deatli are the 
formation of vacuoles or autophagic vesicles that engulf organelles in the cytoplasmic 
compartment (Klionsky and Emr 2000). The cytoplasm is condensed with tightly packed 
organelles and, along with evidence of mitochondrial condensation, autophagy is associated 
with paitial chromatin condensation (Ricci and Zong 2006). Cells dying by autophagy tend 
to be in clusters and phagocytes are not primarily responsible for clearance of the dead cells 
(Schweichel and Merker 1973; Claike 1990).
Apoptosis is a genetically contmlled and defined mechanism of cell death, whereas necrosis 
is the opposite -  uncontrolled cell death -  and is associated with pathological states (Ricci 
and Zong 2006). Necrosis is a result of a pathophysiological state such as infection, 
inflammation, or ischemia leading to trauma that causes a failure in noimal cellular 
mechanisms that balance cellular homeostasis, including energy production and ion
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transport (Nicotera and Melino 2004; Okada and Mak 2004). When cellular energy is 
reduced in necrotic cells, swelling starts to develop followed by membrane lipid damage, 
lack of homeostatic ion pump function, mitochondrial dilatation, and ending in rupture of 
organelles and tlie plasma membrane, releasing cytoplasmic material (Ricci and Zong
2006). An imbalance in intracellular calcium flux and ROS production can lead to the 
stimulation of non-apoptotic proteases (Ricci and Zong 2006). Increased production of ROS 
causes oxidative stress that damages intracellular molecules and organelles resulting in 
necrosis (Figure 1-9) (Ricci and Zong 2006). ROS also cause DNA strand cleavage and 
oxidation of purines, as well as lipid oxidation, resulting in loss of membrane integrity 
(Mamett 2000). These changes often elicit an inflammatory response, which is designed to 
deliver leukocytes to sites of necrosis (Mateo et a l 1999). Thus, leukocytes clear any 
invading microbes and begin the process of breaking down necrotic tissues (Mateo et a l 
1999). Cellular events include emigration of the leukocytes from the microcirculation and 
accumulation at the focus of the injury (Robin Stuart-Harris 2005). The main inflammatory 
responses that are mediated by necrosis are haemodynamic changes, neutrophil 
accumulation, and release of chemical mediators (Robin Stuart-Harris 2005). The 
haemodynamic changes involve initial transient vasoconstriction, followed by massive 
vasodilatation mediated by histamine, and increased vascular peimeability (Robin Stuait- 
Harris 2005). Neutrophils and macrophages accumulate in response to necrosis, and 
chemical mediators of inflammation, such as histamine and cytokines are produced (Robin 
Stuart-Hairis 2005). The major outcomes of inflammation are abscess formation and 
transition to chronic inflammation (Robin Stuart-Harris 2005).
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NECROSIS Normal Cell APOPTOSIS
Cell shrinkage and 
chromatin condensation
Cell swelling
I
. a tApoptotic f
body
Cellular and nuclear lysis 
causes Inflammation
Phagocytosis by 
macrophages or 
nearby cells
Figure 1-9: Morphological changes during necrosis and apoptosis.
Mitotic catastrophe is a mechanism involving the disruption of mitosis caused by 
inappropriate separation of the chromosomes to produce sister chromatids (Weaver and 
Cleveland 2005). In itself, mitotic catastrophe is not considered a form of cell death but is a 
trigger of cell death (Weaver and Cleveland 2005). In normal cells there is a complex 
mechanism that stimulates cell survival via activation of multiple signalling pathways after 
detection of DNA damage (Ricci and Zong 2006). These responses result in suppression of 
the cell cycle and stimulation of DNA repair mechanisms (Ricci and Zong 2006). When 
damage is severe the cell cycle will be permanently arrested and cell death may be induced 
(Ricci and Zong 2006). The lack of cell cycle checkpoints (DNA structure checkpoints) 
during mitosis will result in mitotic catastrophe-associated cell death (Castedo et al. 2004).
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The ‘DNA structure checkpoints’ arrest cells at the G2/M transition in response to un­
replicated DNA or DNA damage, and the spindle assembly checkpoint prevents anaphase 
until all chromosomes have obtained a bipolar attachment to the spindle (Castedo et al. 
2004). Therefore, the presence of checkpoint deficiencies and DNA damage would lead to 
mitotic catastrophe (Castedo et al. 2004). The moiphological characteristics of mitotic 
catastrophe induced cell death include large cells containing many micronuclei or two 
nuclei (Ricci and Zong 2006). The nuclear envelope, which collects chromosomal 
fragments during a mitotic catastrophe, develops into the micronuclei (Ricci and Zong
2006).
1.6 Cancer and cell death defects
Cancer cell progression and prolonged proliferation occur due to a number of defects, 
including defects in apoptosis that result in a high survival rate in cancer cells (Borst and 
Rottenberg 2004). To date, a number of studies have suggested that the induction of 
apoptosis in breast cancer cells is the main endpoint of different chemotlierapies (Mashima 
and Tsumo 2005). However, several factors affect the ability of cancer cells to induce 
apoptosis (Okada and Mak 2004; Mashima and Tsuruo 2005). Hence, inactivation of 
apoptotic cell death may be associated with the development of chemoresistance to a 
number of unrelated anticancer drugs that aie linked witli tumorigenesis (Okada and Mak 
2004; Mashima and Tsuruo 2005).
Apoptosis can be mediated by two patliways: the intrinsic pathway, which is 
mitochondiially mediated, and the extrinsic pathway, which is cell surface receptor (Fas) 
mediated (Okada and Mak 2004). hi many breast cancers and breast cancer cell lines, the
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Fas receptor is down regulated, leading to Fas resistance (Keane et a l 1996). Other 
described defects in breast cancer include the absence of caspase-3 in the MCF-7 breast 
cancer cell line (Janicke et a l 1998; Kurokawa et a l 1999; Simstein et a l 2003). Caspase-3 
is one of the important executioner caspases in apoptosis (Janicke et a l 1998; Kurokawa et 
a l 1999; Simstein et a l 2003). In addition, the inhibitor of apoptosis proteins (lAPs) that 
are involved in the apoptotic pathway are over-expressed in many types of cancers 
(Nachmias et a l 2004).
One of the most common defects in cancer, as mentioned earlier, is mutation in the p53 
tumour suppressor gene (Mashima and Tsuruo 2005). This defect can cause inactivation of 
the apoptotic machinery and lead to tumour development (Mashima and Tsumo 2005). 
Inactivation of apoptosis may results from defects in Apaf-1 and caspase-9, the apoptosome 
complex core machinery in the intrinsic pathway of apoptosis (Soengas et a l 1999; 
Mashima and Tsumo 2005). The function of the apoptosome has been by investigated by 
Mashima and Tsumo (2005) who found that induction of apoptosis was increased in many 
tumours whilst being reduced in others. The Bcl-2 family members are important factors in 
regulating the apoptotic pathway (Johnstone et a l 2002). Bcl-2 is over-expressed in a 
variety of cancers (Reed 1999). In addition, over-expression of Bcl-2 is associated with 
tumorigensis in transgenic mice (Adams et a l  1999). hi confrast, the pro-apoptotic Bcl-2 
family members are inactivated in a number of cancers and defects in these genes also 
stimulate tumorigensis in mice (Adams et a l 1999). Moreover, changes in expression or 
mutations in upstream regulators of Bcl-2 proteins accompany cancer progression 
(Johnstone et a l 2002). For example, the Bad-kinase Akt is regulated by different 
oncoproteins and by the PTEN tumour suppressor (Datta et a l 1999). Thus, Akt over­
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expression and PTEN mutations have frequently been obsei'ved in a variety of solid cancers 
(Datta et al. 1999). The extiinsic pathway or death receptor pathway is also often 
inactivated in tumour cells, and mutations in CD95, TRAIL receptors, and downstream 
signalling pathways may occur (Johnstone et at. 2002). For example, in a metastatic breast 
cancer, TRAIL-R1/R2 was mutated, leading to the suppression of death receptor mediated 
apoptosis (Shin etal. 2001).
Other defects in non-apoptotic pathways have also been reported, such as an alteration in 
autophagic cell death (Okada and Mak 2004). Defects in protein degradation are often 
associated with cancer and there are oncogenes and tumour-suppressor genes that 
collectively have been shown to influence the autophagic pathway (Okada and Mak 2004). 
The autophagic cell death patliway is important in restricting cellulai' transfoimation and 
regulating protein degradation (Okada and Male 2004). Hence, mechanisms that inhibit this 
pathway may lead to tumour progression (Okada and Mak 2004). Inhibition of autophagy 
disrupts the natural turnover of proteins which function as active regulators of cell growth 
and, thus, promotes cell sui'vival (Okada and Mak 2004). The phosphatidylinositol 3-kinase 
class I (PI3K/Akt) signalling pathway stimulates cell growtli in response to mitogenic 
signals (Ng and Huang 2005). This pathway is up-regulated in a number of cancer cells, 
leading to inhibition of autophagy (Mochizuld et a l  2002). A study using cultured breast 
cancer cells treated with tamoxifen, showed that induction of autophagy involved Akt 
down-regulation (Scarlatti et a l 2004). Moreover, the downstream effector of Alct (mTOR) 
was associated with the suppression of the autophagic pathway, since hyperactivation of 
mTOR and Akt signalling could inhibit both apoptosis and autophagic cell death (Arico et 
a l 2001 ; Mochizuki et a l  2002).
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1.7 MCF-7 breast cancer cells: a model for the study 
of cell death induced by chemotherapy
The human breast cancer MCF-7 cell line is derived from a pleural effusion of a patient 
who had metastatic breast cancer in 1970 (Soule et a l 1973; Levenson and Jordan 1997). 
Findings by Levenson and Jordan indicated that the MCF-7 cell line was the first hormone- 
responsive breast cancer cell line (Soule et al, 1973; Levenson and Jordan 1997), Follow-up 
studies in tlie 1970s and 1980s on MCF-7 cells led to the development of monoclonal 
antibodies to ER (Levenson and Jordan 1997). This advance was shortly followed by the 
establishment of new techniques for measuring estrogen and progesterone receptors in 
tumours to determine the applicability of hormone treatment in individual patients with 
breast cancer (Simstein et a l 2003). A study by Yang et a l  (2001) showed that the MCF-7 
cell line is insensitive to a number of chemotherapeutic agents, but is highly responsive to 
doxorubicin and etoposide and undergoes apoptosis when caspase-3 is reconstituted (Yang 
e ta l  2001). Further, MCF-7 cells were studied for their inconsistent apoptotic responses to 
tumour necrosis factor-a (TNF-a) inducing agents and anti-Fas antibodies (Simstein et a l
2003), When MCF-7 cells are subjected to long-term exposure to TNF or chemotherapeutic 
drugs such as doxorubicin they develop resistance (Simstein et a l  2003). In addition, there 
is some recent evidence demonstrating that MCF-7 cells can undergo autophagic cell death, 
A study by Lamparska-Przybysz et a l (2006) on BID-deficient MCF-7 cells revealed a 
connection between apoptosis and autophagy. When placed under metabolic stress MCF-7 
cells lose their ability to induce apoptosis and, therefore, switch to autophagic cell death 
(Lamparska-Przybysz et a l 2006). All these findings suggest that tire MCF-7 cell line is an 
excellent tool for studying breast cancer chemoresistance and susceptibility to cell death 
(Simstein et a l 2003).
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1.8 Aim and objectives of the project
The work in this thesis focuses on the use of in vitro drug resistant tumour cell line models 
to study cell deatli pathways and associated mechanisms underlying the altered responses of 
these cells to cytotoxic agents. My work has concentrated on cancer cell line models 
developed in the laboratory of my supervisor, Dr. Helen Coley. I particularly focused on a 
model cell line derived from MCF-7 cells, MCF-7TaxR. The MCF-7TaxR cell line has in 
vitî'o acquired resistance to the chemotherapeutic agent paclitaxel (Taxol®). Previous work 
carried out by Dr. Coley demonstrated an absence of caspase-9 in the MCF-7TaxR cell line, 
in addition to the absence of caspase-3 already apparent in the parental MCF-7 cells.
Furthermore, due to overexpression of the MDR transporter P-glycoprotein (P-gp) in tlie
MCF-7TaxR cell line, these cells aru expected to exhibit a classical MDR (multidrug
resistant) phenotype. However, unexpectedly, we saw a lack of cross-resistance to a range
of agents such as VP-16 and doxorubicin, which we would normally expect to see in a P-gp
expressing MDR cell line. Moreover, tliere was a collateral sensitivity of MCF-7TaxR cells .
to platinum anticancer agents.
Thus, the curTent study set out to answer an important question: if the MCF-7TaxR cells |
lack significant components of the apoptotic machinery, what is the molecular basis j
underlying the relatively drug sensitive phenotype of these cells? jII
The first part of the project focused on confirming the lack of involvement of caspase- 1
mediated cell death in MCF-7TaxR cells in response to anticancer drugs. Further, I j
monitored temporal changes in apoptotic genes/proteins during the development of !
paclitaxel resistance in MCF-7TaxR cells, compared with parental cells MCF-7.
37 !
CHAPTER 1
In the next part of the study, I considered whether alternative mechanisms of cell death 
might be operating in the cells and studied PCD II autophagic cell death induction in the 
resistant MCF-7TaxR cell line. This part of my work included an assessment of the role of 
the Akt/mTOR pathway in the MCF-7 cell line models.
In the final part of tlie project, I looked for evidence of any epigenetic changes, chiefly 
epigenetic silencing due to méthylation of caspase genes in MCF-7 and MCF-7TaxR cells 
in an effort to characterise the dnig resistance profile further.
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MATERIALS AND METHODS
CHAPTER 2
Materials and Methods
2.1 Purchase of chemicals and reagents, by source
Alexis® Biochemicals, Nottingham, UK.
Rapamycin (purity > 98.0%), staurosporine (purity > 98.0%), LY-294002 [2(4- 
morpholinyl)-8-phenyl-4iï-l-benzopyran-4-oiie] (purity > 98%).
Bayer®, Pharmaceutical Division, Newbury, Berkshif'e, UK.
Ciproxin®, infusion antibiotic (ciprofloxacin).
Bâchent, Switzerland.
Z-Val-AIa-DL-Asp-fluoromethylketone (Z-VAD) (purity > 91.9%).
Beckman Coulter, UK.
Mouse Monoclonal Anti-Fas/CD95 (purified).
Bio-Rad Laboratories Ltd, Herts, UK.
Bio-Rad DC protein assay kit.
Biosource International, Inc, USA.
Alct rabbit monoclonal antibody and phospho-specific Akt/PKB[pS'^^^] rabbit monoclonal 
antibody.
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Bristol Myers Squibb, UK.
Paclitaxel (Taxol®) as a pharmacy preparation for IV infusion purposes.
Calbiochem® Oncogne™, UK.
Annexin V-FITC (fluorescein-isothiocyanate) apoptosis detection kit, (J-actin mouse 
antibody.
Cell Signalling Technology® Inc, (dist?ibuted by Hitchin, Hertfordshire, U.K)
Caspase-7, Caspase-8 and Caspase-9 mouse monoclonal antibodies, mTOR, phospho- 
mTOR (Ser2448) rabbit monoclonal antibodies, p70 S6 Kinase and phospho-p70 S6 Kinase 
(Ser371) rabbit polyclonal antibodies, Bim rabbit antibody. Bad and phospho-Bad (Seri 12) 
rabbit polyclonal antibodies, and LC3B rabbit monoclonal antibody.
Eastman Kodak Company, (distributed by Sigma Aldrich, Poole, U.K)
Kodak BioMax XR Light Film.
Invitrogen™ Life Technologies, Paisley, UK.
NuPAGE® Novex Bis-Tiis gels, MOPS, MES and Tris-Acetate electrophoresis running 
buffers, NuPAGE® PVDF 0.2 pm membranes, NuPAGE® Nitrocellulose membrane. 
Western blotting transfer buffer, HiMark^M PreStained high molecular weight protein 
standards, Novex® sharp protein standards, secondary antibody solutions (alkaline 
phosphatase conjugated anti-mouse and anti-rabbit). Western Breeze® chemiluminescent 
Western blot immunodetection kit, foetal bovine serum (FBS®), Glutamax®, TRIzol® for 
RNA extraction.
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Santa Cruz Biotechnology Inc (distributed by Autogen Bioclear, Wiltshire, UK)
Bcl-2, BECNl and Bax mouse monoclonal antibodies. MDRl H-241 rabbit polyclonal 
antibody.
Sigma, Poole, Dorset, UK.
Porcine Trypsin-EDTA, 0.4% Tiypan blue, RPMI-1640 and DMEM HEPES modified cell 
culture medium, cisplatin, caiboplatin, doxorubicin, verapamil, zebularine, 5-azacytidine, 
tiichostatin A, 3-methyladenine, Nonidet® P-40 detergent, sodium dodecyl sulphate (SDS), 
phenylmethylsulphonylfluoiide (PMSF), aprotinin, leupeptin, sodium orthovanadate 
(NagVO#), 3-(4,5-Dimethylthiazol-2-y 1)-2,5-diphenyltetrazolium bromide (MTT), Hoechst 
33258, acridine orange.
SuperArray, Bioscience Corporation, USA
RT^ qPCR assay-SYBR® Green and primers for Human CDKN2A (pl6), CASP7, and 
CASP9.
Vector Laboratories Inc. Burlingame. CA.
Vectashield Mounting Medium for Fluorescence H-1000.
2.2 Buffers and Solutions
Hypotonic Cell lysis buffer
50 mM Tris-HCl (C4H11NO3 HCl), 150 mM NaCl, adjusted to pH 7.0 with concentrated 
HCl, in milliQ water. The buffer was supplemented with 1% Nonidet® P-40 detergent, 0.2% 
SDS, 1 mM PMSF.
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NuPAGÉ® MOPS SDS
20% MOPS SDS running buffer prepared in 1 L of milliQ water.
NuPAGE^ Transfer Buffer
20% transfer buffer with 10% methanol in 1 L of miliQ water.
Phosphate buffered saline (PBS)
For Ix  strength: 80.0 g NaCl, 11.5 g Na2HPÜ4, 2.0 g KCl, 2.0 g KH2PO4 in 10 L deionised 
water.
Acridine Orange buffer I
20 mM citrate-phosphate, pH 3, 0.1 mM EDTA, 0.2 mM sucrose, 0.1% Triton X-100, in 
milliQ water.
Acridine Orange buffer II
10 mM citrate-phosphate, pH 3.8, 0.1 NaCl, in MilliQ water.
Cytotoxic drugs
Paclitaxel, cisplatin and carboplatin were diluted in sterile 0.9% saline as stock solutions 
and stored at -20 °C until use. Doxorubicin was dissolved in sterile distilled water, stored 
frozen as stock solution. Stock solutions were thawed prior to use. All otirer compounds 
were prepared in DMSO and stored as frozen aliquots prior to use.
43
CHAPTER!
PBS/Triton solution
0.3% Triton-X-100 in PBS (i.e., 100ml of sterile PBS + 300 pi Triton-X 100).
Hi Salt/PBS solution 
23.4 g NaCl per 1 L PBS.
2.3 Cell culture
The human breast carcinoma cell lines MCF-7, T47D and MDA-MB231, and tire human 
cervical cancer HeLa cell line, were obtained from the European Collection of Cell Cultures 
(Porton Down, Salisbury, UK (ECACC)). All cell lines were cultured in DMEM Hepes 
modified medium with 2 mM Glutamax® and supplemented with 10% heat-inactivated 
foetal bovine serum (FBS) at 37 °C. Drug-resistant cell lines with acquired resistance to 
paclitaxel were generated by growth in increasing doses of the appropriate selecting agent 
on successive passages (by Dr Helen Coley, University of Surrey). The MCF-7 and T47D 
paclitaxel resistant cell lines, designated MCF-7TaxR and T47DTaxR, were maintained at 6 
nM and 4 nM paclitaxel, respectively. VP 16 resistant MDA-MB-231 cells, designated 
MDA-MB-231VP16R were maintained in 1 pM VP16. Cultures were grown in drug free 
medium for at least one passage before experimental use. In addition, MCF-7TaxRREV 
cells were established MCF-7TaxR-7 cells (i.e., in excess of 35 passages) that had been 
grown in the absence of paclitaxel for several weeks.
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Cell line Type and Characteristics
MCF-7 Human Caucasian breast adenocarcinoma derived from pleural 
effusion. Cells show epithelial morphology and adherent growth 
mode.
MCF-7TaxR Human breast cancer cells derived from the MCF-7 cell line with 
acquired resistance to the anticancer drug paclitaxel.
MCF-7TaxRREV Breast cancer cells derived from the MCF-7 cell line with acquired 
resistance to paclitaxel and left to grow in the absence of paclitaxel for 
several weeks.
T47D Human breast tumour cell derived from pleural effusion of a ductal 
carcinoma. Cells show epithelial morphology and adherent growth 
mode.
T47DTaxR Breast cancer cells derived from the T47D cell line with acquhed 
resistance to the anticancer dmg paclitaxel.
MDA-MB-231 Human Caucasian breast adenocarcinoma derived from pleural 
efhision. Cells show epithelial morphology and adherent growth 
mode.
MDA-MB-231 VP16R Breast cancer cells derived from the MDA-MB-231 cell line with 
acquired resistance to the anticancer drug etoposide (VP-16).
HeLa Human Negroid cervical epitheloid carcinoma derived from 
cervical carcinoma. Cells show epithelial morphology and adherent 
growth mode.
Table 2-1: Types and characteristics of cell lines used.
2.4 Chemosensitivity Testing
Cytotoxicity was determined by the MTT assay, as described previously (Mosmann 1983). 
The method relies on the measurement of metabolic activity due to the presence of actively 
respiring mitochondria. Cell lines in cell suspension were seeded at a density 2x10'^ or
3x10"  ^cells/ml (depending on cell doubling times) in 200 pi of medium in a 96-well plate.
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Cells were allowed to grow and attach in a humidified incubator for 24 h at 37 °C and 5% 
CO2. hrcreasing amounts of the appropriate drug (50 pi volume), or control medium were 
added. Cells were tlien incubated witli continuous dmg exposure for 72 h or 96 h (for cells 
with longer doubling times, e.g. T47D). The assay was teiminated by incubation with 0.05 
mg MTT in PBS solution for approximately 4 h at 37 °C. The medium was removed by 
careful aspiration and the resulting tétrazolium crystal product was then dissolved in 2 0 0  pi 
DMSO. The absorbance of each well was measured at 540 nm using an automated plate 
reading spectrophotometer (Labsystems Multiskan RC Plate Reader) with Genesis 3.05 
software. The IC50 values were determined as the dmg concentration necessary to cause a 
50% reduction in cell viability compared to untreated controls. Thus, a graph showing cell 
viability versus dmg concentration was produced from the mean absorbance values, by 
calculating the percent growth of drug treated cells relative to control cells. For each dmg 
concentration, treatments were set up in triplicate or quadruplicate which were then 
averaged and the percent of control growth calculated.
2.5 Trypan Blue Assay for cell viability
As a guide for the major experiments, preliminary testing was carried out in order to 
examine the inhibitory effect of Z-VAD (caspase inhibitor) by treating witli paclitaxel as an 
anticancer agent in MCF-7 and MCF-7TaxR cell lines to examine tire induction of apoptotic 
cell death in these cell lines. The test was set as a 96 well plate with cells being grown at a 
density of 2x10"  ^or 3x10"* cells/ml in a 200 pi volume overnight. The next day cells were 
treated with 100 pM Z-VAD for 1 h, and paclitaxel was tiien prepared in a range of 
concentrations by serial dilutions, added to the wells, and incubated over 72 h. Cells were 
then trypsinised, stained with Trypan blite, and counted using a haemocytometer.
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2.6 Annexin V-FITC/propidium iodide apoptosis assay
The Annexin V-FITC conjugated apoptosis detection kit was used as described by the 
manufacturer (Calbiochem® Oncogene™, UK). The Annexin V-FITC/PI method is based 
on the use of two fluorescent probes, Annexin V-FITC and PI, in order to distinguish 
between viable, early apoptotic, late apoptotic, and necrotic cells. When Annexin V-FITC 
binds to the phospholipids of the plasma membrane, phosphatidyl serine (PS) has been 
externalised in an apoptotic cell. However, if cells are dead via necrotic death, their 
degraded cell membrane will allow nuclear staining of PI which will differentiate then from 
apoptotic cells. Hence, PI staining allows for the differentiation between viable and early 
apoptotic cells. The phospholipids of viable cells are located on the inner surface of the 
plasma membrane. The data are presented in a four quadrant format: FI, F2, F3 and F4. FI 
contains cells that are dead or in end-stage apoptosis/necrosis (Annexin negative, PI 
positive), F2 contains cells in mid-phase and late-phase apoptosis (positive for both 
Annexin and PI), F3 contains viable cells (negative for both Annexin and PI), F4 contains 
cells in eaily apoptotic phase (Annexin positive, PI negative).
The MCF-7, MCF-7TaxR and MDA-MB-231 cells were plated at a density of 2x10^  ^ or 
SxlO'^ in T25 flasks and allowed to adhere for 24 h. Cells were treated with either 100 pM 
Z-VAD (apoptosis inhibitor) or 0.5-1 pM staurosporine, or botli (100 pM Z-VAD for 1 h 
then 0.5 pM staurosporine), or medium free of inhibitors for 24 h or 48 h. For the 
experiments looking at tlie effects of Fas, cells were seeded in T25 flasks as control 
untreated and treated with 200 ng/ml Fas or 1 pg/ml cycloheximide, or with both 200 ng/ml 
Fas and 1 pg/ml cycloheximide, and incubated for 48 h or 72 h. Cells were harvested and 
assayed using the Annexin V-FITC/PI method. In addition, different experimental settings
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were also used with the MCF-7 and MCF-7TaxR cell lines. Cells were incubated in normal 
medium, 1% semm medium, or serum free medium for 72 h.
Images of the MCF-7, MCF-7TaxR, and HeLa cells were captured post-tieatment by light 
microscopy (Nikon ECLIPSE TS-lOO) before processing the cells. Botli floating and 
attached cells were harvested and washed twice in cold PBS. Cells were resuspended in ice 
cold binding buffer to develop Annexin V-FITC binding to the phosphatidyl serine on the 
cell surface. Annexin V-FITC (0.002%) was added and incubated at room temperature for 
30 minutes in tlie dark. Cells were then centrifuged for 5 minutes at 1000 ipm. The medium 
was removed and the cells resuspended in ice cold binding buffer and 0,002% propidium 
iodide (PI) was added on ice and away from light and analyzed using a Beckman Coulter 
Epics XL flow cytometer (ai'gon laser, excitation wavelength 488 nm). Samples were 
analyzed by flow cytometiy, using the ELI and FL3 settings, each reading using a 
collection of 10,000 events.
2.7 Fluorescence microscopy of Hoechst 33258 
stained cells
In order to detect the cell morphology characteristic of cell death, MCF-7, MCF-7TaxR and 
T47D cells were stained with Hoechst 33258 for the analysis of changes in nuclear 
morphology as a direct marker for apoptosis (Jones et al. 1998). Cells were seeded in T25 
flasks at 2x10^  ^or 3x10"  ^cells and grown and treated with 1 pM staurosporine for 48h or left 
untreated. Cells were harvested with their medium and 200 pi of each cell suspension was 
added to a slide for cytospin (Cytospin 4 Thermo Electron Corporation, Basingstoke,
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Hants), forming a pellet on the slides. The pellet was fixed with a few drops of ice cold 
methanol for 5-8 minutes, and then washed with PBS for 1 minute, then one drop of a stock 
solution (2 pg/ml Hoechst 33258) was added to the pellet for 5 minutes. Afterwai'ds, the 
pellet was washed with PBS, left to dry, and Vectashield® mounting solution was added to 
the cell pellet to preserve the fluorescence. A coverslip was placed over the pellet on the 
slide and sealed with nail polish. Slides were left to dry for 10-20 minutes and covered with 
foil to avoid light. Stained nuclei were detected by fluorescence microscopy (Nikon Eclipse 
TE2000-S by JENCONS-PLS) Magnification, x40. Images of nuclear staining were 
captured by a Nikon digital camera.
2.8 Whole cell lysis preparation
Different breast cancer cell lines were grown in tissue culture T25 or T75 flasks to 
approximately 40% confluence for 24h. Flasks of cells were treated with different dmgs or 
left untreated for 24, 48 or 72 h. Cells were harvested by scraping the monolayer of 
adherent cells, combining diem with the floating cell population and washing with PBS. 
The supernatant was removed and the cell pellet was incubated for 20 minutes on ice with 
freshly prepared cell lysis buffer. Cells were lysed using a 1 ml syringe and resuspended 
several times for approximately 20 seconds on ice. Cells were centriflrged for 10 minutes, 
and the supernatant was then collected and stored at -20 °C.
The cell protein concentration was estimated using the Bio-Rad DC protein assay.
Following the manufacturer’s instmctions, cell lysate samples were diluted 1:10 in milliQ
water (100 | L i l  total volume) and added to 96 well plates. SDS was added to the NaOH
solution at a ratio of 1:50 and 25 |il was added to the cell lysate samples or the BSA protein
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standaids in the range of 1.5-2.0 mg/ml. The folin reagent (200 |il) was added to the cell 
lysate samples or BSA protein standards. After 10 minutes, the absorbance was measured at 
690 nm using a Lab system Multiscan RC plate reader. The protein concentration of the cell 
lysates was estimated by inteipolation of the BSA protein standard curve and equal protein 
amounts were then used for Western blotting analysis.
2.9 Western Blotting
The Western blotting analysis was performed on cell lysates using the Invitrogen™ hfe 
technologies system. Following tlie manufacturer’s instructions, cell lysate samples ranging 
from 30-50 |Xg were prepared in NuPAGE® LDS sample buffer (1:4, diluted in milliQ 
water) and NuPAGE® reducing agent (1:10, diluted in milliQ water), heated at 70 °C for 10 
minutes, and then subjected to electrophoresis. The proteins were separated on NuPAGE® 
Novex Bis-Tris Gels (7%, 8%, 10%, 12% or 4-12% gradient gels) depending on the protein 
molecular weight subject to detection. Using NuPAGE® MOPS SDS as the mnning buffer, 
samples were transferred to PVDF or nitrocellulose membranes in an apparatus provided by 
the manufacturer. Blocking solution was provided in the Chemiluminescent Western Blot 
Immunodetection Kit from hivitrogen™ prepared with 2-5% milk or BSA to block the non­
specific binding sites on the membrane, according to the manufacturer’s instructions. 
Piimaiy antibody was prepared in antibody diluent provided with the kit in order to probe 
the membrane. The membrane was incubated with the primary antibody solution at 4 °C 
overnight with gentle shaking. The membrane was washed and a suitable secondaiy 
antibody solution, provided witli the kit, was used to probe tiie membrane for 30-45 minutes 
with gentle shaking. The membranes were washed with prepared antibody solution, 
provided with tlie kit, for 5 minutes for a total of three washes. Membranes weie rinsed
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with milliQ water. The signal was detected using a chemiluminescent substrate provided 
with tlie kit and Kodak Biomax Light film. To detect equivalent protein loading, die 
membrane was stripped by incubating at room temperature for 2 h in 1 mM sodium azide in 
PBS and gentle shaking. The membrane was then exposed to an anti-mouse p-actin 
antibody at a dilution 1:20,000.
2.10 Total RNA extraction
Total RNA was extracted with the TRIzol® reagent (Invitrogen™) according to the
manufacturer’s instructions, from T25 or T75 monolayers of the breast cancer cell lines 
MCF-7, MCF-7TaxR, T47D, T47DTaxR and MDA-MB-231, 48 h after the cells reached 
80% confluence. The Trizol reagent was added to cells to disassociate nucleoprotein 
complexes. Chloroform was added and thoroughly mixed to separate DNA and RNA from 
proteins, incubated for 3 minutes, and then centrifuged for 10 minutes at 10,000 g at room 
temperature. The RNA was transferred to isopropanol and incubated for 10 minutes at room 
temperature. After 10 minutes centrifugation at 8000 g at 4 °C , the RNA pellet was washed 
with 75% ethanol and dissolved in RNase free water. The quantity and quality of total RNA 
was checked, RNA was diluted 1:10 with RNase free water and measured using a Nano­
drop spectrophotometer (Agilent). The RNA samples were stored at -80 ®C until use for 
gene microanay or qPCR analysis.
2.11 Gene microarray analysis
RNA was extracted from the MCF-7 and MCF-7TaxR cell lines as described in section
2.10. After the quantity and quality of RNA samples were checked, as described in 2.10
using the Nano-drop spectrophotometer (Agilent), RNA samples were sent on diy ice to
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perform oligo GEAiray human apoptosis microarray profiling of the expression of 112 
apoptosis related genes by the SuperArray Bioscience Corporation, Frederick, USA.
2.12 Quantitative PGR analysis
Two methods for the qPCR analysis were carried out, a one step metliod and a two step 
metliod. However, both methods gave the same results. As described previously, in section
2.10, RNA was extracted with the Trizol reagent. The qPCR analysis was earned out using 
the SYBR Green reagent; the synthesis of cDNA is all in one step with RT-PCR. The kit 
used was a QIAGEN® One-step QuantiTect® SYBR® Green RT-PCR kit. Following the 
manufacturer’s instructions, a mixture was prepared with an RNA concentration of 50-100 
ng/pl, 6.25 pi of QuantiTect SYBR Green RT-PCR master mix, 0.125 pi QuantiTect RT 
mix, 1 pi each of forwai’d and reverse primers, or 1.25 pi foiward and reverse combined 
primer mix, and 1-2 pi RNase-lfee water. The total volume for tire reaction is 12.5 
p 1/reaction. Primers were provided from SuperArray® and reconstituted to give a 10 pM 
working solution. The PCR reactions were carried out as follows: 30 minutes at 50 °C for 
reverse transcription; 15 minutes at 95 °C for the PCR initial activation step; 40 cycles of 
dénaturation for 20 sec at 95°C and annealing for 60 sec at 60 °C.
The second method is a two step analysis or indirect metliod, which involved first strand 
cDNA synthesis in a separate step and was carried out using a reaction mixture of the 
ImProm-IF^ Reverse Transcription System from Promega®. Following tire manufacturer’s 
insfructions, the reaction mixture was made using 0.5 pg RNA, 0.5 pg random primer, 2 pi 
nuclease-free water, and the sample was tlien heated for 5 minutes at 70 °C. To add the 
reverse transcription reaction mix, the mixture was prepared as follows: 5x ImProm-IF^
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reaction buffer, 0.5 mM dNTPs, 1.5 mM MgCL, 20 U recombinant ribonuclease inhibitor, 1 
U ImProm-IF^ Reverse Transcriptase, for each sample mixture. The reaction mixture was 
left at 25 °C for 10 minutes followed by 60 minutes at 42 °C. The reaction was terminated 
by incubation at 70 °C for 15 minutes. The cDNA was then subjected to qPCR using the 
SYBR Green reagent obtained from Stratagene®. The reaction mixture was prepared as 
follows: 1 pi of each primer, 1 pi cDNA template, 12.5 pi SYBR Green reagent, RNase 
free water to 25 pi total volume. Samples were subjected to qPCR analysis. Primers were 
provided from SuperArray® and reconstituted to give a 10 pM working solution. The PCR 
reactions were cairied out as follows: 10 minutes at 95 °C for initial activation; 40 cycles of 
dénaturation for 20 sec at 95 °C, and annealing for 60 sec at 60 °C (Stratagene®-Mx 3000P 
QPCR system).
Primers were human CDKN2A (p i6), caspase-7 and caspase-9, obtained from SuperArray 
Bioscience Corporation.
(pl6) human gene sequence primer 5 ’-3 '\ Forward, CAGAGGATTTGAGGGACAGG; 
Reverse, CTCCTCTTTCTTCCTCCGGT.
Caspase-7 human gene sequence primer 5 ’-3’: Forward,
CCGTGGGAACGTAAGAAGAA; Reverse, GTCTTGATGGATCGCATGG.
Caspase-9 human gene sequence primer 5 ’-3’\ Forward, CCTGCTTAGAGGACACAGGC ; 
Reverse, TTCGACAACTTTGCTGCTGCTTG.
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2.13 Quantitation of acidic vesicies by acridine orange 
staining
Autophagic cell death was assessed in breast cancer cell lines by the quantitation of acidic 
vesicles stained with acridine orange, as described previously (Daizynkiewicz 1990). The 
breast cancer cell lines MCF-7, MCF-7TaxR, and MDA-MB-231 were plated at a density 
of 2x10"  ^or 3x10^  ^cells in T25 flasks and allowed to adhere for 24 h. Cells were then treated 
with 0.5 pM staurosporine, or untreated for 24 h or 48 h. Cells were harvested by 
trypsinisation and washed with PBS, and, tlien 500 pi of buffer was added to all samples. 
To inhibit autophagy, cells previously treated witli staurosporine were treated witli 5 pM 
bafilomycin for 1 h followed by staining with acridine orange (2 pg/ml stock solution 
diluted 1:1000 in buffer II) for 1 h at room temperature in the dark. Samples were then 
analyzed by flow cytometry using FLl (525 nm) and FL4 (630 nm). The cytoplasm and 
nucleoli of stained cells fluoresced bright green and dim red, respectively, whereas 
autophagic cells containing acidic vesicles fluoresce bright red.
2.14 LC-3 Confocal microscopy imaging
MDA-MB-231, MCF-7, and MCF-7TaxR cells were analysed for LC-3. MDA-MB-231 
cells were used as a negative control for LC-3. All cells weie grown in T25 flasks at 
densities of 2x10^ or 3x10^ cells per flask and left untreated, as a control, or treated with 0.5 
pM or 0.25 pM staurosporine. Cells were incubated for 24 h and then harvested and 
processed for cytospin (Cytospin 4 Thermo Electron Corporation, Basingstoke, Hants) 
foiraing a monolayer pellet on the slides. The cytospin slides were fixed with 2-4% 
formaldehyde in PBS for 15 minutes and rinsed with PBS. Slides were covered witli ice-
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cold methanol (100%) and were kept in the freezer for 10 minutes (methanol 
permeabilization stage). Samples were then rinsed twice with PBS for a duration of 5 
minutes. Samples were blocked with 5% anti-goat secondaiy antibody for 1 h and washed 
with PBS three times. This was followed by incubation with the primary antibody LC-3 
using a dilution of 1:200 to 1:100 overnight using PBS/Triton. After draining off the 
blocking serum solution from each slide, 50-100 pi of diluted antibody per cytospin or 
coverslip was added. Slides were incubated overnight in a humidifying chamber in the cold 
room. The next day, slides were washed witli PBS and incubated with Alexa-Fluor diluted 
with PBS/Triton to approximately 1:200 (to conjugate to LC-3) for 2 h. Slides were rinsed 
with PBS and nucleai* dye (1:200 dilutions) was added to the slides for 10 minutes and 
finally washed with high salt PBS. Slides were left to dry and, then, anti-fade and sealed 
cover slips with nail polish were added. Imaging of the slides was carried out using 
confocal microscopy at 40x magnification (Carl Zeiss Laser Scanning System LSM510).
2.15 Electron microscopy for detection of 
autophagosomes.
For detection of autophagosomes in MCF-7TaxR cells and in MCF-7 cells, we performed 
an electron microscopy analysis. MCF-7 and MCF-7TaxR cells were grown in T75 flasks at
a density of 3x10'^, the cells were untreated, or were treated with 0.5 |.iM or 1 j.iM j
jstaurosporine for 48 h. Cells were harvested and collected in 200 pi solution forming a
pellet. The processing and embedding of cells was performed witli collaboration of ,
researchers at Brunei University. Pellets were fixed with 2% glutaraldehyde for 10 minutes j
I
at room temperature, washed with phosphate buffer for 10 minutes three times, and fixed j
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with 1% osmium tetroxide in phosphate buffer for 1 h at room temperature. Cells were 
embedded in 2% agar, heated on a hot block to 50 °C and stirred using a glass rod. The 
consistency was correct when droplets set firmly around the edges on a cold surface. 
Approximately 0,5 ml agar was added to the pellets and very gently mixed so that cells 
were in contact witli the agai-, but still highly concentrated at the tip of the tube. The pellet 
must have no excess phosphate buffer present as this would prevent the agar setting to the 
correct consistency. The agai' with cells was set and cut into small chunks approximately 2- 
3 mm^ using a blade on some dental wax, before being added to a small tube. The samples 
were washed witli distilled water 2 times for 5 minutes and dehydrated with ethanol for 15 
minutes in each of the following ethanol solutions: 30%, 50%, 70%, 90% 2 times, and 
100%. Samples were incubated overnight in propylene oxide at room temperature. The next 
day cells were incubated with fresh resin for 6 h. Cells were embedded by transferring the 
agar- to a plastic mould and adding fresh resin. This was gently mixed with a cocktail stick 
so til at no air bubbles were present at the bottom of the tube and the agar was pushed into 
the tip of the tube. Resin was incubated at 65 °C with lids open. Ultrafine sections of 100 
nm thickness or less were made. Sections were collected on grids and allow to dry for 10-15 
minutes. These sections were stained with 2% uranyl acetate made in distilled water for 1-2 
h by placing the grids on droplets on dental wax in a glass dish followed by washing with 
distilled water. Sections were stained on lead citrate droplets for 4 minutes and left on 
dental wax in a covered glass dish. Potassium hydroxide pellets were added to the dish to 
absorb CO2. The grids were taken for electron microscopy imaging. Samples (grids) were 
analysed by scanning transmission electron microscopy STEM (assisted by Dr. Vladimir 
Stolojan, UniS) (Philips CM200 Transmission Electron Microscopy- using 2 um 
magnification.) at the MSSU- University of Surrey.
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2.16 Statistical analysis
Data were expressed as means ± standard deviation. Significance was determined using a 
two-tailed, paired. Student’s T-test, using the SPSS software or Microsoft Excel. A P-value 
<0.05 indicated a significant difference.
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INDUCTION OF APOPTOTIC 
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CHAPTERS
3 Induction o f Apoptotic Cell Death in Drug
Resistant Human Breast Cancer Cells
3.1 Programmed cell death I - Apoptosis
The term apoptosis is derived from the Greek for ‘falling off’, like leaves fall from trees 
(Kerr et a l 1972). This process is important for tissue development and homeostasis (Wu 
1996; Taylor et al. 2008). Apoptosis was first described by Kerr and colleagues (1972), 
who coined tlie term ‘apoptosis’ for programmed cell death and reported the occurrence of 
apoptosis in adults in relation to health and disease. Normally, apoptosis is a physiological 
process that is vital to embryonic development and the immune system and also occurs in 
the elimination of excess neurones during development (Okada and Mak 2004; Schimmer
2004). During early development of the embryo the role of apoptosis is important in 
configuring the shape of organs and die removal of the interdigital webs of fingers and 
toes (Renehan et al. 2001; Schimmer 2004). In cases such as the immune and nervous 
systems, which produce a high number of cells to serve different functions in tlie body, 
when Üiese cells eventually fail to function, as in making synaptic connections or 
producing specific antigens, apoptotic cell death plays a role in subsequently clearing the 
unwanted cells (Renehan et al. 2001; Okada and Mak 2004). Apoptosis maintains the 
balance of cellular turnover in adulthood, since approximately ten billion cells die every 
day and new cells are produced from the stem cell populations in tire body (Renehan et al. 
2001; Fischer and Schulze-Ostlioff 2005). The control of tissue homeostasis by apoptosis 
is a highly regulated process (Renehan et al. 2001; Okada and Mak 2004). During ageing, 
however, the mechanisms of apoptosis become less controlled and less sensitive to DNA 
damage (Renehan et al. 2001; Okada and Mak 2004; Fischer and Schulze-Osthoff 2005).
59
CHAPTER 3
Hence, there is a relationship between the development of degenerative diseases and 
delayed progression of cell death (Renehan et al. 2001 ; Okada and Mak 2004; Fischer and 
Schulze-Osthoff 2005). Moreover, there is now accumulating evidence that defects in 
apoptosis aie associated with a number of diseases (Thompson 1995). Apoptosis is up- 
regulated in AIDS, as well as in ischemic injury following myocardial infarction and 
stroke, and increased apoptosis is a feature of autoimmune diseases such as hepatitis 
(Renehan et al. 2001). Conversely, a reduction in the apoptotic response is a factor in 
carcinogenesis, autoimmune diseases and some viral infections (Martin et al. 1998; 
Renehan et al. 2001), Therefore, impaired apoptotic function is involved in many 
pathological conditions and, thus, suggests that apoptotic pathways/components represent 
potential therapeutic taigets (Fischer and Schulze-Osthoff 2005).
The morphological and biochemical characteristics of apoptosis show a sequence of 
events resulting in cell death (Kerr 2002; Okada and Mak 2004; Shiozaki and Shi 2004; 
Tardy et a l 2006). Mechanisms of apoptosis can be divided into three stages: (1) initiation 
of apoptosis via inducing agents, (2) activation of caspases, and (3) proteolytic cleavage of 
cellular materials (Simstein et a l 2003), Apoptosis is quite distinct from necrosis, with 
morphological features involving membrane blebbing, cellular shrinkage, nuclear and 
cytoplasmic condensation, and degradation of chromosomes into nucleosomal fragments 
(Okada and Mak 2004; Shiozaki and Shi 2004). A major feature of the apoptotic cascade 
is the activation of a family of proteases called caspases followed by formation of 
‘apoptotic bodies’ that are cleared and removed by phagocytosis (Okada and Mak 2004; 
Shiozaki and Shi 2004). The biochemical events of apoptosis are complex and induced by 
signal transduction events that lead to activation of caspases, which, in turn, cleave
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cellular proteins (Schulze-Osthoff et a l 1998; Tardy et a l 2006). Biochemical changes 
include translocation of phosphatidylserine to the outer leaflet of the plasma membrane 
and extensive inter-nucleosomal genomic DNA degradation carried out by selectively 
activated endonucleases (Schulze-Osthoff et a l 1998; Tardy et a l 2006). There are two 
pathways of apoptosis that have been described in the literature, the extrinsic and intrinsic 
pathways (Figure 3-1). Both pathways involve an activation of caspase cascades 
(Srinivasula et a l 1996; Thomberry and Lazebnik 1998).
Extrinsic Pathway
Ligands
(FasLJNF-a, TRAIL)
Death receptors 
(FaSjTNFR)
Intrinsic Pathway
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Figure 3-1: Schematic representation of the two apoptotic pathways.
(Srinivasula et a l 1996; Thomberry and Lazebnik 1998; Simstein et a l 2003; Okada and 
Mak 2004; Schimmer 2004).
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3.1.1 Apoptotic key reguiators- caspases
Caspases are a group of cysteine-dependent aspartate-specific proteases (Thombeny et a l 
1992; Alnemri et a l 1996). Caspases cleave substrates at Asp-Xxx bonds (Thomberry et 
a l 1992; Alnemri et a l 1996). Approximately fourteen types of caspases have been 
identified in mammals, but not all are involved in apoptotic cell death mechanisms (Cohen
1997). Caspases can be classified into three groups based on their functional activity: (1) 
initiator caspases for apoptosis include caspase-2, -8, -9 and -10; (2) executor caspases of 
apoptotic cell death include caspases 3, 6 and 7; (3), caspases involved in cytokine 
activation include caspase-1, -4, -5, -11, -13 and -14 (Zhang 2004-2005). Not all caspases, 
however, are fully understood in terms of their functionality (Zhang 2004-2005).
Caspases are synthesised as inactive single polypeptides termed zymogens or pro-caspases 
(Zhang 2004-2005). The zymogen consists of an N-terminal prodomain followed by 
sequences containing first large and then small subunits (Zhang 2004-2005). The zymogen 
component of caspases possesses an inhlnsic proteolytic activity in order to initiate the 
apoptotic pathway (Stennicke and Salvesen 1999). When a pro-caspase is activated, it 
requhes two cleavages to transform the zymogen or pro-caspase into a catalytically active 
enzyme (Zhang 2004-2005). These two cleavage reactions involve separation of the 
prodomain from the large subunit and separating the large and small subunits, involving 
Asp-X bond cleavage (Zhang 2004-2005).
Activation of initiator and executioner caspases takes place by two mechanisms, the 
intrinsic and extrinsic patliways (Zhang 2004-2005). The initiator caspases are stimulated 
by recruitment of their zymogen to the corresponding regulator protein (Zhang 2004-
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2005). Executioner caspase activation requires the activation of initiator caspases leading 
to induction of the downstream proteolytic apoptotic pathway (Zhang 2004-2005). The 
initiator caspases play an important part in the apoptotic process by initiating the 
execution phase of the process; hence, different initiators, adaptors and regulators of 
caspases are needed for regulating the proteolytic mechanisms of different cell death 
inducers (Zhang 2004-2005). In Fas- and TNFRl-mediated signal transduction, the 
activation of caspase-8 is important and requires the Fas-associated death domain protein 
(FADD) to initiate catalytic activation (Figure 3-1) (Varfolomeev et a l 1998; Zhang et a l
1998). Activation of caspase-9 and Apaf-1 is essential for DNA damage, corticosteroid-, 
and staurosporine-induced cell death in tliymocytes and embryonic fibroblasts (Hakem et 
a l 1998; Yoshida et a l 1998; Vu et a l 2001). The recruitment of caspase-10 requires 
FADD for TRAIL and Fas mediated signalling of apoptosis (Sprick et a l 2002). In human 
T-cells, both caspase-8 and caspase-10 have been shown to be associated with the death 
effector domain and are important in Fas-induced apoptosis (Wang et a l 2001). Caspase- 
12, which functions in the maturation of cytokines, is also considered an initiator caspase, 
since it was shown to be activated by stress-induced apoptosis in the endoplasmic 
reticulum (Nakagawa et a l 2000; Hitomi et a l 2004).
The executioner caspases are activated following the recruitment of initiator caspases as 
part of the apoptotic cascade (Femandes-Alnermi et a l 1995; Zheng et a l 2000). The 
most important executioner caspase is caspase-3, which was found to be vital for 
embryonic development; caspase-7, another key executioner caspase, has been shown to 
compensate for caspase-3 function (Fernandes-Alnemri et a l 1995; Zheng et a l 2000). 
Studies of caspase-7 showed that a caspase-7 gene defect in cells confers resistance to
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common apoptosis-iiiducing agents such as anti-cancer drugs and disrupts externalisation 
of phosphatidylserine on the plasma membrane and DNA fragmentation (Korfali et al. 
2004).
Caspase function is confrolled by a group of inhibitor of apoptosis proteins (lAPs), 
consisting of a family of regulatory proteins which include XIAP, cIAPl, cIAP2, NAIP, 
ML-IAP, and survivin (Deveraux et al. 1999; Salvesen and Duckett 2002; Sanna et al. 
2002). The lAP family binds selectively to caspase-3, -7 and -9, hence blocking apoptosis 
(Deveraux et al. 1999; Salvesen and Duckett 2002; Sanna et al. 2002; Schimmer 2004). 
lAPs can, however, be inhibited by tlie second mitochondria-derived activator of 
caspase/direct inhibitor of apoptosis-binding protein with low pi (Smac/DIABLO), which 
is released from the mitochondria with cytochrome c (Figure 10) (Mita et al. 2006). Over­
expression of lAPs can be caused by die anti-apoptotic transcription factor, nuclear factor 
kappa B (NF-kB), which can be indirectly stimulated by growth factors via the 
phosphoinositol-3 phosphate (PI3K/Akt) pathway (Conradt and Horvitz 1998).
3.1.2 Intrinsic pathway
The main body of evidence to date confirms that die mitochondria aie the main core of the 
intrinsic pathway along with a number of apoptotic regulators that inhibit or activate 
apoptosis (Adrain and Martin 2001; Wang 2001; Zamzami and Kroemer 2001; Logue and 
Martin 2008). This pathway is induced by different cellular stresses such as heat shock, 
DNA damage or other forms of stress, and die mitochondria starts to release cytochrome c 
from the inter-membrane space into the cytoplasm (Adrain and Martin 2001; Wang 2001; 
Zamzami and Kroemer 2001 ; Logue and Mardn 2008). Subsequently, cytochrome c binds
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to and activates oligomerization of Apaf-1 in the presence of dATP, which assemble 
together in a wheel structure with pro-caspase-9 to build the apoptosome complex 
(sometimes referred to as the “wheel of death”) (Li et al. 1997; Srinivasula et al. 1998; 
Slee et al. 1999). The apoptosome activates caspase-9, followed by activation of the 
executioners caspase-3 and -7, leading to activation of a downstream caspase cascade (Li 
e ta l  1997; Srinivasula efaZ, 1998; Slee etal. 1999).
Although caspase-7 shows no involvement in activation of downstream caspases, caspase- 
3 drives the activation of caspase cascades by proteolysis and leads to activation of 
caspase-2 and 6 (Rodriguez and Lazebnik 1999; Slee et al. 1999; Slee et al. 2001 ; Acehan 
et al. 2002). Different studies on knockout mice have explored the importance of caspase- 
9 and Apaf-1 in activating downstream caspases in tliis pathway (Logue and Martin 2008). 
Other studies have shown that using different stress-inducing agents, such as cytotoxic 
drugs and radiation, on cells derived from caspase-9 null animals, results in resistance to 
these agents (Halcem et al. 1998; Kuida et al. 1998). Apaf-1 usually works as a monitor to 
detect cell damage that results in release of mitochondrial proteins into the cytosol, which 
is not usually found in healthy cells (Logue and Martin 2008). Apaf-1 exists as a 
monomeric protein when cytochrome c is absent, making it unable to bind to pro-caspase- 
9 (Logue and Mar tin 2008).
According to a number of studies, the Bcl-2 family proteins frinction as powertul and 
important regulators of apoptotic patliways (Kroemer 1997; Adams and Cory 1998). 
Evidence that has accumulated in die last few years shows that the Bcl-2 family proteins 
consist of seventeen ruembers: some proteins promotes apoptosis and others inhibit
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apoptotic cell deatli (Logue and Martin 2008). Members of tlie Bcl-2 family typically 
consist of four conserved a-helical domains, BHl, BH2, BH3, and BH4, that are involved 
primarily in the interactions between these proteins (Chittenden et a l 1995; Cheng et a l 
1996; Adams and Cory 1998; Kelekar and Thompson 1998; Reed 1998). The anti- 
apoptotic subfamily members are Bcl-2, B c1-X l, Bcl-w, Bcl-b, Mcl-l, and A l. The pro- 
apoptotic proteins include Bax, Bak and Bok, which have domains homologous to the 
BHl-3 domains, and the pro-apoptotic BH3-only proteins, Bid, Bim, Bad, Bik and 
PUMA, which act as ligands and contain only a BH3 domain (Zhang 2004-2005). These 
proteins function as antagonists/agonists that determine the response of the cell to 
apoptotic death signals and they mostly function in the external mitochondrial membrane 
(Mita et a l 2006). Bcl-2 anti-apoptotic proteins inhibit Apaf-1 mediated activation of 
caspase-9 (Coultas and Strasser 2003). In addition, Bax/Bok proteins promote cytochrome 
c release from the mitochondria whereas Bcl-2 proteins prevent this (Green and Reed 
1998; Gross et a l 1999; Wang 2001). Therefore, it has been suggested that these proteins 
control mitochondrial membrane integrity (Green and Reed 1998; Gross et a l 1999; 
Wang 2001).
3.1.3 Extrinsic pathway
The extrinsic pathway is controlled by a number of tumour deatli receptors and then" 
ligands through induction of signal transduction pathways in order to activate apoptotic 
cascades (Mita et a l 2006; Logue and Martin 2008). The key regulator death receptors are 
TNF superfamily receptors including the firnctional death domain receptors DD, CD95 
(Fas/APO-1) and the TNF-related apoptosis-inducing ligand receptor -1 (TRAIL-1), and 
TRAIL-2 receptors (Mita et a l 2006). Therefore, when a ligand binds to its death
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receptor, the adaptor protein FADD recruits pro-caspase-8 and -10, forming the death- 
inducing signalling complex (DISC), and activates these two caspases (Ashkenazi and 
Dixit 1998; Schulze-Osthoff et al. 1998; Suliman et al. 2001), Consequently, caspase-8 
and -10 result in activation of downsfream executioner caspases leading to induction of 
apoptosis (Mita et al. 2006).
In addition, it has been reported that caspase-8 can amplify the intrinsic pathway by 
stimulating cleavage of Bid via permeabilization of the mitochondrial membrane and give 
rise to caspase-9 activation (Li et al. 1998; Fischer et al. 2003; Mita et al. 2006). 
Apoptosis induced by TRAIL, however, essentially requires the recruitment of FADD to 
the DISC which in turn activates caspases-8 and -10 (Bodmer et al. 2000; Kuang et al. 
2000; Kischkel et al. 2001; Suliman et al. 2001). Any defect or mutation in caspase-8 or 
FADD will be associated with TRAIL resistance (Bodmer et al. 2000; Kuang et al. 2000; 
Kischkel et al. 2001; Suliman et al. 2001).
3.2 Deregulation of apoptotic pathways in cancer
Deregulation and inactivation of apoptotic pathways leads to cell survival and facilitates 
the progression and, therefore, the development of cancer (Taylor et al. 2008). When the 
cell cycle and cell division are not properly controlled, as in cancer cells, there is a 
resulting loss of balance between cell proliferation and cell death (PCD I/apoptosis) (Shao 
et al. 2004; Gerl and Vaux 2005; Tardy et al. 2006). Therefore, the lifespan of the cancer 
cell will be extended, promoting initiation of tumour formation (Shao et al. 2004; Gerl and 
Vaux 2005; Tardy et al. 2006). Deregulation in the intrinsic pathway involves 
overexpression of anti-apoptotic proteins such as Bcl-2 (Gross et al. 1999; Reed 1999). It
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has been reported that cancers have low levels of expression of Apaf-1, a vital component 
in forming the apoptosome complex to activate caspase-9 (Soengas et a l 2001). Defects 
in overexpression of lAPs can result in inhibition of all intrinsic and extiinsic apoptotic 
pathways (Soengas et a l 2001). Hence, overexpression of survivin results in a major 
impact on resistance to treatment and carcinogenesis in a number of cancers (Deveraux 
and Reed 1999; Soengas et a l 1999; Green and Beere 2001). Also, other studies have 
shown an upregulation of the PI3K/Akt pathway, which may be caused by increased gene 
expression of PI3K or Akt and this can promote cell survival and inhibit apoptotic cell 
deatli (Datta et a l  1999; Shayesteh et a l  1999; Di Cristofano and Pandolfi 2000).
Defects in the extiinsic pathway may be caused by mutation or inhibition of death receptor 
expression or poor transport of TRAIL (Jin et a l 2004). Mutations or deletions in various 
caspases have been demonstrated in cancer cell lines. For example, in the MCF-7 breast 
cancer cell line there is a complete absence of the caspase-3 gene owing to a chromosome 
deletion (Kurokawa et a l 1999; Xue et a l 2003). Cancer progression and resistance to 
treatment may be caused by deficient expression of pro-caspase-8 (Ashkenazi 2002). 
Somatic mutations occur in different pro-apoptotic proteins such as the BH3 and Bax 
proteins, as determined in different solid tumours and haematological malignancies 
(Ashkenazi 2002).
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3.3 Aim
In this fust pait of this project, I investigated the in vitro induction of non-caspase- 
dependent or apoptosis independent cell deatli in the breast carcinoma derived cells MCF- 
7 and MCF-7TaxR (with in vitro acquired resistance to paclitaxel). The response to 
anticancer dmgs was examined in MCF-7 cells (lacking caspase-3) in terms of how they 
may activate apoptosis or other forms of cell death in response to cytotoxic insult. We 
hypothesized that MCF-7 cells show a moderate level of apoptotic cell death in response 
to anticancer drug treatments. However, for the MCF-7TaxR variant we would expect a 
severely compromised or reduced apoptotic response under the same conditions. We used 
the MDA-MB-231 and T47D breast cancer cell lines for compaiison as they are caspase 
proficient (no apparent deletions of caspases reported) and, thus, were studied in the same 
manner as positive controls for apoptosis.
3.4 Methods
All methods carried out in this chapter are described in Chapter 2: Methods and Materials. 
I used the MTT assay, Annexin-V FITC/PI protocol and fluorescence microscopy using 
Hoechst nucleai* staining.
3.5 Results
3.5.1 MTT assay for chemosensitivity testing
The MTT dye reduction assay (which assesses cell viability due to mitochondrial activity) 
was used as described (Chapter 2). Preliminary cytotoxicity studies were carried out to 
assess the activity of the anticancer drags paclitaxel, cisplatin, caiboplatin and doxorubicin
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on the MCF-7, MCF-7TaxR, T47D, T47DTaxR and MDA-MB-231 cell lines. Cells weie 
treated with different concentrations of anticancer dmgs (as described in section 2.4- 
Chapter 2). Cell viability was assessed at 72 h or 96 h (according to the cell doubling time 
of the cell line, in order to coincide witlr approximately a 1 0 -2 0 -fold increase in cell 
number) and compared with untreated controls.
Cell lines Cisplatin IC50 
pM
Carboplatin 
IC50 pM
Doxorubicin 
IC50 nM
Paclitaxel 
IC50 nM
MCF-7 17 (±2) 84 (± 8 ) 1000 (±225) 6.5 (± 4.5)
MCF-7TaxR 7.5 (±1.12) 26 (± 8 ) 1080 (±229) 77.7(± 6.1)
MDA-MB-231 5.6 (± 2.7) 15 (± 2) - 4.5 (± 2.2)
T47D 45 (± 7) - - 1.6  (± 0.045)
T47DTaxR 75 (± 9.8) - - 1 0  (± 8 )
Table 3-1: Determination of drug sensitivity of breast cancer cell lines to different 
anticancer drugs.
Data are the mean IC50 values for at least 4 separate experiments (performed in 
quadraplicate) with standard deviation (±SD) in parentheses. IC50 values were determined 
as tlie drug concentration necessary to cause a 50% reduction in cell viability compared to 
untreated controls.
By expressing the IC50 value of the resistant cell line in terms of the dmg sensitive 
parental line (i.e. as a ratio), the level of drug resistance can be calculated for the resistant 
cell line. Hence, the MCF-7TaxR line showed a 77.7/6.5 = 11.9 fold increase in resistance 
to paclitaxel. However, the MCF-7TaxR cell line showed significant sensitivity (collateral 
sensitivity) to cisplatin and caiboplatin when compared to the parental MCF-7 cells. Witli 
doxombicin, the level of drug sensitivity was similai* in both MCF-7 and MCF-7TaxR 
cells. MDA-MB-231 cells showed the highest relative level of sensitivity to the anticancer 
dmgs examined. The IC50 of T47DTaxR cells indicates a decrease in sensitivity to 
cisplatin (approximately 1 .6  fold increase in resistance) and an approximately 6  fold
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increase in resistance to paclitaxel compaied with tlie parent T47D cells.
3.5.2 Preliminary testing of Z-VAD and paciitaxel response in 
MCF-7 and MCF-7TaxR cel is using the Trypan biue 
excision test
In this first phase of the work, I set out to investigate the overall death response in the 
selected human breast cancer cell lines. Preliminary testing was carried out as a guide for 
the design of the major experiments planned for subsequent stages of the work. Using the 
pan-caspase inhibitor Z-VAD, the contribution of apoptotic (caspase-mediated) cell death 
in response to paclitaxel treatment of the MCF-7 and MCF-7TaxR lines was examined. 
The testing was carried out using cells grown in 96 well plates incorporating paclitaxel 
treatment with or without Z-VAD. Cell death after 72 h of drug exposure was assessed 
with Trypan blue staining of cells and quantified using a haemocytorneter.
71
CHAPTER 3
MCF-7 cell line □  Paclitaxel□  Z -V A D f Paclitaxel
jg 40
20 50 100 200
Paclitaxel co n ce n tra tio n s  nM
500
MCF-TTaxR cell line □  Paclitaxel
□  Z -V A D f Paclitaxel
8I
mc
45
40
35
30
25
20
15
10
5
0
C 20 50 100 200 500
Paclitaxel c o n cn tra tio n s nM
Figure 3-2: Determination of the inhibitory effect of Z-VAD on apoptotic cell death 
in MCF-7 and MCF-7TaxR cells.
Cells were harvested following treatment with 100 |iM Z-VAD in the presence or absence 
of different paclitaxel concentrations for 72 h. Cells were stained with Trypan blue as 
described in Chapter 2, Materials and Methods. The percentage of cells staining with 
trypan blue represents the mean percentage of dead cells obtained from three independent 
experiments. Error bars are ± SD. C represents control untreated cells.
Figure 3-2 shows the effect of Z-VAD on MCF-7 and MCF-7TaxR cells in combination 
with paclitaxel treatment. The total average effect of Z-VAD treatment on paclitaxel- 
induced cell death was approximately 5.4% in MCF-7 cells. There was no apparent
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protection of cell death in MCF-7TaxR cells following incubation with Z-VAD.
3.5.3 Effect of staurosporine and Z-VAD on apoptotic cell 
death induction using Annexin V-FITC/PI staining
Annexin V-FITC/PI staining with flow cytometric analysis was performed to investigate 
the induction of non-apoptotic cell death in MCF-7 and MCF-7TaxR cells. The MDA- 
MB-231 cell line (which does not possess any deletions in caspases according to the 
cunent literature) was used as a positive control for apoptosis induction in these 
experiments. We used staurosporine treatment, as previously used by many others, for the 
induction of cell death (Xue et a l 2003). Staurosporine is a protein kinase inhibitor which 
induces cell growth arrest leading to cell death (Tamaoki et a l 1986). In addition, we used 
100 i-iM of Z-VAD (a pan caspase inhibitor) in order to assess the contribution of caspases 
in the cell death response in the different breast cancer cell lines. A concentration of 100 
pM Z-VAD was used, based on previous studies involved MCF-7 cell line (Kirsch et a l
1999), and also on our results, to give a maximal effect without giving rise to significant 
cell death over the experimental period. The treatment protocol for MDA-MB-231 cells 
was only for 24h (as opposed to 48h for MCF-7 lines) as this cell line is very sensitive to 
dmg treatment and a 48h exposure gave rise to very substantial cell death, making 
analysis difficult. The Annexin V-FITC/PI staining method is based on the use of two 
fluorescent probes, Annexin V conjugated to FIPC and propidium iodide (PI) in order to 
distinguish between viable, early apoptotic, late apoptotic, and necrotic cells.
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Figure 3-3: Annexin V-FITC/PI flow cytometric analysis of apoptotic cell death 
induction in human breast cancer cell lines.
The histograms are representative of typical data obtained. Cells were grown in T25 flasks 
and treated with 0.5 pM staurosporine or 100 pM Z-VAD or both for 24 h or 48 h. Cells 
were harvested and processed for Annexin V-FITC/PI staining analysis as described in 
Chapter 2, Materials and Methods, using flow cytometry. The data are presented in a four 
quadrant format: FI, necrotic or end stage apoptosis; F2, mid-phase apoptosis; F3, viable 
cell population; F4, early phase apoptosis.
Figure 3-3 depicts typical data obtained from the Annexin-V FITC/PI analysis. The results 
showed differences between staurosporine treatment versus staurosporine and Z-VAD 
treatments of 41.2 - 92.2%, 81.7 - 90.2% and 65.2 - 66% for MDA-MB-231, MCF-7 and 
MCF-7TaxR cells respectively.
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Figure 3-4: Apoptosis inhibition by Z-VAD treatment in MDA-MB-231 but not in 
MCF-7 and MCF-7TaxR cells.
The graph shows a significant level of apoptosis inhibition in MDA-MB-231 cells in 
response to Z-VAD treatment. MCF-7 and MCF-7TaxR showed no significant inhibition 
of apoptosis. Data shown (obtained from Annexin V -ve/ PI -ve cells (%) quadrant -F3) 
are the means of 4 independent experiments. Error bars represent ±SD. * indicates p-value 
< 0.005 using Student’s paired T-test. (NS) non significant.
Figure 3-4 summarises data obtained from the Annexin V-FITC/PI analysis of four 
independent experiments with the MDA-MB-231, MCF-7 and MCF-7TaxR cells using 
the Annexin V-FITC/PI method, as shown in Figure 3-3. The MDA-MB-231 cells, as a 
consequence of their caspase proficiency, showed significant differences between 
staurosporine treatments without and with Z-VAD treatment, as shown by the viable cell 
populations of 33.6% (±9.65) and 89.9% (±5.17), respectively p=0.004. MCF-7 cells 
showed no significant differences between staurosporine treatment without and with Z- 
VAD 73.2% (±25.69) versus 79.6% (±22.45), p=0.091. A modest effect of Z-VAD 
protection was seen but this contrasted with the effects seen for MDA-MB-231. MCF- 
7TaxR cells, showed no significant difference between staurosporine treatment without 
and with Z-VAD, 71.8% (±15.96) versus 75% (±19.36), p=0.234. Thus, the extent of 
caspase-mediated cell death (as assessed using Z-VAD protection) can be summarised as
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3.5.4 Nuclear Hoechst staining for examination of ceii death 
morphoiogy in human breast cancer ceiis
Nuclear staining was carried out to check cell death morphology in MCF-7, MCF-7TaxR, 
and T47D cell lines with Hoechst 33258 dye (as described in Chapter 2, Materials and 
Methods) after treatment with 1 pM staurosporine for 48 h. Images were collected using 
fluorescence microscopy.
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Figure 3-5: Fluorescence microscopy of the nuclear morphology changes in T47D, 
MCF-7 and MCF-7TaxR.
Control untreated cells are shown (a), (c), and (e) and cells treated with 1 pM 
staurosporine for 48 h shown in (b), (d) and (f). Cells were fixed and stained with Hoechst 
33258. Arrows show dead cells with apoptotic or non-apoptotic features. Magnification, 
40x. Images are representative of repeat experiments (n = 3).
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In Figure 3-5 (b), T47D cells treated witli 1 pM staurosporine for 48 h showed classical 
features of apoptotic cell deaüi associated with nucleai- fragmentation, chromatin 
condensation and formation of apoptotic bodies. Comparing image (b) with image (d), for 
staurosporine treated MCF-7 cells, features of cell death were apparent, with fragmented 
nuclei but no apoptotic body formation, not strictly consistent with apoptotic cell death. 
For MCF-7TaxR cells treated with staurosporine (f), the nuclei appeared intact with a 
relative reduction in cell number but no apoptotic cell death features as seen with 
staurosporine treated T47D cells.
3.5.5 Effect of anti-Fas induced apoptosis, detected using 
Annexin V- FiTC/Pi anaiysis
We went on to examine the effect of CD95 or anti-Fas in mediating apoptotic cell deatli in 
these cells. Cycloheximide (CHX) is an inhibitor of protein synthesis which can induce 
cell death by apoptosis (Tang et al. 1999). Many reports have mdicated that different cells 
become sensitised to cell death by agents such as staurosporine in the presence of 
cycloheximide, possibly due to enliancernent of DISC formation (Tang e ta l  1999). HeLa 
cells were used as a positive control for the effects of FAS and cycloheximide, in accord 
with the previous literature (Wajant et a l  2000). The treatment protocol for HeLa cells 
was only for 48 h (as opposed to 72 h for MCF-7 lines) as this cell line is very sensitive to 
anti-Fas treatment and a 72 h exposure gave rise to very substantial cell deatli, making 
analysis difficult. The experiment used the Annexin V-FITC/PI method of analysis, as 
above.
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Figure 3-6: Light microscopy images of MCF-7, MCF-7TaxR, and HeLa cells 
showing the effect of anti-Fas treatment.
Cells were treated with 200 ng/ml anti-Fas in the absence or presence of 1 pg/ml CHX for 
48 h for HeLa cells, or 72 h for MCF-7 and MCF-7TaxR. (Magnification, lOOx).
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Figure 3-6 shows tlie effect of anti-Fas on HeLa cells and served as a positive control for 
the experiment. The MCF-7 cell line showed some resistance to Fas-induced apoptotic 
cell death compared to the HeLa cell control, hi the case of MCF-7TaxR cells, there was 
also resistance to cell death induction in the presence of anti-Fas. Thus, the MCF-7 and 
MCF-7TaxR cell lines appeared refractory to Fas-mediated apoptosis.
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Figure 3-7: Annexin V-FITC/PI analysis of HeLa, MCF-7 and MCF-7TaxR cells 
shows the effect of anti-Fas and CHX in induction of apoptotic cell death.
The histograms are representative of typical data obtained. Cells were treated with 200 
ng/ml anti-Fas or 1 pg/ml CHX, alone or in combination for 48 h or 72 h. Cells were 
harvested and processed for Annexin V-FITC/PI staining analysis using flow cytometry, 
as described in Chapter 2, Materials and Methods. The data are presented in a four 
quadrant format: FI, necrotic or end stage apoptosis; F2, mid-phase apoptosis; F3, viable 
cell population; F4, early phase apoptosis.
Figure 3-7 shows a representative of typical data obtained from the Annexin-V FITC/PI 
experiments testing the effect of anti-Fas to induce Fas receptor-mediated apoptotic cell 
death in MCF-7, MCF-7TaxR, and HeLa cell lines. HeLa cells were sensitive to Fas- 
induced apoptosis (viable cell population after 48 h =71.3%), consistent with the findings 
of Wajant et al. (2000). In addition, cycloheximide amplified the sensitivity to apoptotic 
cell death (viable cell population =9.7%, but significant cell death was shown with
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cycloheximide alone with a viable cell population of only 16.5%). MCF-7 cells showed 
resistance to Fas-induced cell death with a viable cell population of 86.4%, which was 
reduced by a further 78.3% with the addition of cycloheximide. MCF-7TaxR cells showed 
resistance to anti-Fas, with a viable cell population of 93%, and the combined treatment 
resulting in 84% viability.
OFAS
DCHX
□  FAS+CHX
HeLa MCF-7 MCF-7TaxR
Figure 3-8: Anti-Fas resistance in MCF-7 and MCF-7TaxR cells.
Data shown (obtained from Annexin V -ve/ PI -ve cells (%) quadrant -F3) are the mean of 
3 independent experiments of Annexin V-FITC/PI analysis. Cells were treated with 200 
ng/ml anti-Fas + 1 pg/ml CHX for 72 h. Error bars are the ±SD with levels of statistical 
significance designated by *= <0.005 using Student’s paired T-test. (NS) non-significant, 
for MCF-7 and MCF-7TaxR, p=0.1 and p=0.14, respectively.
As seen in Figure 3-8, in the presence of cycloheximide and anti-Fas treatment, MCF-7 
and MCF-7TaxR cells showed no significant differences compared to control or single 
anti-Fas treatment, which indicates that neither cell line undergoes receptor-mediated cell 
death.
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3.6 Discussion
There is now ample evidence to support the role of cell death mechanisms - particularly 
apoptosis - as important factors governing tumour cell responsiveness to chemoüierapeutic 
agents (Yang et a l 2007). However, one of the major factors related to abnormalities in 
apoptosis is change in caspase expression in cancer cells. Yang et al. (2007) obseiwed that 
defects in, or downregulation of, caspases may be potentially frequent events in breast 
cancer, thus leading to cancer cell progression and development of cancer resistance to 
chemotherapy.
This chapter focused on the use of in vitro drug resistant tumour cell line models to study 
apoptotic cell death pathways and associated mechanisms underlying the altered response 
to cytotoxic agents. We showed that the parental MCF-7 cells will die according to a 
mechanism that par tially involves apoptosis, but a fraction of the cells will die from some 
oüier form of cell death. Importantly, we show here that the paclitaxel-resistant breast 
cancer cell line MCF-7TaxR exhibited the induction of an exclusively non-caspase 
dependent cell death in response to cytotoxic insult.
The cytotoxicity of paclitaxel was determined from data generated using the MTT assay. 
The level of paclitaxel resistance in the MCF-7TaxR cells was calculated as 
approximately 12-fold. Interestingly, MCF-7TaxR cells showed a collateral sensitivity to 
cisplatin and caiboplatin compared to tire parent MCF-7 cells. Levels of sensitivity for 
MCF-7 and MCF-7TaxR to doxorubicin are similar. The Trypan blue screening 
experiment led us to consider the nature of the negligible effect of Z-VAD and compare 
the differences between the MCF-7TaxR and MCF-7 cell lines when exposed to an
85
CHAPTER 3
anticaiicer agent such as paclitaxel. Staurosporine is known as a potent and non-specific 
protein kinase inhibitor and a strong inducer of apoptosis (Tamaold et al. 1986). 
Therefore, it was used as a tool for cell death induction in the Annexin V-FITC/PI 
analysis. It has been reported in the literature that MCF-7 possesses a genetically defective 
form of caspase-3, an important apoptosis inducing effector molecule (Janicke et al. 1998; 
Yang et al. 2001). Furüieimore, a caspase-3-independent pathway for apoptosis in 
staurosporine treated MCF-7 cells has been demonstrated (Janicke et al. 1998). However, 
staurosporine has been shown to initiate death activation in MCF-7 cells mediated by 
caspase activation (Kirsch et al. 1999). Importantly, MCF-7TaxR cells showed no 
significant differences between staurosporine treatment alone or combined with 100 pM 
Z-VAD. The nucleai" morphology appeared fragmented following staurosporine treatment 
in MCF-7 cells- with atypical apoptotic features. It was reported that the lack of caspase-3 
in MCF-7 cells may prevent DNA fragmentation following staurosporine treatment 
(Janicke et al. 1998). The MCF-7TaxR cells treated with staurosporine appeared to be 
undergoing a cell death process with no resemblance to apoptosis. The Fas/CD95 and its 
ligand FasL mediated cell death pathway requires the activation of F ADD, leading to 
caspase-8 activation and triggering the protease cascade which activates the downstream 
effector caspases, caspase-3, -6, -7 (Kuida et al. 1996; Scaffidi et al. 1998). Different 
studies have been reported for the MCF-7 human breast cancer cell line and they indicate 
modest Fas expression, but the cells still possess resistance to Fas-mediated apoptosis 
(Keane et al. 1996; Naujokat et al. 1999). Moreover, Xue et al. (2003) showed that 
caspase-8 and the pro-apoptotic protein Bid were inactivated in MCF-7 cells treated with 
staurosporine upon their commitment to cell death. Our data obtained on MCF-7 cells 
indicating resistance to Fas also agrees witli the work of Naujokat et al. 1999 and Keane et
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a l 1996. There was also marked resistance to Fas mediated cell death seen for MCF- 
7TaxR cells. A study by Lukyanova et a l (2009) showed that MCF-7 cells with resistance 
to cisplatin and doxombicin are characterised by alterations in expression of apoptotic 
proteins (Lukyanova et a l 2009). However, in contrast, our results indicate that MCF- 
7TaxR cells may induce cell death in a wholly caspase independent manner in view of 
experiments involving use of Z-VAD,
Other studies, presented by Xue et a l (2003), revealed that the presence of caspase-3 in 
MCF-7 cells by caspase-3 transfection showed the importance of this enzyme in inducing 
rapid apoptosis, compared to the original MCF-7 line (Buckley et a l 1999; Friedrich et a l 
2001; Yang et a l 2001; Xue et a l 2003). In addition, the paclitaxel resistant MCF-7TaxR 
cell line under study herein is caspase-3 deficient, but shows collateral sensitivity to 
platinum agents compared with the parent MCF-7 cells. Therefore, an important question 
may be asked: what is the mechanism of cell death in human breast cancer cells induced 
by chemotherapeutic agents when caspase-3 is absent? The activity of caspase-3 is 
important in mediating cell death in MCF-7 ; however, there is a possibility that caspase-7 
can only partially compensate for this deletion, at least for MCF-7 cells. Consequently, 
more investigations determining the pr'esence and level of caspases in MCF-7 and MCF- 
7TaxR cell lines are required in order to understand how die system of apoptotic cell death 
is being modulated in response to chemotherapeutic insult. These investigations will be 
carried out in the next chapters to confiim or clarify the apparent lack of caspase 
dependent cell death in MCF-7TaxR cells.
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4 Characterisation o f Paclitaxel Resistant M C f-7
Breast Cancer Cells: Expression o f Apoptotic 
Genes
4.1 Gene Microarray
The evolution of gene micro array technology has revealed novel prospective therapeutic 
targets with the potential of producing new dmgs (Jayapal and Melendez 2006). In 
addition, micro array technology has been important in determining genetic causes of 
various human diseases (Debouck and Goodfellow 1999). Gene micro arrays- which refers 
to a gene array or DNA micro array - have been used in examining multiple types of 
cancers such as breast cancer, prostate cancer and colon cancer (Alon e ta l  1999; Pérou et 
a l 1999; Pérou et a l 2000). This technology allows the examination of thousands of 
genes and their expression at tire same time (Jayapal and Melendez 2006). Micro arrays 
provide information on gene products that are expressed in cancer cells but not in normal 
cells, thus aiding in the detection of tumour markers for diagnostic purposes (Schulze and 
Downward 2001). Moreover, micro array technology is capable of differentiating between 
gene expression in clinically distinct subtypes of leukaemia, lymphoma, breast cancer and 
melanoma (Alon et a l 1999; Alizadeh et a l 2000; Bittner et a l 2000; Pérou et a l 2000).
MicroarTay technology uses RNA extracted from cells or tissue or other biological source 
ruaterials to determine the expression levels of many genes. This technology consists of a 
set of distinct gene-specific, nucleic acid probes imruobilized on a solid support. Thus, 
during a microarTay experiment, RNA is converted to labelled cDNA or RNA by 
enzymatic reactions and, subsequently, hybridized to the immobilized nucleic acid probe.
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The labelled target binds to each gene-specific spot which is typically detected using 
cheiniluminescent, fluorescent or radioactive methods. Each spot produces a signal that 
corresponds to the amount of a message in the original RNA sample.
4.2 Aim
According to data obtained in Chapter 3, caspase dependent apoptotic cell death is absent 
in the MCF-7TaxR cell line and a modest level of apoptosis is observed in MCF-7 cells. 
Therefore, we set out to clarify the specific genetic changes correlated with the lack of 
apoptosis in the MCF-7TaxR paclitaxel resistant cell line. We have obtained a specific 
112 apoptosis gene micro array profile for the MCF-7 and MCF-7TaxR cell lines, hi 
addition, Q-PCR and immunoblotting analyses were carried out for caspase detection as a 
confirmation of the microarray data in the cell lines under investigation.
90
CHAPTER 4
4.3 Results
4.3.1 Apoptosis GEArray analysis for MCF-7 and MCF-7TaxR
cells
Here, we carried out RNA extraction from the MCF-7 and MCF-7TaxR cell lines as 
described in Chapter 2 (Materials and Methods), and assessed the quality and quantity of 
the samples, as previously described. RNA samples for microarray analysis were 
processed by the SuperArray Corp™ (Frederick, California, USA), a commercially 
available service, using the “Apoptosis GEAray DNA Microarray" system. This analysis 
allowed the identification and semi-quantitation of genes associated with the apoptosis 
pathway. The apoptosis array is designed to determine the expression profile of genes tliat 
encode key ligands, intracellular* modulators, receptors, and transcription factors involved 
in the regulation of prograrumed cell death.
The gene list obtained from 3 separate analyses is shown in Table-4.1. The data show the 
most significantly altered gene expression levels comparing the MCF-7 parent cells with 
the paclitaxel resistant MCF-7TaxR cells. The data confirmed the absence of caspase-3 in 
both cell lines, as expected. The caspase-3, 4, 5, 6, 7, and 9 genes were absent from the 
MCF-7TaxR cell line; caspase-6, 7, and 9 were present in tire parent MCF-7 cells. 
Moreover, other major genes in the apoptotic machinery, such as APAFl, Bcl-2, BID, 
F ADD and TNF were absent from the MCF-7TaxR cells, but present in MCF-7 cells. Fas 
gene was absent in MCF-7 and MCF-7TaxR cells.
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(b)
(a)
I
GENE MCF-7 MCF-7TaxR GENE FUNCTION
APAFl P (A) Important for caspase-9 activation foi lowing cytocfirome c release
BAK1 P P Pro-apoptotic protein
BAX P P Stimulates mitochondrial membrane damage
BCL2 P (A) Pro- and anti-apoptotic proteins
BID P (A) BH3 only protein
BIK (A) (A) BH3 only protein
CASP1 (A) (A) Role in cell death induced by activation of inflammasome
CASP2 P P Initiator/executioner caspase
CASP3 (A) (A) Executioner caspase
CASP4 (A) (A) Maturation of cytokine function
CASP5 (A) (A) Maturation of cytokine function
CASP6 P (A) Executioner caspase
CASP7 P (A) Executioner caspase
CASP8 P P Initiator caspase in receptor mediated cell death
CASP9 P (A) Initiator caspase, important for mitochondrial cell death pathway
CASP10 (A) (A) Initiator caspase in receptor mediated pathway
FADD P (A) Adaptor protein, component of DISC, the complex promoting 
activation of caspase-8
TNF P (A) Tumour necrosis factor, required for caspase-8 activation
FAS (A) (A) Fas, receptor important for inducing extrinsic pathway
Table 4-1: Table 4-2: Apoptosis gene list obtained for MCF-7 and MCF-7TaxR cells 
using tbe SuperArray Apoptosis GEArray© system.
(a) Figure showing microarray analysis of apoptotic genes spotted and assembled on an 
immobilising solid support, (b) Table showing the major apoptotic gene expression levels 
in MCF-7 and MCF-7TaxR cell lines (with gene function described), (P) = presence of 
gene expression; (A) = absence of gene expression. Data obtained from 3 separate 
analyses.
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4.3.2 Demonstration of caspase-8 expression in MCF-7 and 
MCF-7TaxR ceils by immunoblotting
Caspase-8 is a crucial factor for initiating the extrinsic apoptotic pathway (Mita et al. 
2006). Therefore, it is important to demonstrate the expression of caspase-8 in MCF-7 and 
MCF-7TaxR, in order to verify the existence of the extrinsic apoptotic pathway in these 
model systems.
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Figure 4-1: Western blotting for caspase-8 expression in untreated MDA-MB-231, 
MCF-7 and MCF-7TaxR cells, or cells exposed to staurosporine 48 bours.
Whole cell lysates were prepared following a 48 h staurosporine treatment, as described in 
the Materials and Methods. Samples (50|ig protein) were electrophoresed on a 10% 
polyacrylamide gel, transferred to a PVDF membrane, and exposed to monoclonal 
caspase-8 antibody (Cell Signaling Technology®). Bands were detected using a 
chemiluminescent substrate (Invitrogen™). (Data shown were obtained by Dr. Helen 
Coley, UniS).
Earlier studies were carried out by Dr. Helen Coley for the detection of caspase-8 in the 
MCF-7 and MCF-7TaxR cell lines. The MDA-MB-231 cell line was included in this 
analysis as a positive control for caspase-8 expression. Figure 4-1, (data obtained from Dr. 
Helen Coley), shows clear constitutive caspase-8 expression in MCF-7 and MCF-7TaxR 
cells. The MDA-MB-231 cells constitutively expressed pro-caspase-8 (55kDa), the levels
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of which were diminished following staurosporine treatment as a consequence of caspase 
activation (data not shown). Interestingly, the extent of caspase-8 activation for botli 
MCF-7 and MCF-7TaxR cells appeared to be less than that seen with the caspase 
proficient line MDA-MB-231.
4.3.3 Detection of apoptotic caspases and Bcl-2 anti-apoptotic 
protein in MCF-7 and MCF-7TaxR cells
According to the microaiiay data, the genes for caspase-7, caspase-9 and Bcl-2 were not 
expressed in MCF-7TaxR cells, but were expressed in tlie parental MCF-7 cells. To verify 
these data, Western blotting analysis was carried out to confirm the levels of caspase-7, 
caspase-9 and Bcl-2. This analysis was also carried out following paclitaxel and 
staurosporine treatment of MCF-7 and MCF-7TaxR cells in order to give an indication of 
functionality. Also, other human breast cancer cell lines were used as positive controls in 
the Western blotting analysis, i.e. MDA-MB-231, MDA-MB-231 VPR (etoposide 
resistant), T47D and the paclitaxel resistant T47DTaxR cell lines for die detection of 
caspase-7 and caspase-9.
94
CHAPTER 4
O
%
(/)
S
9
5)
2r^
uccs
tn
«occ%
2ccI
Pro-caspase-7 35 kDa 
Cleaved caspase-7 30 kDa 
20 kDa
Pro-caspase-9 47kDi 
Cleaved caspase-9 3SkDa
(a) p-Actin
Pro-caspase-7 SSkDa
(b) P-Actin
Figure 4-2: Western blotting for caspase-7 and caspase-9 expression of wbole cell 
lysates of MCF-7 and MCF-7TaxR cells with staurosporine or paclitaxel treatment.
In (a) and (b), cell lysates were made following a 1 pM staurosporine treatment for 24 h, 
48 h, or treatment with 100 nM paclitaxel for 48 h or 72 h, as described in the Materials 
and Methods. Samples (50pg protein) were electrophoresed on a 10% polyacrylamide gel, 
transferred to a PVDF membrane and exposed to monoclonal anti-mouse caspase-7, or -9 
(Cell Signaling Technology®) at 1:1000 dilutions and exposed to anti-mouse alkaline 
phosphatase ( I n v i t r o g e n ™ ) .  Bands were detected with a chemiluminescent substrate 
(Invitrogen^^). Data are representative of repeat experiments (n = 4).
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As seen in Figure 4-2, MCF-7 cells expressed pro-caspase-7 and caspase-9 with partial 
activation, shown by the appearance of cleaved forms, following staurosporine treatments 
and lesser activation of pro-caspase-7 with paclitaxel treatment. In marked contrast, the 
MCF-7TaxR cells showed a complete lack of caspase-7 and caspase-9 expression, as seen 
for all samples analysed. These data are in agreement with the microarray data (Table 4- 
1). Absence of these proteins in MCF-7TaxR cells is highly suggestive of a major defect 
in the intrinsic apoptotic pathway.
Pro-caspase-7 35k Da 
Cleaved caspas-7 30kDa
Pro-caspase-9 47kDa
p-Actin
(O
&
Figure 4-3: Western blotting for caspase-7 and caspase-9 constitutive expression of 
MDA-MB-231, MDA-MB-231VP16R, T47D and T47DTaxR cells.
Cells were lysed as described in the Materials and Methods. Samples (50pg protein) were 
electrophoresed on a 10% polyacrylamide gel, transferred to a PVDF membrane and 
exposed to monoclonal caspase-7, or -9 antibodies (Cell Signaling Technology®) at 
1:1000 dilution and exposed to anti-mouse alkaline phosphatase (Invitrogen™). Bands 
were detected using a chemiluminescent substrate (Invitrogen™). Data are representative 
of repeat experiments (n = 3).
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The Western blotting analysis in Figure 4-3, showed that T47D, T47DTaxR, MDA-MB- 
231 and MDA-MB-231 VPR cells express caspase-7 and caspase-9 constitutively, and the 
levels do not appear to change with the acquisition of a drug resistant phenotype. The 
evidence for a small band of activated, cleaved caspase-7 is sometimes noted for cells in 
culture but is not considered to be of any great significance.
Bcl-2 26kDa>
p-Actin
Figure 4-4: Western blotting analysis for Bcl-2 expression in control and 
staurosporine or paclitaxel treated MCF-7 and MCF-7TaxR cells.
Whole cell lysates were made following 24 h or 48 h staurosporine treatment, as described 
in the Materials and Methods. Samples (50pg protein) were electrophoresed on a 10% 
polyacrylamide gel, transferred to a PVDF membrane and exposed to monoclonal anti­
mouse Bcl-2 (Santa Cmse. Inc) at 1:1000 dilution and exposed to anti-mouse alkaline 
phosphatase (Invitrogen™). Bands were detected by chemiluminescent substrate 
(Invitrogen™). Data are representative of repeat experiments (n = 3).
Figure 4-4 shows a total absence of Bcl-2 expression in MCF-7TaxR cells compared to 
MCF-7 cells, in both control and staurosporine treated cells. These data are in agreement 
with the apoptosis microarray results shown above.
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4.4 Quantitative PCR anaiysis of caspase-7  and -9 
mRNA expression
As shown in previous sections of this chapter, there is no expression of caspase-7 or 
caspase-9 in tlie paclitaxel resistant MCF-7TaxR cell line. To confirm this observation, we 
performed quantitative PCR analysis for MCF-7 and MCF-7TaxR. RNA was extracted 
from MCF-7 and MCF-7TaxR cells with the Trizol reagent, as described previously in 
Chapter 2, section 2.12. The PCR method used the QIAGEN® One-step QuantiTect® 
SYBR® Green RT-PCR reagents. The PCR reactions were carried out using a TaqMan® 
700 ABI Prism instmment (Applied Biosystems). The Act values were calculated as the 
relative differences between expression levels of test genes (caspase-Jand -9) and a house 
keeping gene (p-actin). The fold change was equal to 2^'^
Human caspase-7 and caspase-9 primers were obtained from SuperArray® as 10 pM 
working solutions. The primers were designed for amplification of tlie NM_001227.3 
fragment of the caspase-7 gene and the NM_001229.2 fragment of the caspase-9 gene. 
Caspase-7 human gene sequence primer 5 ’-3 Forward, 
CCGTGGGAACGTAAGAAGAA; Reverse, GTCTTGATGGATCGCATGG.
Caspase-9 human gene sequence primer 5 ’-3’\ Forward,
CCTGCTTAGAGGACACAGGC; Reverse, TTCGACAACTTTGCTGCTGCTTG.
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Figure 4-5: qPCR analysis for caspase-7 and caspase-9 expression in the MCF-7 and 
MCF-7TaxR cell lines.
Act levels of caspase-7 and caspase-9 mRNA were significantly diminished in MCF- 
7TaxR cells. Data shown are the mean of 3 repeat experiments (performed in duplicate); 
error bars indicate ±SD.
The data in Figure 4-5 show clearly that the caspase-7 and caspase-9 gene expression was 
virtually undetectable in the MCF-7TaxR cell line. These data are in agreement with the 
microarray data and the Western blotting analysis shown above.
4.5 Discussion
A large body of evidence has been established that supports the notion that apoptotic 
defects can develop in a cancer cell (Jaattela 1999; Evan and Vousden 2001). Moreover, 
these defects occur following exposure to chemotherapeutic agents during the 
development of drug resistance in tumours (Jaattela 1999; Evan and Vousden 2001). 
These processes contribute to cancer progression and tumour proliferation (Jaattela 1999; 
Evan and Vousden 2001). In the present work, the paclitaxel resistant MCF-7TaxR cells 
showed major alterations and defects in the apoptosis pathway as a consequence of 
developing paclitaxel resistance. The absence of a number of effector and executioner 
caspases was shown in MCF-7TaxR cells. These results agree with the previous data in
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Chapter 3, which showed the induction of non-caspase dependent cell death in response to 
treatment of these cells with cytotoxic agents. In contrast with the MCF-7TaxR line, death 
may be induced in the parental MCF-7 cells according to a mechanism that involves some 
apoptosis and potentially some other form of cell death. A number of studies have 
reported the significance of MCF-7 breast cancer cells as a perfect tool for studying 
apoptosis or other altered forms of cell death mechanisms due to tlieh lack of caspase-3 
expression (Simstein et al. 2003). The MCF-7 cell line has been proposed to be an ideal in 
vitro model for the study of caspase independent cell death (Kurokawa et al. 1999; 
Simstein e ta l  2003).
The microarray analysis, Western blotting and qPCR analysis we carried out has provided 
us with ample evidence of a lack of caspases in our novel drug resistant breast cancer fine 
MCF-7TaxR. The microarray analysis confirmed the absence of the caspase-3 gene from 
MCF-7 cells, consistent with previous work (Janicke et a l  1998; Buckley et a l  1999; 
Friedrich et a l 2001; Yang et a l 2001; Xue et a l 2003). In addition, and as we expected, 
caspase-3 is lacking in tlie MCF-7TaxR cell line. Our contributions to studies on breast 
cancers, along with the work of others, indicate that the lack of caspase-3 transcription and 
protein expression may be an important factor in tlie pathogenesis of breast cancer 
(Devarajan et a l 2002). hiiportantly, a lack of caspase expression has been cited as an 
important and frequent phenomena. Moreover, in the case of caspase-3, low or 
unmeasurable levels have been reported for approximately 75% of breast cancers 
(Devai'ajan et a l 2002). Considering other caspase foims, caspases -4 and -5 are involved 
in the maturation of cytokine function (Galluzzi et a l 2008). Microairay analysis showed 
that the caspase-4 and -5 genes were also lacking in MCF-7TaxR and MCF-7 cells, and,
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based on then- function, there is a suggestion that tlieir role in apoptosis is not as crucial as 
other caspases (Marzo et al. 1998; Martinon and Tschopp 2004).
The MCF-7TaxR paclitaxel resistant cell line showed that the greater proportion of its 
apoptotic machinery was either lacking or markedly down-regulated. Caspase-7 may 
compensate for tlie lack of caspase-3 function in the case of MCF-7 cells (Twiddy et a l 
2006). In fact, it has been reported tliat caspase-7 and caspase-3 are almost identical in 
their substrate specificity (Fernandes-Alnemri e ta l  1995). In addition, cells that possess a 
defect in the caspase-7 gene are more resistant to apoptotic cell death-inducing drugs and 
cause a delay in the extemalization of phosphatidylserine (as measured by the Annexin V- 
FITC/PI method) and in DNA fragmentation (Korfali et a l 2004). A previous study 
revealed tliat a loss in apoptotic activity may occui” when caspase-7 is mutated in cancers 
(Soung et a l 2003). Thus, our data and previous studies suggest that somatic mutation, 
deletion, or silencing of caspase-7 may be involved in the apoptotic resistance of cancer 
cells (Soung et a l 2003). Therefore, the lack of caspases-6, and -9 in MCF-7TaxR cells 
suggests that the route of cell death in this cell line is predominantly non-caspase 
dependent.
The data obtained thus far prompt an important question: how does the MCF-7TaxR cell 
line commit to cell death in response to chemotherapeutic dmg exposure? Both caspase-9 
and Apaf-1 are required for initiating the mitochondrial pathway and DNA damage. A 
study showed that the absence of Apaf-1 expression or activity may impair formation of a 
functional apoptosome in numerous cancers, e.g. melanoma, leukaemia, glioblastoma, and 
gastric cancer (Pommier et a l 2004). Therefore, according to our data, the absence of
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caspase-9 and Apaf-1 in MCF-7TaxR strongly suggests the lack of commitment to the 
intrinsic pathway of apoptosis.
The Fas-associated deatli domain (FADD) protein requires the TNF-receptor associated 
death domain (TRADD) protein, resulting in apoptosis via activation of caspase-8 through 
the extrinsic pathway (Ashkenazi and Dixit 1998; Lowe and Lin 2000). This leads to 
activation of the other caspases causing cleavage of cellular targets and, thus, apoptotic 
cell death results (Ashkenazi and Dixit 1998; Lowe and Lin 2000). As a consequence, 
defects in FADD can prevent the activation of caspase-8 and, consequently, weaken the 
receptor mediated cell death pathway or the apoptotic extiinsic pathway (Yeh et al. 1998; 
Lowe and Lin 2000). It has been widely reported that there is cross-talk between the two 
apoptotic pathways -  extrinsic and intrinsic - since they share the executioner caspases, 
caspase-3, caspase-7 and caspase-6, in addition to the involvement of Bid cleavage (Mita 
et al. 2006). Furthermore, the mitochondrial regulators can be changed or disrupted in 
their function by the extrinsic pathway regulator (Mita et al. 2006). Hence, each pathway 
can interact and influence the other to induce cell death (Mita et al. 2006). Other studies 
have reported changes in the response of apoptosis to chemotherapy in breast cancer (Mita 
et al. 2006). According to all these different studies, TNF, Fas, and the death domain of 
FADD are vital elements in initiating extrinsic apoptosis (Bodmer et al. 2000; Kuang et 
al. 2000; Kischkel et al. 2001; Suliman et al. 2001). Importantly, in the present study, all 
these elements are absent from the MCF-7TaxR cells according to the microarray data, in 
addition to loss of executioner caspases (-3,-7,-6). Moreover, this result explains the 
resistance of MCF-7TaxR to anti-Fas (as shown in Chapter 3). Although earlier findings 
(by Dr Helen Coley) revealed the expression of caspase-8 in botli MCF-7 and MCF-
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VTaxR cell lines, there was some indication tliat there was minimal activation of this 
caspase form following staurosporine treatment (see Figure 4.1). The microarray data 
revealed the presence of caspase-10 in MCF-7TaxR and MCF-7 cells, but it has been 
suggested that caspase-8 and -10 may not be activated due to major apoptosis defects in 
Fas, TNF, and FADD, as well as the absences of the executioner caspases-3,-6,-7, the 
effector caspase-9, and Apaf-1 in MCF-7TaxR cells.
Bcl-2 family members serve as pro- and anti-apoptotic regulators, each consisting of 
between one and four Bcl-2 homology (BH) domains. The anti-apoptotic members Bcl-2, 
Bcl-XL, Bcl-w, Bcl-b, Mcl-l, and A1 all contain four BH domains (Petros et al. 2004). 
The pro-apoptotic Bcl-2 members contain between one and three BH domains; the pro- 
apoptotic members Bax, Bak and Bok contain BH domains 1-3 (Petros et al. 2004). The 
other pro-apoptotic members, such as Noxa, PUMA, Bad, Bim, Bis and Bik, containing a 
single BH-3 domain (so-called BH3-only proteins) as well as otlier functional domains 
which may control protein stability or allow interactions witli other regulators (Petros et 
al. 2004). Many earlier investigations concentrated on studying tlie interactions between 
these proteins and how the ratio of pro- to anti-apoptotic Bcl-2 family members controls 
the release of cytochrome c (Logue and Maitin 2008). The microarray data showed that 
Bid (coding for a BH-3 only protein) is absent from MCF-7TaxR cells. This particular 
pro-apoptotic BH3-only protein may serve as an important link between the extrinsic and 
intrinsic pathways of apoptosis since it is cleaved to a more active form, tBid (truncated 
Bid), by caspase-8 which is itself activated following engagement of death receptors (Mita 
et al. 2006). In the absence of executioner caspases, the unavailability of the pro-apoptotic 
protein Bid, even though caspase-8 is available, would severely compromise any apoptotic
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response -  as is the case in MCF-7TaxR cells. These data confh'm that the extrinsic and 
intrinsic pathways cannot function in response to cytotoxic insult, hi addition, the 
microarray data and Western blotting analysis also revealed a complete absence of Bcl-2 
from the MCF-7TaxR cells. Bcl-2 is an anti-apoptotic protein and its absence in the MCF- 
7TaxR cell line is supposed to promote the induction of apoptosis. However, the story is 
entirely different in this particular cell line, since the absence of Bcl-2 would indicate a 
pro-apoptotic effect, but, due to the substantial lack of the most cmcial apoptosis 
machineiy, caspase-3, -4, -5, -6, -7, -9, 10 and Apaf-1, Bid, Fas, TNF, FADD, TRADD, 
apoptosis is a very unlikely event for these cells.
On the one hand, the executioner caspases, caspase-6, -7, are present in MCF-7 cells, 
suggesting that they may compensate for the absence of caspase-3 as tlie executioner 
caspase (Tang et a l 2000). These executioner caspases have been shown to promote 
apoptosis by cleaving cellular substrates that induce the moiphological and biochemical 
features of apoptosis (Wolf and Green 1999). Blanc et a l (2000) studied the influence of 
caspase-3 and how it is necessary in regulating the mitochondrial pathway through 
caspase-9 activation. Cytochrome c release from mitochondria occurs following cisplatin 
treatment and was controlled by transfected caspase-3 in MCF-7 cells (Blanc et a l  2000). 
The data also showed that cytochrome c release may be partially regulated or affected by 
the caspase-3 substrate by causing a delay in cytochrome c release in caspase-3 deleted 
MCF-7 cells (Blanc et a l 2000). The effector caspases-8, -9, -10 are still present in the 
MCF-7 cell line, as confirmed in the microaiiay data. Caspase-8 expression in MCF-7 
cells was confirmed earlier by Dr. Helen Coley. A study by Xue et a l (2003), showed that 
caspase-8 and Bid were not activated in staurosporine treated MCF-7 cells (lacking
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caspase-3), but were activated in MCF-7 cells transfected witli caspase-3 (Xue et al. 
2003). Moreover, our Western blotting analysis confirmed that caspase-7 and caspase-9 
were constitutively expressed in untreated MCF-7 control cells and became paitially 
activated in cells treated with staurosporine. However, there was lesser activation of 
caspase-7 by MCF-7 cells following paclitaxel treatment. According to our study, MCF- 
7 cells successfully activate the mitochondrial apoptotic cell death pathway in response to 
treatment with anticancer drugs. In agreement, a study by Twiddy et al. (2006), showed 
that MCF-7 cells may undergo mitochondrial dependent apoptosis via caspase-7 activation 
(Twiddy et al. 2006). This result agrees with our finding that caspase-7 may compensate 
for caspase-3 absence as an executioner caspase in MCF-7 cells. However, in the present 
study only a modest activation of caspase-7 was evident following cell stress induction via 
paclitaxel treatment of MCF-7 cells. This occuiTed in spite of very marked morphological 
changes of the cultures which were suggestive of loss of cell viability (data not shown).
In our study, the microaiiay data indicated an absence of Fas gene expression, which 
indicated that the extrinsic pathway is partially compromised, in the MCF-7 cell line. This 
finding is also consistent witli our previous findings fi'om Chapter 3, when we carried out 
the Annexin V-FITC/PI experiment in order to examine the induction of apoptosis by Fas. 
MCF-7 cells showed resistance to anti-Fas treatment, as shown previously (Naujokat et al. 
1999). Although MCF-7 cells are proficient in TNF and FADD gene expression 
(according to our apoptosis microarray analysis). Fas is essential for caspase-8 activation 
leading to cytochrome c release (Blanc et al. 2000; Twiddy et al. 2006). Thus, our 
observation in MCF-7 cells suggests drat the apoptosis pathway mediated by caspase-8 is 
non-functional in response to anticancer drugs due to the lack of Fas, and this obseivation
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is consistent with previous findings (Naujokat et al. 1999; Xue et al. 2003). Moreover, 
cytochrome c release from the mitochondria and caspase-8 activation by Fas have both 
been implicated in chemotherapy-induced apoptosis (Friesen et al. 1996; Boesen-de Cock 
et al. 1999; Fulda et al. 1999; Blanc et al. 2000). MCF-7 cells may undergo apoptosis in 
response to chemotherapy through the intiinsic pathway, involving sequential activation 
of caspase-9 and -7 (Twiddy et al. 2006; Coley 2008). One study showed that activation 
of both die intrinsic and extrinsic apoptotic pathways in MCF-7 cells treated with 
selenadizole derivatives, which is inconsistent with our finding and previous studies (Chen 
et al. 2008).
The pro- and anti- apoptotic Bcl-2 family proteins are key regulators in the apoptotic 
pathway. Different studies of die Bcl-2 protein, which examined induction of apoptotic 
cell death by chemotherapeutic agents or ionizing radiation, demonstrated that 
overexpression of Bcl-2, localized in the mitochondrial membrane, may prevent cell death 
(Vaux et al. 1988; Nunez et al. 1989; Hockenbery et al. 1990). The Bcl-2 protein was 
shown to be constitutively expiessed in MCF-7 cells in control and dmg treated cells. A 
previous study showed that overexpression of Bcl-2 can inhibit apoptosis induced by most 
chemotherapies such as alkylating agents and topoisomerase inhibitors (Karnesaki et al. 
1993; Walton et al. 1993; Pommier et al. 2004). These previous reports provide evidence 
that apoptosis could, under some circumstances, be inhibited in MCF-7 cells. In addition, 
MCF-7 cells have more recently been considered as a model of non-caspase-mediated cell 
death, or as a representative model of autophagy (Ogier-Denis and Codogno 2003). 
Different studies have explored the possibility of autophagic cell death in MCF-7 cells 
when tieated witli different chemotherapies. A study by Fazi et al. (2008), showed the
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induction of autophagic cell death in response to the drug Fennetinide in the MCF-7 cells 
and also showed the induction of apoptosis in caspase-3 reconstituted MCF-7 cells (Fazi 
et al. 2008). This means that when apoptosis is defective, autophagic cell death may take 
over (Lefranc et a l 2007; Fazi et al. 2008). We and others have suggested that the MCF-7 
cell line can commit to cell death by apoptosis and autophagic cell death.
In summary, the MCF-7TaxR cell line is a novel cell line due to the profound absence of 
apoptotic genes (Figure 4-5). The microarray data presented in this chapter gave us an 
insight into the complexity of the modifications occurring in the MCF-7TaxR cell line as a 
consequence of the drug resistant phenotype and are consistent with earlier data in Chapter 
3. Our data confirmed, for the first time, that dmg resistant cancer cells, such as the MCF- 
7TaxR cell line, may fail to undergo apoptotic cell deatli. All the apoptotic defects that 
may be present result in a cancer cell that, although compromised in its ability to carry out 
apoptosis, may commit caspase-independent cell death. Therefore, our data are strongly 
suggestive of the presence of an alternative form of cell death for MCF-7TaxR cells. At 
this stage, I hypotliesized this to be the second type of programmed cell death: autophagy.
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Figure 4-5: Major alterations in apoptosis, PCD I, occur in the MCF-7TaxR cell line.
All the main components of executioner caspases are absent in MCF-7TaxR cells, in 
addition to caspase-9, Apaf-1, Fas, Bid, TNF, FADD and TRADD.
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5 Characterisation o f Paclitaxel Resistant MCF-7 
Breast Cancer Cells: Changes in Expression o f  
Proteins During The Evolution o f Drug Resistance
5.1 Multiple drug resistance (MDR)
One of the major problems that faces breast cancer patients undergoing chemotherapeutic 
treatment is the development of multi-drug resistance (MDR), resulting in a failure to cure 
the disease (Gottesman and Ling 2006; Higgins 2007; Coley 2008; McGrogan et al. 
2008). Multi-dmg resistance is a phenomenon in which cancer cells, exposed to one 
anticancer dmg, simultaneously show resistance (cross-resistance) to various anticancer 
dmgs that are stmcturally and functionally different from the initial anticancer dmg, 
resulting in an acquired resistance tenned multi-drug resistance (MDR) (Gottesman et al. 
2002; Yusuf e? al. 2003; Choi 2005; McGrogan et al. 2008).
The mechanism of MDR is the amplification of the multiple drug resistance gene (MDRl), 
which is associated with over-expression of a transporter protein called P-glycoprotein (P- 
gp) (Gottesman et al. 2002; Coley 2008). P-gp belongs to a class of the ATP-dependent 
transporter family, also called the ATP-binding cassette (ABC) family (Gottesman et al. 
2002; Coley 2008). P-gp is a phospho-glycoprotein with a molecular weight of 170 kDa, 
consisting of two ATP-binding cassette energy and two transmembrane regions (Chen et 
al. 1986; Coley 2008). Each transmembrane region contains six transmembrane domains 
(Chen et al. 1986; Coley 2008). The P-gp transporter’s role is to bind to a wide range of 
hydrophobic dmgs and natural products such as doxorubicin and paclitaxel (Table 5-1) 
(Schinkel et al. 1997; McGrogan et al. 2008). When a drug binds to P-gp, tlie resulting
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conformational change gives rise to the activation of one of the ATP domains resulting in 
hydrolysis of ATP (Ramachandra et al. 1998; McGrogan et al. 2008). This action results 
in efflux of tlie dmg from tire intracellular to the extracellular compartment (Figure 5-1), 
thus preventing adequate accumulation of the dmg inside the cell and, hence the basis for 
dmg resistance (Ramachandra et al. 1998; McGrogan et al. 2008).
Substrates of P-gp (MDRl)
Anthracyclines Doxorubicin
Daunorubicin
Epirubicin
Mitoxantrone
Topoisomerase Inhibitors Etoposlde
Tenlposide
Vinca alkaloids Vinblastine
Vincristine
Taxanes Paclitaxel
Docetaxel
Alkaloids Cepharanthine
Homoharringtonine
Antitumor antibiotics Actinomycin D
Mitomycin C
Antimetabolites Cytarabine
Acrid In es Amsacrine
Anthracenes Bisantrene
Table 5-1: The most common anticancer drugs wliich bind to the P-gp drug 
transporter. Adapted from (Coley 2008).
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Anticancer 
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Figure 5-1: Anticancer drug transport in the absence and presence of P-glycoprotein.
(a) The passive diffusion of an anticancer drug into a cancer cell results in subsequent 
induction of cell death (absence of P-gp). (b) The effects on drug transport due to 
expression of P-gp transporter in a multi-drug resistant cancer cell results in subsequent 
cell survival. (Gottesman etal. 2002)
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P-gp expression may be detected in untreated breast cancers (Leonessa and Clarke 2003; 
Saeld et a l 2005). Moreover, P-gp expression was examined by a meta-analysis which 
found that 40% of all breast cancer tumours express P-gp, although there were some wide 
differences (heterogeneity) reported between different studies and evidence of inter­
individual heterogeneity (Trock et a l 1997; Coley 2008). The levels of P-gp were not 
different between metastatic and non-metastatic breast cancer disease (Trock et a l 1997; 
Coley 2008). However, the levels of P-gp (MDRl) were higher after treatment with 
chemotherapy or hormonal therapy, increasing by up to 1.8 fold (Trock et a l 1997; Coley 
2008). These data suggest that tumour resistance due to P-gp (MDRl) expression can be 
induced after exposure to a single anticancer drug (Trock et a l 1997; Coley 2008).
As mentioned previously, failure in curing cancer is at least in part due to tlie failure to 
accumulate enough chemotherapeutic agent intra-tumorally (Choi 2005; Coley 2008). 
Therefore, with high expression levels of MDR transporters, cancer cell sensitivity to 
drugs will be particularly affected (Choi 2005). There are a large number of research 
papers that have focused on P-gp inhibitors/modulators which reverse the action of P-gp 
when used in conjunction with chemotherapy (reviewed in Choi 2005; Coley 2008). Early 
clinical trials studied P-gp modulators in acute leukaemia; cancerous cells surviving 
chemotherapy treatment with modulators gave rise to a clinical relapse, but had reduced P- 
gp expression (List et a l 1993; Maiie et a l 1993). Other studies on P-gp modulators have 
shown evidence of inhibition in P-gp expression, albeit rather limited (Gottesman 2002). 
Some of the early first generation modulators included calcium blockers such as verapamil 
and the immunosuppressant cyclospoiine A (Gottesman 2002). A study performed with 
second generation modulators, showed a great increase in efficacy of the cytotoxicity of
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the compound but very high toxicity was observed (Gottesman 2002). The newest 
generation of modulators (third generation) could be promising and less toxic with high 
specificity (Gottesman 2002). These compounds include XR9756 (Tariquidar), RIO 1933, 
and LY3 35979 (Gottesman 2002).
5.2 Taxane resistance
Paclitaxel and docetaxel belong to the family of taxane anticancer agents. This class of 
anticancer drugs is used in tlie treatment of breast, ovarian, non-small cell lung cancer and 
prostate cancers. Taxanes are micro tubule stabilizing agents; microtubules normally 
function in maintaining the cell shape, cell signalling, division and mitosis (Jordan and 
Wilson 2004). Therefore, microtubules are an excellent cancer target for a number of 
available micro tubules inhibitors such as taxanes (Jordan and Wilson 2004). Taxanes 
specifically target the spindle microtubule dynamics of the p-subunit in tubulin by 
interfering with and suppressing the metaphase/anaphase transition, causing inhibition of 
mitosis and inducing apoptosis (Jordan and Wilson 2004; Kamath et a l 2005). The 
cytotoxic effect of paclitaxel and docetaxel were studied in vitro and are time and drug 
concentration dependent (Braakhuis et a l 1994; Torres and Horwitz 1998; Hernandez- 
Vargas et a l 2007). Their IC50 value for cytotoxicity is in the nanomolar* range for a 
number of cell lines (Braakhuis et a l 1994; Torres and Horwitz 1998; Hernandez-Vargas 
et a l 2007). Elevated concentrations of paclitaxel inhibit mitosis and result in G2/M cell 
cycle arrest followed by apoptosis (Jordan et a l 1996).
The development of taxane resistance in cancer cell lines has been extensively studied and 
different mechanisms of drug resistance have been described (Cabral 2000; Dumontet
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2000; Oit et al. 2003). Paclitaxel was shown to be a substrate for P-gp (Schinkel et al. 
1997; McGrogan et al. 2008). Expression o f MDRl was assessed by the National Cancer 
Institute in 60 cancer cell lines using a quantitative real time-polymerase chain reaction 
(qPCR) analysis (Alvarez et al. 1995; McGrogan et al. 2008). They found low levels of 
MDRl expression, with elevated sensitivity to paclitaxel in the cell lines (Alvarez et al. 
1995; McGrogan et al. 2008). The efflux of taxanes to the extracellular* compartment by 
P-gp can lead to a reduction in dr*ug efficacy (Ehrlichova et al. 2005). Development of 
taxane resistance is complex, and may involve defects in tubulin (Kavallaris et al. 1999; 
Kamath et al. 2005). Over-expression of the P-III tubulin isotype has been described as a 
factor underlying paclitaxel resistance (Kavallaris et al. 1999; Kamath et a l 2005). Also, 
it has been reported that resistance to docetaxel is associated with over-expression of P- 
tubulin isotypes I-IV (Hasegawa et a l 2003; Paradiso et a l 2005). Conversely, reduced 
levels of tubulin have been associated with taxane resistance (Wang and Cabral 2005). 
The multi-resistance associated protein (MRP) is anotlier class of drug efflux pump 
implicated in developing taxane resistance (Borst et a l 2000; Hopper-Borge et a l 2004). 
MRPl, a 190 kDa protein, was first shown to be overexpressed in a doxorubicin resistant 
lung cancer* cell line in the absence of MDRl/P-gp expression (Cole et a l 1992). 
Moreover, human epidermal growth factor receptor* 2 (HER2), encoded by the proto­
oncogene HER2/neu, was shown to be overexpressed in many breast cancer cell lines and 
leads to resistance to paclitaxel (Yu et a l 1998). Taxane acquired resistance involves 
alterations in apoptotic programmed cell deatli signalling (Kutuk and Letai 2008). Hence, 
paclitaxel utilizes the mitochondrial apoptotic pathway to mediate apoptosis in breast 
cancer cell lines (Tudor et a l 2000; Sunters et a l  2003). According to another* study 
(Kutuk and Letai 2008) involving paclitaxel resistant breast cancer cell lines, the key
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mediator in development of resistance was an alteration in mitochondrial apoptotic 
pathway control.
5.3 Aim
After studying the induction of caspase-independent cell death in MCF-7TaxR cells 
(Chapter 3 and 4), and from the microairay data in Chapter 4, it is clear that many 
important apoptotic genes aie absent from the MCF-7TaxR cells. In this study, we focused 
on detecting changes in levels of P-glycoprotein (MDRl gene product), caspase-7, 
caspase-9, the anti-apoptotic protein Bcl-2, and the pro-apoptotic proteins Bax, Bim and 
Bad, during the evolution of paclitaxel resistance. By selecting various cultures of MCF- 
7TaxR cells at different passages, we were able to see the sequence of events that 
contributed to the final resistant phenotype.
5.4 Methods
The methods used in this study were the MTT assay. Western blotting analysis and 
quantitative PCR analysis. All methods are explained in Chapter 2, Methods and 
Materials.
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5.5 Results
5.6 Development of the paclitaxel resistant MCF- 
7TaxR cell line
To develop a resistant cell line model, MCF-7 cells were made resistant to paclitaxel and 
resulted in the MCF-7TaxR cell line. The sensitivity of the developing variant MCF- 
7TaxR cell line to die anticancer drugs paclitaxel, doxorubicin, and cisplatin, was tested at 
passage 8 , passage 18, and passage 23 using the MTT assay (Table-5-2) (Figure 5-2). IC50 
values (calculated as the dose necessaiy to cause a 50% reduction in cell viability, relative 
to untreated control cells) were calculated from the dose response curves.
Cell Lines Paclitaxel ICsouM Doxorubicin ICso nM Cisplatin ICgopM
MCF-7 5.5 (±2.6) 1000 (±225) 12.7 (±2.2)
MCF-7TaxR 8 9.0 (±1.1) 1080 (±229) 12.3 (±3.5)
MCF-7TaxR 18 162.7 (±21.7) 3296 (±828) 5.8 (±2.8)
MCF-7TaxR 23 220 (±33) 2346 (±735) 6.1 (±1.1)
Table 5-2: Sensitivity of tbe breast cancer cell line MCF-7 and its paclitaxel resistant 
derivative MCF-7TaxR to anticancer drugs at different cell passage numbers.
The IC50 values aie die means for at least 4 separate experiments (perfoimed in triplicate) 
with paclitaxel (nM), doxorubicin (nM) and cisplatin (pM) as determined by the MTT 
assay. The ±SD values aie shown in parentheses. The numbers in the left hand column 
after MCF-7TaxR indicate the cell passage number. Cells were incubated with each dmg 
for 72 h. The IC50 values were calculated as the dose necessary to cause a 50% reduction 
in cell viability, relative to untreated control cells.
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Figure 5-2: Changes in drug sensitivity in developing paclitaxel resistant MCF- 
7TaxR cells.
IC50 values are the means for at least 4 separate experiments (performed in triplicate), and 
were determined by the MTT assay for the parent MCF-7 and MCF-7TaxR passage 8, 18 
and 23 cells. Cells were incubated for 72 h, with paclitaxel (nM), doxorubicin (nM), and 
cisplatin (pM). Error bars represent the ±SD.
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As shown in Table 5-2 and Figure 5-2, the original MCF-7 cells were highly sensitive to 
paclitaxel (ICso= 5.5 nM). However, as the number of cell passages in paclitaxel 
containing medium increased, the paclitaxel IC50 values gradually incmased, showing that 
a paclitaxel resistant cell population was emerging. The paclitaxel resistant MCF-7TaxR 
cell line showed a relatively low level of resistance after 8  passages (IC5o= 9 nM) in 
paclitaxel containing medium, but this increased with further cell passages. The paclitaxel 
IC50 values were 162.7 nM and 220 nM at passage 18 and 23, respectively. The increase 
in paclitaxel resistance was paralleled by a modest but transient increase in doxorubicin 
resistance. However, MCF-7TaxR cells failed to become resistant to cisplatin, even after 
23 cell passages in paclitaxel. On the contrary, collateral sensitivity to the agent 
developed.
5.7 P-gp (MDR1) expression
We examined the levels of the MDRl drug transporter P-gp in the human breast cancer 
cell line MCF-7 during treatment with the anticancer drug paclitaxel. MCF-7TaxR cells 
were harvested at different cell passages 8 , 23, 53, and MCF-7TaxRREV (MCF-7TaxR 
cells that had been grown in the absence of drug for several passages to ascertain whether 
the phenotype was reversible) were also examined. The expression of P-gp was 
determined at each of the passages by irnmunoblotting analysis as described in section 2.9 
in Chapter 2 (Materials and Methods).
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Figure 5-3: Overexpression of P-gp (MDRl) in paclitaxel resistant MCF-7TaxR 
cells.
Cells were lysed as described in Materials and Methods. Samples (50 pg protein) were 
electrophoresed on a 7% SDS-polyacrylamide gel, transferred to a PVDF membrane, and 
blotted with an MDRl (Santa Cruz Biotechnology, Inc.) rabbit polyclonal antibody at a 
dilution of 1:200 before being exposed to anti-rabbit alkaline phosphatase (Invitrogen™). 
Bands were detected using a chemiluminescent substrate (In vitro gen™). Data are 
representative of repeat experiments (n = 3).
The data in Figure 5.3 shows that P-gp expression increased in MCF-7TaxR cells treated 
with paclitaxel. The MCF-7 parental cells and the MCF-7TaxR cells at cell passage 8 did 
not show detectable levels of P-gp. However, P-gp expression gradually increased with 
further passages of the MCF-7TaxR cell line. At passage 18, a modest increase in P-gp 
expression was observed, followed by an even greater increase at passage 23, as indicated 
by the intensity of the band at 170 kDa. P-gp expression was also observed in MCF- 
7TaxR passage 53 and in MCF-7TaxRREV cells, suggesting that the dmg resistant 
phenotype was likely to be stable in the latter case.
120
CHAPTER 5
5.8 Caspase-7 and caspase-9 expression
We looked for changes in the expression of caspases during the acquisition of paclitaxel 
resistance in MCF-7 cells. Caspase-7 and caspase-9 were detected in MCF-7 and MCF- 
7TaxR cells at selected passage numbers in paclitaxel-containing medium and MCF- 
7TaxRREV cells by Western blot analysis as described previously.
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Figure 5-4: Caspase-7 expression in MCF-7TaxR cells decreases with cell passage in 
paclitaxel-containing medium.
Cells were lysed as described in Materials and Methods. Samples (50 pg protein) were 
electrophoresed on a 10% SDS-polyacrylamide gel, transferred to a PVDF membrane, and 
then exposed to a monoclonal anti-mouse caspase-7 (Cell Signaling Technology®) at a 
1:1000 dilution before being exposed to anti-mouse alkaline phosphatase (Invitrogen™). 
Bands were detected using a chemiluminescent substrate (Invitrogen™). Data are 
representative of repeat experiments (n = 3).
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Figure 5-5: Caspase-9 expression in MCF-7TaxR cells decreases with cell passage 
number in paclitaxel containing medium.
Cells were lysed as described in Materials and Methods. Samples (50 pg protein) were 
electrophoresed on a 10% SDS-polyacrylamide gel, transferred to a PVDF membrane, and 
exposed to a monoclonal anti-mouse caspase-9 antibody (Cell Signaling Technology®) at 
a 1:1000 dilution before being exposed to anti-mouse alkaline phosphatase (Invitrogen™). 
Bands were detected using a chemiluminescent substrate (Invitrogen™). Experiments 
were repeated more than three times. Data are representative of repeat experiments (n = 
3).
The Western blot data shown in Figures 5-4 and 5-5 show that caspase expression 
decreased as the MCF-7TaxR cells became more resistant to paclitaxel. Caspase-7 and 
caspase-9 were present in the MCF-7 parental cells and the MCF-7TaxR cell line at 
passage 8 and passage 18, indicating that a substantial change in the apoptotic mechanism 
occurred in these cells as they developed resistance to paclitaxel. Significant changes in 
caspase expression occurred around passage 23 when caspases-7 and -9 could no longer 
be detected. The MCF-7TaxR cells at passage 53 and the MCF-7TaxRREV cells 
continued to show a complete lack of caspase-7 and-9 expression, further indicating the 
stability of the drug resistance phenotype.
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5.9 Quantitative PCR analysis of caspase-7  and -9 
mRNA expression
As established in previous section, there is no expression of caspase-7 and caspase-9 in 
MCF-7TaxR with acquisition paclitaxel resistance. To confirm this, we examined the 
detection of caspase-7 and caspase-9 genes expression in these cells. We performed 
quantitative PCR analysis with MCF-7 and MCF-7TaxR cells at selected passages and 
also with MCF-7TaxRREV cells. RNA was extracted with the Trizol reagent from MCF-7 
and MCF-7TaxR cells, at pre-determined cell passages as described previously in Chapter 
2, section 2.12. The QIAGEN® One-step QuantiTect® SYBR® Green RT-PCR method 
was used. The PCR reactions were carried out using TaqMan® 700 ABI Prism (Applied 
Biosystems). The Act values were calculated as the relative differences between 
expression levels of test genes (caspase-7din.0. -9) and a house keeping gene ((3-actin). The 
fold change was equal to Human caspase-7 and caspase-9 primers were obtained
from SuperArray® as 10 pM working solutions. The primers were designed for 
amplification of the NM_001227.3 fragment of the caspase-7 gene and the NM_001229.2 
fragment of the caspase-9 gene
Caspase-7 human gene sequence primer 5 ’-3’: Forward, 
CCGTGGGAACGTAAGAAGAA; Reverse, GTCTTGATGGATCGCATGG.
Caspase-9 human gene sequence primer 5 ’-3': Forward,
CCTGCTTAGAGGACACAGGC ; Reverse, TTCGACAACTTTGCTGCTGCTTG.
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qPCR Analysis of Caspase-7
M CF-7 M G F-7TaxR8 M C F-7T axR 18 M C F-7T axR 23 M C F 7 T ax R 5 3  M CF-7TaxRREV
(b)
Cell lines ▲ ct values for caspase-7
MCF-7 4.05
MCF-7TaxR8 4.24
MCF-7TaxR18 2.15
MCF-7TaxR23 0.07
MCF-7TaxR53 0.06
MCF-7TaxRREV 0.05
Figure 5-6: qPCR analysis of caspase-7 gene expression in MCF-7 and MCF-7TaxR 
cells.
(a) Act levels of caspase-7 mRNA decreased with the emergence of paclitaxel resistance 
in the MCF-7TaxR cell line. Data are the mean of 3 independent experiments (performed 
in duplicate); error bars, ±SD. (b) The table shows the Act values in MCF-7 and MCF- 
7TaxR cell lines at different passage numbers.
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qPCR Analysis of Caspase-9
(a) M CF-7 M CF-7TaxR8 M CF-7TaxR18 M CF-7TaxR23 M CF-7TaxR53 MCF-7TaxRREV
(b)
Cell lines ▲ ct values for caspase-9
MCF-7 0.35
MCF-7TaxR8 0.34
MCF-7TaxR18 0.20
MCF-7TaxR23 0.0069
MCF-7TaxR53 0.0008
MCF-7TaxRREV 0.0017
Figure 5-7: qPCR analysis of caspase-9 gene expression in MCF-7 and MCF-7TaxR 
cells,
(a) A ct levels of caspase-9 mRNA decreased with the emergence of paclitaxel resistance 
in die MCF-7TaxR cell line. Data are the mean of 3 independent experiments (performed 
in duplicate); error bars, ±SD. (b) The table shows the Act values of caspase-9 in MCF-7 
and MCF-7TaxR cell lines at different passage numbers.
The data in Figure 5-6 and 5-7 quantified the levels of caspase-7 and caspase-9 gene 
expression in human breast cancer cell lines during the acquisition of paclitaxel resistance. 
Caspase-7 and caspase-9 were detected in the MCF-7 parent cell line and the MCF- 
7TaxR cell line at passage 8. In MCF-7TaxR passage 18 cells, the expression levels of 
both genes (caspase-7 and caspase-9) began to decrease. When die cell line started to
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become resistant at passage 23, the MCF-7TaxR cells had lost nearly all detectable 
caspase-7 and caspase-9 gene expression. At passage 53, caspase gene expression could 
no longer be detected in tlie MCF-7TaxR cell line or in the MCF-7TaxRREV cell line. 
These data indicate tliat the MCF-7TaxR cell line undergoes reductions in the 
transcription of apoptotic genes concomitant with the emergence of paclitaxel resistance.
5.10 Changes in anti-apoptotic and pro-apoptotic 
protein expression
As established previously, significant deficiencies in the main apoptotic regulators, 
caspase-7 and caspase-9, were observed in MCF-7TaxR cells during the acquisition of 
paclitaxel resistance. We also examined the expression of other apoptotic regulators such 
as the pro-apoptotic proteins Bax, Bim, Bad, and the anti-apoptotic Bcl-2, in the parental 
MCF-7 and the MCF-7TaxR cell lines at predetermined cell passage numbers of cells 
grown in paclitaxel containing medium using immunoblotting analysis.
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Figure 5-7: Changes in pro- and anti-apoptotic protein expression in human breast 
cancer cell lines during the acquisition of resistance to paclitaxel.
Cells were lysed as described in Materials and Methods. Samples (50 pg protein) were 
electrophoresed on a 10% SDS-polyacrylamide gel, transferred to a PVDF membrane, 
and, then, exposed to an anti-mouse Bax antibody, anti-mouse Bcl-2 antibody, anti-rabbit 
Bim antibody, anti rabbit Bad or P-Bad (Seri 12) antibodies (obtained from Cell Signaling 
Technology® or Santa Cruz Biotechnology, Inc.) at 1:200 or 1:1000 dilution before being 
exposed to anti-rabbit or anti-mouse alkaline phosphatase (Invitrogen™). Bands were 
detected using a chemiluminescent substrate (Invitrogen^^), Data are representative of 
repeat experiments (n = 3).
Figure 5-8 shows that Bax (a pro-apoptotic protein) was expressed in all cell lines 
examined, irrespective of the cell passage number. The expression of Bcl-2 (anti- 
apoptotic) and the BimL isoform (pro-apoptotic) were readily detected up to cell passage 
18, after which the expression of both proteins underwent a drastic reduction at passage 
23. As a result of alternative splicing, Bim exists in three isoforms, Bimgu BimL and Bim^ 
(O'Connor et al. 1998). Other forms of Bim (Bimnt 23 kDa and Bim  ^ 12 kDa) were not
127
CHAPTERS
detected in the MCF-7 parental cells. Looking at approximate ratios of P-Bad: Bad 
(judged by eye) there are small fluctuations seen throughout the sample series. However, 
there are no marked changes for the levels of Bad and P-Bad during the emergence of 
paclitaxel resistance in this cell line model.
5.11 Discussion
The development of acquired resistance to chemotherapy has a negative impact on the 
effective treatment of human tumours (Pommier et al. 2004). Many cancers initially show 
good clinical response to chemotherapy and some will actually be completely cured of the 
disease (Pommier et al. 2004). Therefore, understanding tlie mechanism of anticancer 
drug resistance is still a major obstacle for the successful treatment of cancer (reviewed 
by- Coley 2008).
In tliis study, we showed tliat the breast cancer cell line MCF-7 become resistant to 
paclitaxel after a short duration of exposure (3 weeks). Many studies of paclitaxel 
resistance in cell lines models have been conducted and various mechanisms have been 
identified (Cabral 2000; Dumontet 2000; Orr et al. 2003). One of the reported 
mechanisms is the overexpression of ABC tianspoiters, such as P- 
glycoprotein/MDRl/ABCBl and ABCB4 (MDR2) (Hopper-Borge et al. 2004). It was 
sui-prising to find that MCF-7TaxR cells developed collateral sensitivity to cisplatin. 
Overall, the MCF-7TaxR cell line did not show a phenotype that was consistent with the 
classical P-gp theory, i.e. development of cross resistance to other structurally unrelated 
natural product anticancer drugs (Gottesman 2002; Gottesman et al. 2002). Expression of
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P-gp was reported in a number of tumours with resistance to a variety of micro tubules 
agents such as paclitaxel and vinca alkaloids (Penson et al. 2004; Haii et al. 2006). Here, 
we confirmed the expression of P-gp by Western blotting analysis in the MCF-7TaxR cell 
line, indicating tliat the P-gp transporter is a potential mechanism of resistance to 
paclitaxel in this cell line. MCF-7TaxR cells at passage 18 to passage 23 appeared to be 
the point at which cells developed the drug resistant phenotype. When the MCF-7TaxR 
cell line reached passage 23, P-gp protein expression was strongly upregulated, which is 
generally associated with the MDR phenotype. Previous studies showed that different cell 
lines with acquired resistance to paclitaxel were derived using either a single, high dose of 
paclitaxel or by step-wise increments of increasing paclitaxel (Dumontet et al. 1996; 
Cabral 2000). However, in some studies, paclitaxel resistance was shown to come about as 
a consequence of multiple factors many of which had an unknown basis (Hari et al. 2006). 
A study by Li et al. (2009) demonstrated the overexpression of P-gp in MCF-7 cells with 
acquired resistance to doxorubicin and shuilar results have been reported in gastric cancer 
cells (Du et al. 2005; Li et al. 2009). Some of the mechanisms are mutations in tubulin, 
overexpression of P-gp, changes in expression of microtubule-associated proteins, or 
alteration in apoptosis proteins (Poruchynsky et al. 2001; Martello et al. 2003; Hari et al. 
2006).
The presence of drug resistance can affect the accumulation of drug intracellulariy and, 
further, this process may be exacerbated by alterations in other factors such as apoptotic 
proteins (Johnstone et al. 2002). The two main pathways in apoptosis (programmed cell 
death I) are the intrinsic pathway through the mitochondria and the extrinsic pathway, as 
discussed earlier in Chapters 1 and 3. A large body of evidence has indicated that
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inactivation of apoptosis leads to tumour progression (Jaattela 1999; Evan and Vousden 
2001). Therefore, human tumours may possess defective or mutated pro-apoptotic genes 
or may over-express anti-apoptotic proteins to confer chemoresistance (Mathiasen and 
Jaattela 2002). Here, we assessed caspase-7 and caspase-9 expression by Western blotting 
and qPCR in MCF-7 cells over the time course of acquisition of resistance to chronic 
paclitaxel exposure. These data were consistent with our previous data in Chapters 3 and 
4, which indicated that the MCF-7TaxR cell line is resistant to apoptosis and, thus, the cell 
line may undergo caspase-independent cell death. It was suggested that P-gp is involved in 
inhibition of the apoptosis cascade in Chinese hamster ovary fibroblasts (Robinson et a l
1997). Also, it has been reported that a major cause of blocking apoptotic cell death is the 
presence of P-gp overexpression (Pawlik et a l 2005).
Paclitaxel utilizes the mitochondrial apoptotic pathway to mediate apoptosis in breast 
cancer cell lines (Tudor et a l 2000; Sunters et a l 2003). Defects in apoptotic cell deaüi 
mechanisms include alterations in the ratio of expression of pro-and anti-apoptotic 
proteins of the Bcl-2 family associated with acquired paclitaxel resistance (Kutuk and 
Letai 2008). The Bcl-2 family members classified into pro-apoptotic proteins that promote 
apoptosis include Bax and Bak (BHl-3 domain of Bcl-2 homology) (reviewed by- 
Strasser et a l 2000). The BH3 subfamily of pro-apoptotic proteins includes Bid, Bim, Bad 
and PUMA {reviewed by- Strasser et a l 2000). In addition, the anti-apoptotic subfamily 
includes Bcl-2, Bcl-xi and Mcl-l (which share BHl-4 domains); this group inhibits 
apoptosis (reviewed by- Strasser et a l 2000). In our investigation of the expression of 
different anti-and pro-apoptotic proteins, a gradual loss in expression was seen in MCF- 
7TaxR cells whilst developing paclitaxel resistance. For example, the Bax pro-apoptotic
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protein was expressed constitutively in the MCF-7 cell line and all MCF-7TaxR sub lines, 
which is consistent with our previous microarray data. The BH3-only protein Bim induces 
Bax activation which undergoes confoimational change and oligomerization causing 
permeabilization of the outer mitochondrial membrane allowing cytochrome c release 
from the mitochondria, which initiates the intiinsic apoptotic pathway (Kutuk and Letai 
2008). Thus, the expression of Bax in the parental MCF-7 cells indicates an activation of 
the intrinsic apoptotic pathway (MCF-7 cells possess caspase-9, -7), in agreement with our 
previous finding and those of others (Kutuk and Letai 2008). However, although 
paclitaxel resistant MCF-7 cells at passages 18, 23 and 53 cells express Bax, , MCF- 
7TaxR cells failed to initiate tlie intrinsic pathway due to the lack of caspase-7, 9 and 
Apaf-1 and other factors, according to our previous findings. It has been reported that the 
pro-apoptotic protein Bax can be activated by Bid (Kutuk and Letai 2008) and this was 
absent fiom MCF-7TaxR cells. Considering other Bcl-2 family members, Bim, a pro- 
apoptotic protein, consists of a three isoforms, B in iE L , B in iL  and Bims (B im -e x tra  long, Bim. 
long and B im -sh o rt) as a result of alternative splicing (O'Connor et a l 1998). These isofonns 
are cytotoxic and have different forms of regulation by various pro-death and pro-suiwival 
signalling pathways (Ley et a l 2005). The expression of these isoforais vaiies in different 
cell types and tissues (O'Reilly et a l 2000). Bim, located in other sub-cellular 
compartments, translocates to die mitochondria to activate Bax and Bak (O'Connor et a l 
1998). BimL and Bims are more potent inducers of apoptosis than BiiusL (O'Connor et a l
1998). However, the long isoforms of BimL and BimEL aie regulated by phosphorylation 
by c-Jun N-terminal kinase in response to different stress which stimulates apoptotic cell 
death (Lei and Davis 2003; Hubner et a l 2008). In this study, we observed that BimL was 
expressed in the MCF-7 parental line and the MCF-7TaxR cells at passage 8. According
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to tiie literature, MCF-7 cells may express BimEL form (Suyama et a l  2007). However, 
the antibody used for Western blotting analysis in that work was not the same as the one 
used in my study. Hence, given the very variable nature of the performance of different 
antibodies it is difficult to draw conclusions. However, the difference seen between MCF- 
7 and MCF-7TaxR for BimL expression is very marked - with total absence in the 
paclitaxel resistant line. The apoptosis microaiTay platform did not include Bim, which 
might have given more support to our findings. Decreased BimL expression was detected 
at passage 18 in MCF-7TaxR cells when the resistance to paclitaxel was becoming 
established. Subsequently, loss of BimL expression was detected in MCF-7TaxR cells at 
passage 23. Bim functions to promote death by interacting with pro-survival Bcl-2 
proteins at the mitochondria; however, this function may be restrained by interactions 
between Bim and the microtubule-associated dynein complex, specifically via binding to 
dynein light chain 1 (DLCl, or LC8). This in turn may implicate Bim in death aiising 
from disruption of the micro tubule or cytoskeletal network (Puthalakath et a l 1999). 
Therefore, it has been reported that Bim is involved in mediating apoptosis by paclitaxel 
(Bouillet et a l 1999; Sunters et a l 2003). In addition, it was demonstrated in in vivo 
studies that apoptotic induction in paclitaxel treated cells is essentially dependent on the 
action of Bim (Tan et a l 2005). A study by Kutuk and Letai (2008), showed that the 
MDA-MB-468 breast cancer cell line with acquired resistance to paclitaxel was associated 
with decreased Bim levels (Kutuk and Letai 2008). This is consistent with our findings 
showing deficient levels of Bim in our paclitaxel resistant MCF-7TaxR cells. The pro- 
apoptotic factor Bad regulates apoptosis induction fiuough inhibiting the anti-apoptosis 
Bcl-2 family members Bcl-2, Bcl-xi and Mcl-l (reviewed by- Strasser et a l 2000). Bad 
activation stimulates the action of Bak and Bax, pro-apoptosis members leading
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cytochrome c release, followed by mitochondrial apoptotic pathway induction (Cheng et 
a l 2001). Thus, survival factors such as IL-3 can inhibit the apoptotic activity of Bad by 
stimulating intracellular signalling pathways that result in the phosphorylation of Bad at 
Seri 12 and Seri36 (Zha et al. 1996). Phosphorylation of Bad at these sites results in 
binding of Bad to 14-3-3 proteins and inhibition of Bad binding to Bcl-2 and Bcl-xi, thus 
mediating apoptosis induction (Zha et al. 1996). Bad and phospho-Bad, a pro-apoptotic 
protein, showed low to moderate expression in parent MCF-7 cells. A study by 
(Bemdtsson et al. 2005) showed phosphorylation of Bad at Serl28 in paclitaxel treated 
fibroblasts. Considering other Bcl-2 members, a high level of Bcl-2 phosphorylation was 
shown clinically in breast tumours (Shitashige et al. 2001). In addition, increased 
resistance to taxanes is also associated with inhibition of Bcl-2 phosphorylation 
(Shitashige et al. 2001). Detection of the anti-apoptotic factor Bcl-2, as seen in the MCF-7 
patentai cell line, was consistent with the previous apoptosis micro array findings. At 
passage 18 of the MCF-7TaxR cell line, a significant changing point in the cell line 
development, the Bcl-2 levels were reduced. Moreover, complete loss in Bcl-2 expression 
was detected at passage 23 in the MCF-7TaxR cell line. Thus, the loss of Bcl-2 expression 
in MCF-7TaxR may lead to inhibition of the binding of pro-apoptotic Bad to Bcl-2 (due to 
their absence) (Zha et al. 1996). Taken together, these results indicate that alterations in 
the Bcl-2 family of proteins - whether a decrease or increase- are associated with acquired 
paclitaxel resistance in breast cancer cells.
In summary, the data shown in the present chapter suggest that acquisition of paclitaxel 
resistance is a multifactorial process. In the case of the MCF-7TaxR cell line, this 
acquisition of resistance involved overexpression of P-gp and extraordinary alterations in
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the expression of apoptotic proteins. Interestingly, the differences in passage number from 
18 to 23 passages means tliat over a period of only 2 weeks drastic changes occurred in 
apoptotic protein expression. The parental MCF-7 cells have already been identified as 
being deficient in caspase-3 according to previous studies and our findings further indicate 
that other apoptotic genes may also be absent (Kurokawa et a l 1999; Simstein et a l 
2003). The apoptotic defect in caspase-3 in MCF-7 cells appears to contribute to a major 
modification in tlie way these cells develop paclitaxel resistance. Some studies of human 
breast cancers have shown that caspase-3 deficiency at the mRNA and protein levels may 
account for approximately 75% of cases of breast cancer (Devarajan et a l 2002). 
However, MCF-7TaxR cells appear to retain sensitivity to many types of chemotherapies 
and this provides strong - albeit indirect - evidence that these cells have become proficient 
in recruiting a non-caspase mediated form of cell death. Identification of altered apoptotic 
genes may be useful in predicting the response to paclitaxel in tumours of breast cancer 
pati
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6 Investigation o f Alternative Cell Death 
Mechanisms: Autophagic Cell Death in Human 
Breast Cancer Cells
6.1 Overview of autophagic cell death
Autophagy is an ancient physiological process which has an essential role in cell 
physiology and pathology (Yang et al. 2005). Autophagy was originally described by de 
Duve and Wattiaux in 1966. They demonstrated the development of lysosomes and 
showed that autophagy was involved in the turnover of long lived proteins in mammalian 
cells (de Duve C.& Wattiaux 1966; Dunn 1994; Klionsky and Ohsumi 1999). Autophagy 
has a crucial function in cellular' degradation of long-lived proteins and cytoplasmic 
organelles and, therefore, increased catabolism will increase autophagic activity, which 
may be important in different stress conditions (Gozuacik and Kimchi 2004). The 
autophagic process plays a role in cell survival during starvation by providing a source of 
energy (Moretti et al. 2007). In addition, autophagy may induce programmed cell death 
type n (PCD n), termed autophagic cell death, under extreme stress circumstances as an 
alternative non-apoptotic cell death (Yang et al. 2005). Therefore, autophagy may be 
either a cell survival mechanism during starvation or a cell death mechanism under stress 
conditions when, for example, apoptotic cell deatli (PCD I) may be inhibited (Moretti et 
al. 2007). Defects in autophagy have been demonstrated for diseases such as cancer and 
neurodegenerative disease such as Alzlieimer's and Parkinson's disease (Edinger and 
Thompson 2004).
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Autophagy literally means, in Greek, “to eat oneself’ whereby the cell switches to a 
catabolic metabolic programme to degrade cell constituents in order to provide energy for 
cell sui*vival during nutrient stress (Edinger and Thompson 2004). Basically, cells undergo 
autodigestion following deprivation of nutrients and this prolongs cell survival (Tsujimoto 
and Shimizu 2005). Thus, autophagy processes change from catabolic survival to cell 
deatli chaiacterised by the engulfinent of cytoplasm and cytoplasmic constituents such as 
organelles including mitochondria and endoplasmic reticulum by a double or multi­
membrane sac or vesicles (Edinger and Thompson 2004; Gozuacik and Kimchi 2004). 
When the membranous sacs are formed in a double membrane structure called the 
autophagosome (Edinger and Thompson 2004; Gozuacik and Kimchi 2004), the 
autophagolysosomes are then produced by a fusion of the outer membrane of the 
autophagosomes and lysosomes, where contents are then sequestered and degraded 
(Figure 6-1) (Gozuacik and Kimchi 2004; Yorimitsu and Klionsky 2005). Therefore, cells 
digest themselves to induce death in the form of autophagic cell death (Edinger and 
Thompson 2004).
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Figure 6-1: Autophagy as a cell survival process in mammalian cells or as a cell 
death pathway in cancer cells and other diseases.
The sequential recruitment of autophagy proteins (Atgl2-Atg5) and the conjugation of 
LC-3 (Atg8) occurs at the isolation membrane after the activation of the Beclin 1 complex. 
Then, after the formation of the autophagosome, LC-3 II binds to the luminal side of the 
autophagosome membrane and is recycled in the cytosol. However, the Atg 1 complex 
may be involved in individual steps of autophagosome development. The ultimate step is 
the fusion between the autophagosome and lysosome, and degradation of sequestered 
materials including LC3-II. Adapted from (Lefranc etal. 2007; Pattingre et al. 2008).
The molecular mechanism of autophagy is genetically controlled by autophagic genes 
called APG (autophagy) and AUT (auto-phagocytosis) in the yeast Saccharomyces 
cerevisiae which are conserved in mammalian cells (Tsukada and Ohsumi 1993; Thumm 
et al. 1994; Ohsumi 2001; Huang and Klionsky 2002). As a result of these studies, Apg 
and Aut have finally been named in the unified nomenclature ‘Atg’ (autophagy-related) 
genes (Tsukada and Ohsumi 1993; Thumm et al. 1994; Ohsumi 2001; Huang and
138
CHAPTER 6
Klionsky 2002; Klionsky et al. 2003). The Atg proteins are involved in the formation of 
autophagosomes that include the Atgl complex which integrates signalling from TOR 
(Target Of Rapamycin) kinase (Klionsky et al. 2003; Pattingre et al. 2008). This complex 
is involved in several steps during the nucléation and expansion steps of autophagosome 
formation (Shintani and Klionsky 2004). In addition, the Beclin 1 (a yeast Atg6 
oithologue)/class HI PI3K (hVps34) complex is involved in the nucléation phase (Kondo 
et al. 2005). Another marker for autophagic cell deatli is LC-3 (the microtubule-associated 
protein 1 light chain 3, MAPI LC-3), the mammalian homolog of yeast Atg8, which is 
involved in autophagosome formation and is located on the autophagosome membrane 
(Kabeya et al. 2000; Mizushima et al. 2004). LC-3 and Atg 12 are both two ubiquitin-like 
conjugating systems; A tgl2 conjugates Atg5 during die initiation step and promotes the 
conjugation of LC-3 to phosphtidylethanolamine for the elongation step (Pattingre et al. 
2008). The recycling pathway is controlled by Atgl and Atg9, which mediates the 
shuttling of Atg proteins (Reggiori et al. 2005; Young et al. 2006). The maturation of 
autophagosomes requires tlie activity of Rab GTPases (Gutienez et al. 2004; Jager et al.
2004).
6.2 Regulation of autophagic cell death
Autophagic cell death is regulated by different signalling pathways implicated in 
tumorigensis (Moretti et al. 2007). These signalling processes include phosphoinositide 3- 
kinases (PI3K), Alct, and the mammalian target of rapamycin (mTOR) pathway (Moretti et 
al. 2007) (Figure 6-2). In die presence of nutrients and growth factors, the 
PI3K/Akt/mTOR pathway is activated, causing autophagy suppression and activation of 
cell proliferation (Chen and Karantza-Wadsworth 2009). Thus, inhibition of the
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PB K/Akt/mTOR axis may lead to stimulation of autophagy (Chen and Kaiantza- 
Wadsworth 2009).
The PI3K family enzymes confer an essential function in the autophagic pathway (Lefranc 
et a l 2007; Moretti et a l 2007). The PI3K family also functions in cell growth and 
differentiation, apoptosis, cytoskeletal organization, and membrane trafficking (Toker and 
Cantley 1997; Cantley 2002). Class III PI3K is involved in the eariy stages of 
autophagosome production (Kondo et a l  2005; Lefranc et a l 2007). Class I PI3Ks 
produces PI(3,4)P2 and PI(3,4,5)P3 which bind to Akt (Meijer and Codogno 2004; Ng and 
Huang 2005; Moretti et a l 2007). The class III PI3Ks have been shown to phosphorylate 
phosphatidylinositol (PI) to produce phosphatidylhiositol-3,4,5-triphosphate PI(3)P 
(Moretti et a l 2007). This mechanism is involved in tire transfer of lysosomal enzymes of 
the trans-Golgi network to lysosomes (Kondo et a l 2005; Linder and Shoshan 2005). 
Dysregulation in the PI3K patliway can lead to increases in tumorigensis and promote 
chemotherapy resistance, as reported in cancers such as prostate, breast, pancreatic, 
ovarian, and stomach cancers (Nicholson and Anderson 2002). The tumour suppressor 
phosphatase and tensin homologue deleted from chromosome 10 (PTEN), which is a 
lipid/protein phosphatase, dephosphorylates PI at the 3 position and hence downregulates 
the PI3K/Alct cascade (Wu et a l 1998). Thus, PTEN is an antagonist of the Akt/PI3K 
patliway and positively regulates autophagy (Ng and Huang 2005). The occurrence of 
frequent somatic mutations or deletion of PTEN has been reported for many types of 
cancers (Steck et a l 1997; Freeman et a l 2006). PTEN regulates different products 
generated from PI3K class I activity (Arico et a l 2001). Dysregulation or mutations in 
PTEN result in activation of the Alct cascade and inliibition of autophagy (Arico et a l
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2001).
Importantly, there is a central protein in PI3K class III pathways called Beclin 1 {Atg 6 or 
BECN1) (Petiot et al. 2000; Boy a et a l 2005). Beclin 1 is an essential protein required for 
binding to PI3K class III and forms a complex to stimulate vacuolar formation and 
induction of autophagic cell death (Kondo et a l 2005). The Beclin 1/PI3K class III 
complex found on the trans-Golgi network is involved in the isolation membrane that 
controls autophagy (Motyl et a l 2006). It was reported the Beclin 1 gene shows mono- 
allelic deletion in 40%-70% of breast, ovarian, and prostate cancers (Aita et a l 1999; 
Moretti et a l 2007). Beclin 1 is expressed in MCF-7 breast cancer cells (Liang et a l 
1999). According to Liang et al. (1999), Beclin 1 expression was absent in 8 of 11 tested 
human breast carcinoma cell lines (Liang et a l 1999). There are different compounds diat 
may be used as tools for tlie investigation of autophagy, such as 3-methyladenine (3-MA), 
which inhibits autophagosome formation by inhibiting PI3K class HI activity (Moretti et 
a l 2007; Chen and Karantza-Wads worth 2009) (Figure 6-2). It was demonstrated that the 
addition of 3-MA to MCF-7 cells led to a reduction in autophagy via Beclin 1 inhibition 
(Liang et a l 1999). LY294002 and wortmannin are both PI3K inhibitors that inhibit 
kinase activity through different mechanisms (Blommaart et a l 1997; Aki et al. 2003; 
Chen and Karantza-Wadswoith 2009). LY294002 is derived from the naturally occurring 
bioflavonoid quercetin and it inhibits PI3K by competitive inhibition of the ATP binding 
site on the p85a subunit (Vlahos et a l  1994). Thus, LY294002 has been used as an 
autophagy inhibitor, via inhibition of PI3K (Moretti et a l 2007; Yang et a l 2008; Chen 
and Karantza-Wadswoith 2009). Wortmannin (derived from a fungal metabolite) inhibits 
PI3K via targeting the p i 10 subunit of PI3K (Powis et a l 1994; Wymann et a l
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1996)(Figure 6-2).
The mTOR signalling patliway has been closely associated with autophagy regulation 
(Pattingre et al. 2008). The TOR protein is a Ser/Thr protein kinase that has been 
identified in all eukaryotic cells as being derived from a single gene (Pattingre et al. 
2008). TOR was first found in yeast as a target for the antifungal drug rapamycin 
produced by Streptomyces hygroscopicus (reviewed in Ng and Huang 2005). Thus, 
rapamycin irdiibits TOR activity and induces autophagy in yeast and mammalian cells (Ng 
and Huang 2005). mTOR is a large protein of 289 kDa that is a kinase (Yang et al. 2005) 
and a gatekeeper for autophagy, inducing its inhibition (Yang et al. 2005). The mTOR 
pathway is regulated by two mechanisms. Firstly, mTOR controls autophagy by 
downstream effectors such as the S6K substrate and 4E-BP1 (Cardenas et al. 1999). 
Secondly, mTOR acts directly or indirectly to affect Atg proteins leading to interference 
with autophagosome formation (Levine and Klionsky 2004). Proteins in the mTOR 
pathway involve phosphorylation of S6K and its target libosomal protein S6, causing 
inhibition of autophagy (Scott et al. 2004). The Akt pathway works in concert with 
mTOR, since Alct activates mTOR leading to autophagy inhibition (Ng and Huang 2005).
The family of death associated kinases includes the death associated protein kinase 
(DAPK) and DAPK-related protein-1 (Ng and Huang 2005). Overexpression of these 
proteins induces autophagy in different cancer cell lines (hibal et al. 2002). A dominant- 
negative construct of DAPK-related protein -1 in MCF-7 breast cancer cells produced a 
decrease in both starvation and autophagy induction following tamoxifen treatment (Ng 
and Huang 2005). Moreover, reduced expression levels of DAPK in HeLa cells led to
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decreased interferon-y-induced autophagy (Ng and Huang 2005). In addition, the Ras 
pathway regulates autophagy in two ways. Firstly, Ras inhibits autophagy by activating 
class I PI3K and the Akt/mTOR pathway (Budovskaya et al. 2004; Furuta et a l 2004; Li 
et a l 2007). Secondly, the Ras pathway induces autophagy via the 
RAF1/MEK1/2/ERK1/2 pathway (Pattingre etal. 2003)(see Figure 6-2).
M P 3 J I I
MEK1/2
LY294002
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Figure 6-2: Summary of autophagy regulation, showing the important signalling 
pathways involved. Adapted from (Chen and Karantza-Wadsworth 2009).
6.3 Defects in autophagic cell death in cancer cells
Different studies have recently reported that a defect in autophagic pathways may 
correlate with cancer cell progression and proliferation (Okada and Mak 2004). The 
earliest link between autophagy and cancer was found in the late 1970s (Lefranc et al.
2007). It was found that the extent of autophagy activity is lower in cancer and was 
correlated with cancer cell survival (Ng and Huang 2005). However, different studies
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showed that autophagy activity possesses a tumour suppressor function during the eaiiy 
stages of tumour development (Kondo et a l 2005). A study by Toth et a l (2002), on 
pancreatic adenocarcinoma revealed a reduction in autophagy activity (Toth et a l 2002). 
This study suggested tliat the level of autophagy first increases at an early stage of cancer 
or in the pre-malignant stage with a reduction in autophagy activity during the tiansition 
of adenoma to adenocarcinoma (Ng and Huang 2005). Therefore, under certain conditions 
a deficiency or defect in autophagy may contribute to the development of cancer (Ng and 
Huang 2005).
The autophagic mechanism is a major pathway for recycling long-lived proteins and 
increases their degradation rate, which leads to a reduction in cellular protein mass (Ng 
and Huang 2005). For cancer cells with a high level of cellular proliferation, induction of a 
high level of autophagy may inhibit proliferation (Ng and Huang 2005). Another vital 
function of autophagy is the elimination of damaged organelles and, therefore, when tlie 
autophagic mechanism is dysregulated, it causes accumulation of these organelles in cells, 
leading to an to increase in genotoxic related mutations (Ng and Huang 2005). A study on 
endothelial cells showed that autophagic cell death features occur in the presence of 
endostatin, an angiogenesis inhibitor (Chau et a l 2003; Ng and Huang 2005). These 
findings indicate that autophagic cell death causes inhibition of angiogenesis, leading to 
the suppression of tumour progression (Chau et a l  2003; Ng and Huang 2005).
There are other defects occurring in a cancer cell that affect the autophagic process, and 
some of these defects are in oncogenes and tumour suppressor genes that control and 
influence the autophagy pathway (Ng and Huang 2005). These genes include PTEN, class
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I PI3K, Akt and Ras (Ng and Huang 2005). Dysregulation of the Akt/PKB pathway is 
involved in tumorigensis and resistance to therapy in breast, prostate, pancreatic, ovarian, 
and stomach cancers (Nicholson and Anderson 2002).
6.4 Autophagic cell death Is an alternative to apoptosis in 
cancer
A large body of evidence in tlie literature has demonstrated a correlation between loss of 
apoptotic cell death responses in cancer cells and additional decreases in autophagic 
activity as a contributory process leading to carcinogenesis (Hanahan and Weinberg 2000; 
Green and Evan 2002; Gozuacik and Kimchi 2004). The autophagic mechanism may have 
dual fimctions in cultured cancer cells, delaying apoptosis pathways in one cell type and at 
the same time promoting cell death in another cell (Yang et al. 2005). Cells may undergo 
caspase-independent autophagic cell death, which may or may not be accompanied by 
signs of apoptosis (Assuncao Guiniaraes and Linden 2004). However, in otiier situations, 
cells may have options to select between autophagic cell deatli and apoptotic cell death 
(Assuncao Guimaraes and Linden 2004). An IL3-dependent cell line induced to undergo 
cell death by IL-3 deficiency led to activation of autophagy, but not autophagic cell death, 
because autophagy in this case was a survival mechanism (Lum et al. 2005). However, a 
study on murine embryonic fibroblast (MEFs) that were deficient in Bax/Bak (pro- 
apoptotic proteins), showed non-apoptotic cell death when exposed to different cytotoxic 
agents, such as etoposide, staurosporine and tiiapsigargin, even though all these agents are 
apoptosis inducers (Tsujimoto and Shimizu 2005). The features of cell death in MEFs 
revealed a loss in clonogenicity and positive propidium iodide staining of the plasma 
membrane with no signs of membrane disruption, and electron microscopy analysis
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demonstrated evidence of a number of double-membrane vesicles (Shimizu et a l 2004). 
The vesicles in MEF cells were later confirmed to be autophagosomes by the presence of 
LC-3, a marker of autophagic cell deatli, and Atg8, which was concentrated on the 
autophagosomes but present Üiroughout the cytoplasm (Shimizu et al. 2004). According to 
these earlier data, autophagic cell death involves association of autophagosome formation 
with autophagy proteins, which leads to cell death after exposure to cytotoxic insult 
(Shimizu et al. 2004). This established the existence of alternative cell death mechanisms 
(Shimizu et al. 2004). However, the field is still developing, but, in general, prior studies 
on autophagic cell deatli have revealed that autophagic cell death follows cytotoxic insult 
when apoptotic cell death is compromised for whatever reason (Tsujimoto and Shimizu
2005).
6.5 Aim
This chapter focuses on investigating the alternative cell death mechanism in paclitaxel 
resistant MCF-7TaxR cells following a line of enquiry directed towards understanding 
autophagic cell death.
6.6 Methods
Methods used in this chapter are Western immuno-blotting analysis, cytotoxic MTT assay, 
acridme orange staining experiment by flow cytometry analysis, confocal microscopy and 
electron microscopy imaging. All methods were described in Chapter 2 (Methods and 
Materials).
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6.7 Results
6.7.1 Detection of Beclin 1 and LC-3 expression in paciitaxei
resistant MCF-7TaxR ceils
Beclin 1 is known to interact with class HI PI3Ks and to induce autophagy (Aita et aL 
1999; Moretti et al, 2007). As human Beclin 1 is deleted in 40-70% of breast and ovarian 
cancers (Aita et al. 1999; Liang et al. 1999), it is, therefore, important to assess the 
molecular mechanism of autophagic cell death in MCF-7TaxR cells by examining the 
expression of Beclin 1. In addition, we detected LC-3 expression in parental MCF-7 and 
MCF-7TaxR cells treated with staurosporine using Western blot analysis. LC-3I was 
localized to tlie cytosol, suggesting that, during the autophagy process, LC-31 is cleaved 
and conjugated to phosphatidylethanolamine to form LC-3 H, which is important for 
autophagosome formation (Kondo et a l 2005). LC-3 detection has been used to estimate 
the abundance of autophagosomes in previous studies (Kondo et a l 2005).
147
CHAPTER 6
Beclin 1 60 kDa
P-Actin
U
LC-31 16 kDa 
LC-3I114 kDa
Î
Ü)
2
9)
2
gS
CM
CO
o 2oc OC
5 8
t : I:iL
i
(n
t2oc
I
P-Actin
Relative densities of bands on Western blots
MCF-7 C MCF-7 0.5 MCF-7 0.5 mM MCF-7TaxR C MCF-TTaxR MCF-7TaxR
Relative ratio UM St. 24 h St. 48 h 0.5uM St. 24 h O.SpMSt. 48 h
LC-3II/LC-3I 1 0.8 0.7 0.6 1 0.7
Figure 6-3: Expression of Beclin 1 and LC-3 in staurosporine treated MCF-7 and 
MCF-7TaxR cells.
Whole cell lysates were made following 24 h or 48 h 0.5 pM staurosporine treatment, as 
described in the Materials and Methods. Samples (50 pg protein) were electrophoresed on 
a 10%-12% SDS-PAGE gel. The proteins were then transferred to a PVDF membrane and 
probed with a polyclonal ant-rabbit BECNl antibody (Santa Cmz Biotechnology Inc) or a 
monoclonal anti-rabbit LC3B antibody (Cell Signaling Corp), at a 1:200 or 1:1000 
dilution, respectively. The immunoreactive bands were revealed by further incubation of 
the immunoblot with an anti-rabbit alkaline phosphatase antibody (Invitrogen™) followed 
by incubation with a chemiluminescent substrate ( I n v i t r o g e n ™ ) .  The densitometric ratios 
of LC-3II were calculated with respect to LC-31. Data shown are representative of repeat 
experiments (n = 3).
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In Figure 6-3, Western blot analysis showed that Beclin 1 was expressed in untreated and 
staurosporine treated MCF-7 and MCF-7TaxR cells. The level of Beclin 1 was increased 
in MCF-7TaxR cells following treatment with staurosporine, an effect not seen for MCF-7 
cells. An important autophagic marker, LC-3 was also examined. The two forms, LC-3 1 
and II, were expressed in MCF-7 and MCF-7TaxR cells in the presence and absence of 
0.5 pM staurosporine.
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Figure 6-4: Expression of LC-3 in MCF-7 and MCF-7TaxR following treatment with 
verapamil.
Whole cell lysates were made following 24 h or 48 h 5 pM verapamil treatment, as 
described in the Materials and Methods. Samples (50pg protein) were electrophoresed on 
a 12% SDS-PAGE gel. The proteins were then transferred to a PVDF membrane and 
probed with a monoclonal anti-rabbit LC3B antibody (Cell Signaling Corp) at a 1:1000 
dilution. The immunoreactive bands were revealed by further incubation with an anti­
rabbit alkaline phosphatase antibody (Invitrogen™) followed by incubation with a 
chemiluminescent substrate (Invitrogen™). The densitometric ratios of LC-3II were 
calculated with respect to LC-31. Data shown are representative of repeat experiments (n = 
3).
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It can be seen from Figure 6-4 that MCF-7TaxR cells had higher levels of LC-3II than 
MCF-7 parental cells, following treatment with 5 pM verapamil. Since verapamil is a Ca"**^  
channel antagonist, these results suggest that verapamil may stimulate autophagic ceU 
death (Williams et al. 2008). During the autophagic process, LC-31 is converted to LC-3II 
which is involved in autophagosome formation. Therefore, the high ratio of LC-3II to LC- 
31, indicates that verapamil treatment enhanced the induction of autophagic cell death. The 
MCF-7 cells showed higher levels of LC-31 than the converted form LC-3II, suggesting a 
higher level of autophagic activity in MCF-7TaxR cells. These data were confirmed and 
explored in more detail in the following sections.
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6.7.2 Autophagic vacuole detection by acridine orange 
staining using fiow cytometric analysis
To detect autophagic cell death in the MCF-7 and paclitaxel resistant MCF-7TaxR cell 
lines, we performed acridine orange staining with flow cytometry, which has been widely 
used for the identification of autophagy, offering a semiquantitative assessment of the 
process (Klionsky and Ohsumi 1999). Acridine orange was used to stain the acidic 
vesicles associated with autophagic vacuoles in MCF-7 and MCF-7TaxR cells. MDA- 
MB-231 cells were used as a negative control. The treatment period for MDA-MB-231 
cells was 24 h (as opposed to 48 h for the MCF-7 cell lines), as this cell line is very 
sensitive to drug tieatment and a 48 h exposure gives rise to very substantial amounts of 
cell deatli, making analysis difficult. Cells were treated witli staurosporine and 
bafilomycin (an autophagy inhibitor). Bafilomycin inhibits the vacuolar H^-ATPase, the 
enzyme that mediates acidification of autophagic vacuoles (Paglin et a l 2001). Samples 
were analysed using flow cytometric analysis and acridine orange staining was measured 
at 630 nm for red fluorescence and at 525 nm for green fluorescence (Figure 6-5).
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Figure 6-5: Quantitation of acidic vesicles in MDA-MB-231, MCF-7, and MCF- 
TTaxR cells by acridine orange staining using flow cytometric analysis.
The histograms are representative of typical data obtained. Cells were treated with 5 pM 
bafilomycin or 1 pM staurosporine, or both drugs for 24 h or 48 h. Cells were harvested 
and processed for acridine orange staining as described in the Materials and Methods. 
Samples were then analysed using flow cytometric analysis of acridine orange stained 
cells at 630 nm for red fluorescence and at 525 nm for green fluorescence.
The data presented in Figure 6-5 are representative of the acridine orange staining analysis 
for MDA-MB-231, MCF-7, and MCF-7TaxR cells. In (a), treatment of MDA-MB-231 
cells with staurosporine resulted in a decrease in the percentage of living cells (F3), and 
the decrease was similar to that in cells treated with bafilomycin in the presence of 
staurosporine. These results indicate that no inhibitory effect of bafilomycin on autophagy 
was present in these cells and most likely indicates an absence of this form of cell death. 
In (b), MCF-7 cells treated with staurosporine showed a decrease in the live cell 
percentage (F3). In (c), staurosporine treatment resulted in a drop in the number of (F3)
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live MCF-7TaxR cells. The cell death of MCF-7TaxR cells was suppressed when the cells 
were treated with staurosporine and bafilomycin, again indicating the presence of 
autophagic cell death in the presence of cellular stress.
□  1 uM  S t
n  1 uM  S t +  5  u M  B af
* * *
MDA-MB-231 M CF-7 MCF-TTaxR
Figure 6-6: Inhibition of autophagy in MCF-7TaxR cells treated with bafîlomycin.
The graph shows a significant level of autophagic cell death inhibition in MCF-7 and 
MCF-7TaxR cells treated with bafilomycin. Data (obtained from the low acridine orange 
staining, F3 quadrant) are means of 3 independent experiments; error bars show ±SD. ** 
p = 0.038, and *** p = 0.012, using a paired Student’s T-test.
As shown in Figure 6-6, there was no significant difference in red fluorescence between 
MDA-MB-231 staurosporine treated cells and those treated with both staurosporine and 
bafilomycin (p= 0.921). These data suggest that MDA-MB-231 cells are devoid of 
autophagic cell death. However, there was a significant difference between MCF-7 cells 
treated with staurosporine and MCF-7 cells treated with both staurosporine and 
bafilomycin (p= 0.038). Additionally, there was a significant difference between MCF- 
7TaxR cells treated with staurosporine and those treated with both staurosporine and 
bafilomycin (p=0.012). These data indicate an inhibitory effect of bafilomycin on 
autophagic cell death in MCF-7 cells, with an even more pronounced effect in MCF-
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7TaxR cells. The level of autophagy seen in the breast cancer cell lines examined can be 
ascribed the following order: M DA-M B-231« MCF-7< MCF-7TaxR.
6.7.3 Detection of the autophagic ceii death marker LC-3 by 
immunostaining
The localization of LC-3, a subunit of microtubule-associated proteins lA  and IB, was 
investigated in MCF-7 and MCF-7TaxR cells. LC-3 has been described as a reliable 
marker for autophagic activity (Kabeya et al. 2000; Mizushima et al. 2004). MDA-MB- 
231 cells were used as a negative control for LC-3 detection as we failed to see any 
evidence of autophagy in this model. In order to make valid comparisons between the 
various cell lines, it was necessary to use the same instrument imaging settings for MCF- 
7TaxR cells as for MCF-7 and MDA-MB-231 cells.
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Figure 6-7: Confocal microscopy imaging of LC-3 in MCF-7 and MCF-7TaxR cell 
lines.
Cells were incubated with 0.5 pM or 0.25 pM staurosporine for 24 h, harvested, and 
processed as described in Materials and Metliods. Imaging of the cells was caiiied out by 
confocal microscopy (Carl Zeiss Laser Scanning System LSM510 (multi scan mode, 2 
channels, wavelengtlis 488 nm and 633 nm). The MCF-7TaxR cells treated with 
staurosporine in (j) and (k) revealed a high level of LC-3 staining, as did the controls (i). 
In the enlarged image (L2), a higher level of LC-3 staining was observed in the MCF- 
7TaxR cells than in the MCF-7 cells (hi and h2). Data are representative of repeat 
experiments (n = 3).
In Figure 6-7, the MDA-MB-231 untreated staurosporine treated cells showed no evidence 
of LC-3 staining, indicating the absence of autophagy in these cells. LC-3 was clearly 
detectable in the contix)! untreated MCF-7TaxR cells as well as in the treated MCF-7TaxR 
cells, where the LC-3 level was higher and more intense. The changes in tlie intracellular- 
localization of LC-3, as seen in the MCF-7TaxR images (Figure 6-7) and in the enlarged 
image (12), indicates a substantial recruitment of LC-3 to autophagic membranes, 
indicating autophagic activity, hr the MCF-7 untreated control, LC-3 localization was also 
detectable and was the same as in MCF-7 cells treated witli staurosporine, although the 
LC-3 level was lower than in MCF-7TaxR cells.
6.7.4 Electron microscopy analysis of autophagic vacuole 
formation
For the detection of autophagosomes in MCF-7TaxR cells and MCF-7 cells, we 
performed an electron microscopy analysis. Electron microscopy is one of the methods of 
choice for the investigation of autophagic cell death, and its use has been established in 
numerous studies (Klionsky et a l  2007). The electron microscopy analysis was carded out 
as described in Chapter 2 under Materials and Methods. The processing and embedding of
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cells was performed in collaboration with Brunei University, Department of Biosciences. 
Samples (on copper grids) were analysed by scanning transmission electron microscopy 
(STEM, Philips CM200 TEM) at the MSSU, University of Surrey. Imaging was 
performed by Dr Vladimir Stolojan (Figure 6-8).
Figure 6-8: Electron microscopy imaging for MCF-7 cells.
Electron microscopy was carried out as described in Chapter 2, Materials and Methods. 
Images of MCF-7 control cells, and treated with 0.5 pM staurosporine for 48 h. The 
images were obtained using a Philips CM200 Transmission Electron Microscope (power 
200kVx 13.0k). The bar indicates 5 pm or 2 pm magnification. A+B= artefact, C=possible 
burning by E.M source (shown by arrows), D=membrane blebbing, N=nucleus.
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Figure 6-9: Electron microscopy imaging for in MCF-7TaxR cells.
Electron microscopy was carried out as described in Chapter 2, Materials and Methods. 
Images of MCF-7TaxR control cells, and treated with 1 pM staurosporine for 48 h. The 
images were obtained using a Philips CM200 Transmission Electron Microscope (power 
200kVx 13.0k). The bar indicates 2 pm magnification. A= possible artefact effecting 
nuclear morphology, B= marked membrane blebbing, C= multiple small vesicle formation 
(shown by arrows), D= artefact, N=nucleus.
In Figure 6-8 and Figure 6-9, artefacts include problems with condition of cells prior to 
embedding (excessive membrane blebbing in untreated cells 6.9.B). Shrinkage of nucleus 
and cytoplasm seen in 6.8.A; evidence of problems with section cutting (possible
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problems witli embedding resin consistency) seen in 6.8.B and 6.9.D.
The electron microscopy images in Figure 6-8 and Figure 6-9, were taken for possible 
autophagosome detection in MCF-7 and MCF-7TaxR cells. However, due to the technical 
artefacts, images were difficult to inteipret. However, the cytoplasm in MCF-7TaxR 
treated wiüi staurosporine (6.9 bottom left and right) indicated a high number of small 
vesicle formation (possibly lysosomal). Control and staurosporine treated MCF-7 cells 
showed more intact cytoplasm with less vesicular structures apparent. Evidence of 
autophagolysosome structures was inconclusive due to technical difficulties e.g. artefact, 
resolution used and limited number of clear images showing cellular stinctures.
6.7.5 inhibition of autophagy by the inhibitors 3-MA and 
LY294002 detected by the MTT assay
Our previous observations showed some evidence of autophagosome formation in MCF- 
7TaxR cells (based on LC3 examination). Therefore, we decided to explore tliis further 
using different PI3K inhibitors that have been widely used to cause autophagy inhibition 
in prior studies (Liang et al. 1999; El-Kholy et al. 2003; Moretti et al. 2007). We used 3- 
metliyladenine (3-MA), which has been used to inhibit vacuole formation via PI3K class 
111 inhibition during autophagy (Moretti et al. 2007). Also, we used LY294002 which was 
demonstrated in a previous study to inhibit the kinase activity of PI3K (Blommaait et al. 
1997; Chen and Karantza-Wadsworth 2009). The experiment was cairied out using the 
MTT cell viability assay (Figure 6-9 and 6-10). Doses of 300 nM 3-MA or 10 pM 
LY294002 were administered concomitantly with a cytotoxic dm g dose of cisplatin for a
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72 h period to the MCF-7 and MCF-7TaxR cells in 96 well plates. Results were expressed 
as IC50 values, which were calculated as the drug doses that caused 50% cell death relative 
to the untreated controls, as described in the Materials and Methods.
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Figure 6-10: A signifîcant loss of cisplatin cytotoxicity in MCF-7 and MCF-7TaxR 
cells in response to 3-methyladenine co-administration.
MTT assay, MCF-7 and MCF-7TaxR cells were grown in 96 well plates at a cell density 
of 2x10^ - 3xlO'*/ml for 24 h. After treatment with cisplatin or a combination of cisplatin 
and 300 nM 3-MA, the cells were incubated for a further 72 h. Each data point is the mean 
of 3 independent experiments (performed in triplicate); error bars are ±SD.
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Figure 6-11: A significant loss of cisplatin cytotoxicity in MCF-7TaxR cells in 
response to LY294002.
MTT assay, MCF-7 and MCF-7TaxR breast cancer cells were grown in 96 well plates to a 
cell density of 2x1 O'* - 3xlO'*/ml for 24 h. After treatment with cisplatin or a combination 
of cisplatin and 10 pM LY294002, the cells were incubated for 72 h. Each data point is the 
mean of 3 independent experiments (performed in triplicate); error bars are ±SD.
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Cells Cisplatin (ICso) 
pM
Cisplatin + 3-MA (iCso) 
pM
Cisplatin + LY294002 ( I C 5 0 )  
pM
MCF-7 20.6 (±1.15) 34 (±4.5) p=0.036** 31 (±11.7) p=O.M**
MCF-7TaxR 6.2 (±1.5) 17 (±7.4) p=0.046** 34 (± 1.4) p =0.01***
Table 6-1: The IC50 values for MCF-7 and MCF-7TaxR cells treated with cisplatin, 
cisplatin +3-MA, or cisplatin + LY294002.
The IC50 values are the means of 3 independent MTT assays (performed in triplicate); the 
±SD values are shown in parentheses, p values were calculated using a paired Student's 
test of cisplatin IC50 versus the IC50 of cisplatin with 3-MA or LY294002. p**< 0.05,
p***<0.02..
As shown in Figures 6-10 and 6-11, 300 nM 3-MA or 10 pM LY294002 was administered 
concomitantly with a cytotoxic drug dose of cisplatin for 72 h to MCF-7 and MCF-7TaxR 
cells. The statistical significance in the differences in cisplatin cytotoxicity with co­
administration of either 3-MA or LY294002 is shown in Table 6-1. The LY294002 
inhibitor was more efficient in reducing drug sensitivity than 3-MA in MCF-7TaxR cells.
6.7.6 Detection of Akt/mTOR expression by Western blot 
analysis
The PI3K/Akt/mTOR pathway axis is a prototypic survival mechanism, and constitutive 
activation of this pathway is commonly encountered in human cancers (LoPiccolo et al.
2008). Abnormal activation of this pathway has been shown to cause inhibition of 
autophagy (Arico et a l 2001; Ueno et a l 2008). Therefore, it was relevant to investigate 
the expression of Akt/mTOR and its downstream effector S6K in MCF-7 and MCF- 
7TaxR cells in response to staurosporine or the mTOR inhibitor rapamycin. Cells treated 
with 0.5 pM staurosporine were subjected to Western blot analysis to detect the 
expression of Akt, mTOR, and S6/P-S6K. In addition, cells were treated with a dose of
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rapamycin (40 pM), which was chosen after testing of different doses of rapamycin in the 
MTT assay (data not shown) with MCF-7 and MCF-7TaxR cells. The data we obtained 
indicated that 20 pM rapamycin had no effect on cell viability. Moreover, we note that 
rapamycin analogues such as RADOOOl are many fold more potent in vitro than 
rapamycin (based on other studies carried out in our laboratory, unpublished). Thus, we 
treated cells with 40 pM rapamycin and, then, performed Western blot analysis for mTOR 
expression.
Akt 60kDa
P-Akt[pS*^] 65 kDa
P-Actin
Relative densities of bands on Western blots
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ratio
MCF-7 C MCF-7 0.5 mM 
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MCF-TTaxR C MCF-7TaxR 0.5 
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pM St. 48 h
P-Akt/ Akt 0.72 0.3 0.3 0.74 0 0.2
Figure 6-12; Detection of Akt/P-Akt expression in MCF-7 and MCF-7TaxR cells 
following staurosporine treatment.
Whole cell lysates were made following 24 h or 48 h 0.5 pM staurosporine treatment, as 
described in the Materials and Methods. Samples (50 pg protein) were electrophoresed on 
a 10% gel. After transfer of the proteins to a PVDF membrane, the membrane was probed 
with a polyclonal anti-rabbit Akt antibody or a monoclonal anti-rabbit P-Akt [pS**^ ]^ 
antibody (Biosource) at dilutions of 1:200 for both. Then, the blot was exposed to an anti­
rabbit alkaline phosphatase antibody (Invitrogen™). Bands were detected using a 
chemiluminescent substrate (Invitrogen™).The densitometric ratios of P-Akt were 
calculated with respect to Akt. Data are representative of repeat experiments (n = 3).
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As shown in Figure 6-12, the ratio of phosphorylated Akt:Akt was similar for both control 
MCF-7 parental and paclitaxel resistant lines. After treatment with staurosporine for 24 h 
or 48 h, MCF-7 cells expressed Akt, whereas MCF-7TaxR cells showed only a wealc 
signal for Akt protein. Phosphorylated-Akt [pS'*^ ]^ was reduced in staurosporine treated 
MCF-7 cells, whereas it was completely absent in MCF-7TaxR cells under the same 
conditions.
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Figure 6-13: Expression of mTOR and 70S6K in MCF-7 and MCF-7TaxR cells 
following staurosporine treatment.
Whole cell lysates were made following 24 h or 48 h 0.5 pM staurosporine treatment, as 
described in the Materials and Methods. Samples (50 pg protein) were electrophoresed on 
a 7% or a 12% gel. After transfer to a PVDF membrane, the proteins were probed with 
polyclonal anti-rabbit mTOR/P-mTOR (Ser2448) antibodies or S6K/P-S6K (Ser371) anti­
rabbit antibodies (obtained from-Cell Signaling Corp) at a dilution of 1:1000. The 
membrane was then exposed to an anti-rabbit alkaline phosphatase antibody 
( I n v i t r o g e n T M ) ,  Bands were detected by using a chemiluminescent substrate 
(Invitrogen^^). The densitometric ratios of P-mTOR and P-S6K were calculated with 
respect to mTOR and S6K respectively. Data shown are representative of repeat 
experiments (n = 3).
In Figure 6-13, mTOR protein was expressed in untreated MCF-7 and MCF-7TaxR cells 
as well as in MCF-7 and MCF-7TaxR cells treated with staurosporine. However, 
phosphorylated mTOR was only expressed in the control and staurospoiine-treated MCF- 
7 cells. The MCF-7TaxR control and treated cells showed some expression of mTOR, but
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the treated cells showed no evidence of phosphorylated mTOR (Ser 2448). S6K and its 
phosphorylated form, P-S6K (Ser371), were detected in both untreated and staurosporine- 
treated MCF-7 cells. Untreated MCF-7TaxR cells showed a low but detectable level of 
S6K protein expression, but S6K and P-S6K (Ser371) expression was abolished following 
staurosporine treatment.
mTOR 289 kDa
P-mTOR (Ser2445) 289 kDa
P-Actin
Relative band density ratios on Western blots.
Relative ratio MCF-7 C
MCF-7 40 (jM Rap. 48 h MCF-7TaxR C MCF-7TaxR 40 pM Rap. 48 h
P-mTOR/mTOR 0.36 0 0.47 0
Figure 6-14: Expression of mTOR and P-mTOR in MCF-7 and MCF-7TaxR cells 
following rapamycin treatment.
Whole cell lysates were made following 24 h or 48 h 40 pM rapamycin treatment, as 
described in the Materials and Methods. Samples (50 pg protein) were electrophoresed on 
a 7% gel, and the proteins were transferred to a PVDF membrane. After probing with 
poly-clonal anti-rabbit mTOR/P-mTOR antibodies (Ser2448) (obtained from-Cell 
Signaling Corp) at a dilution 1:1000, the blot was exposed to an anti-rabbit alkaline 
phosphatase antibody (Invitrogen™). Bands were detected using a chemiluminescent 
substrate (Invitrogen™). The densitometric ratios of P-mTOR were calculated with 
respect to mTOR. Data shown are representative of repeat experiments (n = 3).
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Figure 6-14 shows that MCF-7 and MCF-7TaxR cells treated with rapamycin expressed 
varying amounts of mTOR. hi control untreated MCF-7 and MCF-7TaxR cells, mTOR 
and P-mTOR (Ser2448) were expressed. When MCF-7 and MCF-7TaxR were treated 
with rapamycin, there was a complete abolition of phosphorylated mTOR (Ser2448), 
indicating that rapamycin inhibits the phosphorylation of mTOR.
6.7.7 Serum free medium deprivation test for autophagy 
inhibition in MCF-7 and MGF-7TaxR cells.
To further evaluate the inhibition of autophagy in MCF-7 and MCF-7TaxR cells, we grew 
MCF-7 and MCF-7TaxR cells in serum free medium (absence of essential growth 
factors), hai'vested them, and then fiuther processed them for Annexin V-FITC/PI analysis 
to reveal the presence of an apoptotic population. This approach was used because the 
removal of serum growth factors horn the culture medium switches off the 
autophagy-suppressive pathway dependent on PI3K class I (Petiot et a l  2000). This 
analysis was carried out by seeding cells in standard medium (containing essential growth 
factors) in parallel with cells seeded in 1% serum containing medium and semm free 
medium for 72 h. Cells were tlien harvested and processed for Annexin V-FITC/PI 
labelling.
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Figure 6-15: Annexin V-FITC/PI analysis of MCF-7 and MCF-7TaxR cells in the 
presence of 1 % serum medium or serum free medium.
The histograms are representative of typical data obtained. Cells were seeded in standard 
culture medium containing 10% PCS, 1% PCS, or in serum free medium for 72 h and 
harvested and processed for Annexin V-FITC/PI staining as described in Chapter 2, 
Materials and Methods. The percentages of cells in each of the quadrants represent the 
mean of three experiments.
The data shown in Figure 6-15 indicate that both MCF-7 and MCF-7TaxR cells respond to 
semm deficiency with an increased level of apoptosis. MCF-7 and MCF-7TaxR cells 
grown in 1% medium showed no alteration in cell viability compared to control cells. 
Using semm free medium, 16.6% early apoptotic cells were detected in MCF-7 cells and 
8.8% were detected in MCF-7TaxR cells.
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Figure 6-16: Data analysis of Annexin V-FITC/PI staining of MCF-7 and MCF- 
7TaxR cells.
The graph shows the differences in cell death inhibition in serum free medium and in 1% 
serum medium compared to controls (cells with -ve Annexin V-FITC/ -ve PI staining 
quadrant, F3). MCF-7 and MCF-7TaxR cells were no significantly different in control 
versus serum free medium. (#) p>0.05, using a paired Student’s t-test. Error bars, ±SD. 
Data shown are representative of repeat experiments (n = 3).
6.8 Discussion
In this chapter, we provided evidence for upregulation of the autophagic cell death 
pathway in paclitaxel resistant MCF-7 breast cancer cells. We used the most widely used 
methods for autophagic cell death detection, including confocal microscopy analysis of 
LC-3, detection of Beclin 1, LC-3 and Akt/mTOR by Western blotting, acridine orange 
staining and flow-cytometry analysis, and detection of autophagy inhbition using different 
agents (3-MA and LY294002), with cell viability readouts.
MCF-7 cells have already been established as models for the investigation of alternative 
cell death responses due to the constitutive absence of caspase-3 in these cells (Kurokawa 
et al. 1999; Simstein et al. 2003; Lamparska-Przybysz et al. 2006). This major apoptotic
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defect gives rise to a number of changes in the routing of cell death signals in MCF-7 
cells, and in the development of drug resistance, as we observed for tlie paclitaxel resistant 
MCF-7TaxR model. A previous study demonstrated induction of autophagic cell death in 
MCF-7 cells witli tamoxifen treatment (Bursch et a l 1996). Another study, by Cui et a l 
(2007), showed induction of autophagy in MCF-7 cells treated by oridonin, a Chinese 
herbal extract that is widely used in the clinical setting (Cui et a l 2007). Our screen for 
apoptotic genes in paclitaxel resistant MCF-7TaxR cells demonstrated a complete absence 
of most major apoptosis regulators, such as caspase-3, -6, -7, and caspase-9, which led us 
to hypothesize that a non-apoptotic process such as autophagy is likely to be the 
predominant cell death mechanism operating in these cells.
Beclin 1 is an essential and major regulator of autophagy; it is alternatively refeiTed to as 
the mammalian autophagy gene Atg6, which is required for autophagosome formation in 
conjunction with class III PI3Ks (Kondo et a l 2005). Different studies have reported that 
frequent loss of Beclin-1 protein expression in breast cancers correlates with the loss of 
tumour suppressor functions of Beclin-1 (Liang et a l  1999). Beclin-1 is an important 
autophagy regulator, since human Beclin-1 is mono-allelically deleted in approximately 
75% of ovariatr cancers, 50% of breast cancers, and 40% of prostate cancers (Aita et a l 
1999). In addition, the level of Beclin 1 protein was significantly decreased in 18 of 32 
breast cancer cases using irnmunohistochemical analysis, suggesting a carcinoma cell- 
specific loss of Beclin 1 expression (Gozuacik and Kimchi 2004). Here, we demonstrated 
that expression of Beclin-1 increased in MCF-7TaxR staurosporine treated cells. The 
expression of Beclin 1 in MCF-7TaxR cells suggests that the cells are potentially 
autophagy positive. The tumour suppressor properties of Beclin 1 were demonstrated in
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vitro by clonogenic assays and in vivo by assessing tiimorigenicity in nude mice (Liang et 
a l 1999; Liang et a l 2001). In subsequent studies, Beclin 1 expression was detected in 
MCF-7 breast cancer cells and associated with increased formation of autophagic vesicles, 
which is consistent with our current findings (Gozuacik and Kimchi 2004). Also, in our 
investigation, Beclin 1 was expressed in MCF-7 control and staurosporine treated cells, 
and this result agrees with previous studies involving the MCF-7 cell line (Liang et a l 
1999).
Another major maiker for the presence of autophagosome formation is LC-3, as described 
in various studies (Kondo et a l 2005). LC-3 is the microtubule-associated protein 1 light 
chain 3 (MAPI LC-3), the mammalian homolog of yeast Atg8, which participates in 
autophagosome formation and is an important element of autophagosome membranes 
(Kondo et a l  2005). LC-31 is a marker for autophagy induction and is subsequently 
converted to tlie lipid conjugated form, LC-3II, which is associated with acidic autophagic 
vacuoles, the so-called autophagolysosomes (Kabeya et a l 2000; Mizushima et a l 2004). 
Formation of LC-3II leads to upregulation of the major autophagy proteins Atg5 and 
Beclin 1 (Figure 6-1) (Kabeya et a l 2000; Mizushima et a l 2004). In addition, different 
studies have shown that the LC-3II form is mainly localised to the autophagosome 
membranes (Kabeya et a l  2000). A study of PC-3 human prostate cancer cells, showed 
the presence of the processed LC-3II form, which is indicative of the redistribution of LC- 
3n to autophagosomes, by immunoblotting cell lysates from sulporaphane treated cells 
(Herman-Antosiewicz et a l 2006). Here, we demonstrated by Western blotting, the 
constitutive expression of LC-3/Atg8 (LC-3 I and II) in both MCF-7 and MCF-7TaxR 
cells, and in staurosporine treated samples. Furthermore, the MDR inhibitor verapamil has
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been suggested to stimulate autophagic cell death (Williams et a l 2008), and treatment of 
MCF-7 and MCF-7TaxR cells with verapamil increased expression of LC-31 and II in 
both cell types. However, LC-3II was expressed at a much higher level in MCF-7TaxR 
cells. These data were further corroborated by confocal microscopy which detected the 
localisation of LC-3 in the cytoplasm of the cells. MCF-7TaxR cells showed a higher LC- 
3 level than MCF-7 cells. In a study of MCF-7 cells administered fenretinide, cells died 
via autophagic cell death (Fazi et a l 2008). The MCF-7 cell response to fenretinide 
treatment was associated with an increase in Beclin 1 expression with conversion of LC-3 
to the autophagic vesicle-associated LC-3II form with a shift from a uniform distribution 
to a more punctuate staining pattern and an increase in lysosome/autophagosome 
formation (Fazi et a l 2008). The positive detection of LC-3 was very important, since this 
protein is widely recognized as a maiker for autophagic cell death (Yang et a l 2008).The 
detection of LC-3 is considered proof of the development of the early stages of autophagy 
(Yang et a l 2008) and, hence, positive detection of LC3 in MCF-7TaxR cells is a further 
indication of the presence of autophagy in these cells.
The fonnation of autophagic vacuoles is a characteristic feature of autophagic cell death in 
cells responding to different cytotoxic treatments (Paglin et a l 2001; Daido et a l 2004). 
Acridine orange is a dye tliat moves freely across biological membranes in an uncharged 
state, and is characterised by green fluorescence (Arvan et a l 1984; Mains and May 1988; 
Traganos and Darzynkiewicz 1994; Heiman-Antosiewicz et a l 2006). However, the 
protonated foim of acridine orange accumulates in acidic compartments and forms 
aggregates, which are characterised by red fluorescence (Arvan et a l 1984; Mains and 
May 1988; Traganos and Darzynkiewicz 1994; Herman-Antosiewicz et a l 2006).
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Acridine orange stains lysosomes, which are involved in autophagosome formation, since 
the number of lysosomes is usually higher in autophagic cells (Kanzawa et a l 2004). 
Lysosomes are normally acidic and, therefore, acridine orange stains the acidic vesicles or 
autophagolysosomes (Kanzawa et a l 2004). Our data generated from acridine orange 
staining experiments with flow cytometry revealed a positive detection of acidic vesicles 
in both MCF-7 and MCF-7TaxR cells, compared to MDA-MB-231 cells. The use of the 
autophagy inhibitor bafilomycin produced a significant inhibition in MCF-7 cells, and 
even more so in MCF-7TaxR cells. Bafilomycin inhibits the vacuolai' HLATPase, the 
enzyme tliat mediates acidification of autophagic vacuoles (Paglin e ta l 2001). From tliese 
experiments, the MCF-7TaxR cell line was shown to undergo the greatest amount of 
autophagy in response to staurosporine freatment. These data agree with the results of the 
confocal microscopy experiments. Therefore, tlie levels of autophagic cell death activity 
can be expressed in following tlie order: MCF-7TaxR»MCF-7 >»M DA-M B -231. A 
previous study showed that autophagy could be induced in MCF-7 cells using plumbagin, 
an anticancer drug that induces G2-M anest and blocks cell proliferation (Kuo et a l
2006). However, according to our data, electron microscopy imaging did not show 
evidence of autophagosomes formation in MCF-7TaxR or MCF-7 cells due to a technical 
artefact. However, a previous study with MCF-7 cells showed evidence of autophagosome 
formation by electron microscopy imaging (Kuo et a l 2006). However, our electron 
microscopy imaging showed an altered cytoplasm in staurosporine treated MCF-7TaxR 
compared to control but no obvious double membrane structures characteristic of 
autophagosome formation.
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The use of class III PI3K inhibitors, such as 3-MA, has been shown to block autophagic 
sequestiation in cancer cells (Klionsky et al. 2007; Chen and Karantza-Wadsworth 2009). 
The drug 3-MA inhibits autophagic sequestration by inhibiting the PI3K class III mVps34 
(Petiot et a l 2000). LY294002, also a class I and III PI3K inhibitor (Blommaait et al. 
1997; AM et al. 2003; Chen and Karantza-Wadsworth 2009). We investigated the extent 
of autophagy taMng place in MCF-7 versus MCF-7TaxR cells. Our data demonstrated a 
significant inhibition in cell viability in response to 3-MA in MCF-7 and MCF-7TaxR 
cells. Also, LY294002 produced a marked inhibitory effect on cell death which was more 
significant for MCF-7TaxR cells. Taken together, our data are consistent with previous 
studies indicating the autophagy suppressive effects of LY294002 and 3-MA (Blommaart 
etal. 1997; AM et al. 2003; Chen and Karantza-Wadsworth 2009).
A number of earlier studies reported that the Akt pathway is deregulated in different 
malignancies, leading to increased cancer cell proliferation and survival (Huang and Hung 
2009). Activation of tlie class I PI3K/Akt pathway has been shown in numerous cancers, 
such as breast cancers, since receptor tyrosine Mnases (RTKs) and the epidermal growth 
factor receptor (EGFR) are widely overexpressed in many cancers, leading to activation of 
the class I PI3K/Akt pathway (Huang and Hung 2009). hi addition, activation of class I 
PI3K/Akt confers acquired resistance to chemotherapies in cancers and is associated with 
apoptosis resistance by its phosphorylation of downstream targets (Huang and Hung
2009). Constitutive activation of the PI3K/Akt/mTOR pathway is a common occurrence in 
human cancers, such as ovarian, breast, and gastric cancers (Lee et al. 2005). Akt and 
phosphorylated-Akt proteins are slightly inhibited in MCF-7 cells, but are even more so in 
MCF-7TaxR cells. Thus, inhibition of these proteins in MCF-7TaxR cells is likely to be
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associated with autophagic cell death activation, which is consistent with previous studies 
(Nair and Klionsky 2005; Arsham and Neufeld 2006; Suzuki and Ohsumi 2007). A study 
on glioma xenografts used class I PI3K and mTOR inhibitors which inhibit Akt 
phosphoiylation and block cell proliferation without inducing apoptosis (Fan et al. 2006). 
We observed an inhibition of PBK/Akt in response to staurosporine treatment in MCF- 
7TaxR cells, but not in MCF-7 cells, which indicated autophagic cell death in the foimer. 
mTOR is another recognised downstream target of the Akt pathway and the gatekeeper of 
autophagy (Nair and Klionsky 2005; Yang et al. 2005; Arsham and Neufeld 2006; Suzuki 
and Ohsumi 2007). In response to staurosporine treatment, mTOR expression was 
obsei-ved in MCF-7TaxR cells, where P-mTOR was completely absent compared to MCF- 
7 cells. Staurosporine is a protein kinase C (PKC) inhibitor that inhibits P-mTOR in MCF- 
7TaxR cells. Thus, our data may indicate that MCF-7TaxR cells are highly sensitive to 
autophagic cell death. S6K (p70S6K) is another important downstream effector in the 
mTOR pathway, and its expression correlates with autophagic activity (Codogno and 
Meijer 2005; Klionsky et al. 2005). Inhibition of mTOR function can occur as a result of a 
block to phosphorylation of downstream molecules such as P-S6 kinase (P-p70S6K) and 
eukaiyotic initiation factor 4E-binding protein 1 (4E-BP1), leading to G 1-arrest and 
induction of autophagy (Huang and Houghton 2003; Sawyers 2003; Takeuchi etal. 2005). 
The expression of S6K and P-S6K were examined in the MCF-7 and paclitaxel resistant 
cell lines following staurosporine treatment. S6K and P-S6K were not expressed in MCF- 
7TaxR cells, indicating inhibition of the expression of these proteins in these cells. This 
result was expected, since mTOR inhibition was previously observed in the MCF-7TaxR 
cell line. Since S6K inhibition was due to inhibition of its principal regulator mTOR, this 
downstream substrate should also be inhibited, as observed in MCF-7TaxR cells.
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Rapamycin, one of the main mTOR inhibitors, has chemotherapeutic antitumor activity in 
various models (Aoki et al. 2001; Faivre et al. 2006). Rapamycin is a highly specific 
inhibitor of mTOR activity which binds to the cytosolic FK-rapamycin binding protein 
(FKBP-12) (Kuimasheva et al. 2006). The FKBP-rapamycin complex binds to the FK- 
rapamycin binding (FRB) domain of mTOR, resulting in inhibition of mTOR function 
(Kuimasheva et al. 2006). According to tlie results of Western blot analysis, die P-mTOR 
level was reduced following a 40 pM rapamycin treatment, in both MCF-7 and MCF- 
7TaxR cells. We tested 20 pM rapamycin on the expression of P-mTOR in MCF-7TaxR 
and MCF-7 cells, but it did not inhibit mTOR activity (data not shown); this reflects 
differences in the responses of cancers cells to anticancer drugs. However, the use of both 
staurosporine and rapamycin helped us to delineate the differences between the MCF-7 
and MCF-7TaxR cell autophagic processes. The activity of autophagy is increased in 
response to nutrient deficiency (Codogno and Meijer 2005). In addition, the removal of 
serum growth factors fiom culture medium switches off the autophagy-suppressive 
pathway dependent on PI3K class I (Petiot et al. 2000). Our results using serum fiee 
medium and the Annexin V-FITC/PI analysis showed the presence of apoptotic cells 
among the MCF-7 cell population, whereas MCF-7TaxR cells exliibited no apoptotic cell 
deatli.
Our findings are the first to show that the paclitaxel resistant breast cancer cell line MCF- 
7TaxR readily commits to an autophagic cell death mechanism in response to various 
cytotoxic insults. MCF-7 cells undergo autophagic cell death, but also maintain some 
ability to undergo apoptosis. MCF-7TaxR cells responded markedly to autophagic 
inhibitors such as bafilomycin, as shown by acridine orange staining, and showed
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response to PI3K inliibitors, including 3-MA and LY294002, with an autophagy- 
suppressive effect resulting in reduced sensitivity to cisplatin. In conclusion, paclitaxel 
resistant MCF-7TaxR breast cancer cells commit to cell death in response to a cytotoxic 
insult via autophagic cell death-PCD II, but not via apoptosis mechanism or PCDI.
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7 Evidence fo r  Epigenetic Silencing o f Apoptotic
Genes in an M C f-7  Paclitaxel Resistant Cell Line
7.1 Overview of epigenetlcs in breast cancer
The term epigenetic is defined as the changes occurring between genes and environment 
with the development of a specific phenotype without changes in the DNA nucleotide 
sequence (Teodoridis et a l 2004). Different alterations may occur in the DNA, including 
chemical modification of proteins that are associated with DNA (Herman and Baylin 
2003). Other changes occur in DNA, such as promoter méthylation, which involves 
cytosine located 5' to guanosine, named CpG islands or CpG dinucleotides (Herman and 
Baylin 2003). Another type of epigenetic event includes histone modification (Chekhun et 
a l 2007). Hyper-methylation commonly occurs in nearly every type of cancer resulting in 
loss of gene expression; however, méthylation may also occur in normal cells or tissues 
(Visvanathan et a l 2006), Different studies have implicated the existence of DNA 
méthylation and histone modifications in cancer-dmg resistant cells (Chekhun et a l
2007). The existence of epigenetic silencing of genes such as BRCAl may occur during 
tumour progression (Esteller et a l 2000; Umbricht et a l 2001). hi addition, DNA 
méthylation of the BRCAl gene has been demonstrated in breast hyperplasia and 
carcinoma (Esteller et a l 2000; Umbricht et a l 2001). DNA modifications caused by 
germ-line mutations aie more stable and interfere witli the DNA sequence, in contrast to 
epigenetic modification which may possibly be reversed using different demetliylating 
agents and histone de acétylation inhibitor compounds (HDAC inhibitors), making tliem a 
potential taiget for cancer therapy (Herman and Baylin 2003). Recently, application of 
epigenetic detection in breast cancer was considered for early diagnosis, prevention and
182
CHAPTER 7
treatment, but is still under investigation by clinicians and researchers (Visvanathan et a l 
2006).
The mechanism of DNA méthylation involves the transfer of a methyl group to carbon 5 
of cytosine (Teodoridis et a l  2004). In a cancer cell, this mechanism is increased, leading 
to a block in gene transcription (Figure 1-8) (Teodoridis et a l 2004). The group of 
enzymes involved in this specific mechanism is the family of DNA methyltransferases 
(DNMT), DNTMl, DNTMT3a and DNTMT3b (Bhd and Wolffe 1999; Liu et a l 2003). 
DNMTI functions within the DNA replication complex which in turn binds to hemi- 
methylated DNA in order to maintain the méthylation pattern after DNA replication 
(Vertino et a l 2002). Defects in DNMTI function, or DNMTI overexpression, lead to 
changes in genetic imprinting causing embryonic lethality - this is termed de novo 
méthylation (Li et a l 1993; Biniszkiewicz et a l 2002; Teodoridis et a l 2004). DNA 
méthylation usually inhibits binding of transcription factors to gene promoters leading to 
suppression of gene transcription (Teodoridis et a l 2004). The DNA méthylation 
mechanism causes binding of a family of methyl-binding domain (MBD) proteins that 
bind specifically to methylated CpG sites on the DNA (Teodoridis et a l 2004). The MBD 
family members all share a common methyl-binding domain and tliree of these proteins 
are associated witli large protein complexes containing the histone deacetylase HDACl 
(Teodoridis e ta l  2004).
The other type of epigenetic alteration occurring in cancer is histone modifications which 
include acétylation, méthylation, and phosphorylation (Teodoridis et a l 2004). In a 
normal cell, DNA is tightly compacted to prevent transcription factors from accessing a
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gene (de Ruijter et al. 2003). The DNA is tightly packed by the chromatin and organised 
into protein-DNA complexes (Wade 2001; de Ruijter et al. 2003). The chromatin basic 
structure is composed of an octamer of four core histoires (H2/H4 tetramer) and two 
H2A/H2B dimers surrounded by 146 bp of DNA (Ito et al. 2000; Strahl and Allis 2000). 
Therefore, the DNA is highly organised and capable of facilitating control of gene 
expression (Ito et al. 2000; Strahl and Allis 2000). Prior to transcription, the compact 
DNA is inaccessible, and it is available for DNA binding proteins by modification of the 
nucleosome (Ito et al. 2000; Strahl and Allis 2000). However, the acétylation and 
deacetylation processes are kept in balance via an equilibrium between tlie activities of 
histone acetyltransferases and histone deacetylases (HDACs) (Wade 2001). Nevertheless, 
increased deacetylation activity can lead to a reduction in the level of gene transcription, 
as may be seen in cancer cells (Figure 7-1) (Ito et al. 2000; Wade 2001). This form of 
histone deacetylase activity is responsible for epigenetic histone modification (de Ruijter 
et al. 2003; Teodoridis et al. 2004). Histones deacetylases function to remove the acetyl 
groups from lysine in the N-terminal tails of histones, yielding a positively charged amino 
group and making a strong interaction between the histone N-terminus and the negatively 
charged DNA backbone allowing die DNA to be less accessible for transcription factors 
(Stmlil 1998; Strahl and Allis 2000; Teodoridis et al. 2004). In vitro studies with histone 
deacetylase inhibitors showed reduced tumour cell line proliferation and increased 
apoptosis in some cases (Marks et al. 2000; Marks et al. 2001).
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Figure 7-1: Epigenetic modifîcation of DNA in cancer cells.
Levels of méthylation (Meth) and histone deacetylatlon (HDAC) are increased, leading to 
a block gene transcription in caner cells resulting cancer cell proliferation. (AC) acetyl 
group. (Teodoridis et al. 2004).
Overexpression of a DNA methyltransferase (MGMT) has been correlated with the 
magnitude of cyclophosphamide resistance in human lung tumour xenografts (Mattem et 
a l 1998). MGMT is an 06-methyl guanine methyltransferase, a DNA repair enzyme that 
functions to remove a potentially mutagenic alky 1-group from the 06  position of guanine 
(Mattem et a l 1998). The breast cancer resistant protein gene (BCRP) is associated with 
epigenetic regulation which may be relevant to the development of drug resistance (Doyle 
and Ross 2003). BCRP is regulated by cytosine méthylation in drug resistant cells (Doyle 
and Ross 2003). FancF is important for activation of a DNA repair complex containing
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BRCAl and BRCA2, since a defect in this pathway results in inhibition of DNA damage 
repair and increased risk for cancer development (Olopade and Wei 2003). Méthylation of 
the FancF gene was observed in ovarian cancer cell lines and in acute myeloid leukaemia 
(Taniguchi et ah 2003; Tischkowitz et a l  2003).
However, otlier méthylation reactions, such as defects in méthylation in pro-apoptotic 
genes, can lead to drug resistance (Teodoridis et a l 2004). Different pro-apoptotic genes 
that are susceptible to méthylation include Apaf-1, caspase-8, Fas, TRAIL and others 
(Santouiiidis et a l 2001; Hopkins-Donaldson et a l 2003). The Apaf-1 gene was shown to 
be methylated in melanoma cells but tlie process may be reversed by administration of 
DNMT inhibitors leading to increased Apaf-1 transcription and increased apoptosis 
induction by doxorubicin, coiTelated with increased dmg sensitivity (Soengas et a l 2001). 
As mentioned earlier, Apaf-1 is a crucial protein in the intrinsic apoptotic pathway which 
binds to and promotes pro-caspase-9 activation in the presence of cytochrome c triggering 
downstream executioner caspase cascades. Metliylation of other apoptotic genes, for 
example, the gene encoding caspase-8, has been observed in tumours; however, using 
demethylating agents resulted in a reversal of gene méthylation and re-expression of the 
gene leading to increased apoptosis and chemosensitivity (Fulda et a l 2001).
7.1.1 DNA méthylation inhibitors
There are a number of demethylating agents that have been used for reversing méthylation 
via targeting DNA methyltransferases (DNMTs) to restore gene expression in cancer cells 
(Teodoridis et a l 2004). These agents are small molecule inhibitors including 5-aza-2- 
deoxycytidine (decitabine), 5-azacytidine, dihydro-5-azacytidine (DHAC) and procaine,
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hydralazine and zebulaiine. Moreover, it has been reported that demethylating agents are 
able to restore sensitivity to a broad range of chemotherapies such as cisplatin, epirubicin 
and temozolomide (Strathdee et al. 1999; Plumb et al. 2000). The commonly used small 
molecule inhibitor of the DNMTs is 5-aza-2-deoxycytidine which causes déméthylation 
and re-expression of silenced genes (Bender et al. 1998; Rush et al. 2004). Additionally, 
5-aza-2-deoxycytidine has been shown to induce apoptosis via DNMT inhibition (Dowell 
and Minna 2004; Oka et al. 2005; Schneider-Stock et al. 2005). A study using prostate 
cancer cells showed that following treatment with 5-aza-2-deoxycytidine, the cells 
exhibited increased sensitivity to apoptosis induction following cisplatin treatment (Fang 
et al. 2004).
7.1.2 Histone deacetylase Inhibitors
Histone deacetylase inhibitors can activate expression of many genes that have been 
suppressed such as those involved in apoptotic signalling and cell cycle control (Donadelli 
et al. 2003). HDAC inhibitors act to prevent removal of acetyl groups from histoires 
residues (Teodoridis et al. 2004). The commonly used HDAC inhibitors in cancer 
treatment are trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) (Smith 
and Workman 2009). HDAC inhibitors are effective in treatment of haematological 
malignancies in vivo, as well as for use in in vitro studies (Teodoridis et al. 2004).
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7.2 Aim
This chapter focuses on finding evidence of any epigenetic changes that may have 
occurred in the paclitaxel resistant breast cancer cells MCF-7TaxR. This aim has been 
facilitated by treatment with demethylating agents, including 5-aza-cytidine and 
zebulaiine, or with the HDAC inhibitor trichostatin A, in order to identify possible 
masked apoptotic genes, e.g. caspases- 7 and -9.
7.3 Methods
Quantitative PCR analysis was carried out for detection of different apoptotic genes 
following treatment with demethylating agents (DNMT inhibitors) and HDAC inhibitors 
of cultured cells over a number of in vitro passages. The qPCR method is described in 
Chapter 2.
7.4 Results
7.4.1 Detection of caspase-7 and -9 in breast cancer ceiis 
foiiowing treatment with epigenetic reversai agents using 
quantitative PCR analysis
We carried out qPCR analysis in order to identify changes in apoptotic regulator genes, 
such as caspase-7, -9, following treatment of drug sensitive and drug resistant breast 
cancer cells with a combination of demethylating agents and HDAC inhibitors. The breast 
cancer cells were MCF-7, MCF-7TaxR, MCF-7TaxRREV, and they were treated with 
DNMT and HDAC inhibitors (DHcocktail). The treatment groups were named MCF- 
7DHcocktail and MCF-7TaxRDHcocktail, respectively. Also, we tested the detection of
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the p i 6 (CDKN2A) gene as an internal control to verify the efficiency of the 
demethylating agents and HDAC inhibitors treatments. The pl6  gene, as previously 
published, is silenced in MCF-7 cells (Bachman et a l 2003; D'Amico et al. 2004) and we 
therefore looked for tliis transcript in our qPCR analysis to indicate the effectiveness of 
the cocktail in unmasking gene expression. The analysis was carried out on MCF-7, MCF- 
7DHcocktail, MCF-7TaxR, and MCF-7TaxRDHcocktail cells. Cells were treated with a 
combination of 100 pM zebulaiine, 2.5 pM 5-azacytidine and 150-300 j.iM TSA and 
incubated with the drugs for approximately 72 h. Cells were treated every other passage, 
and the number of treatments was four (MCF-7 cells) or five (MCF-7TaxR cells). The 
MCF-7 cells were more sensitive to the treatment, as indicated by an MTT assay used to 
check cellular sensitivity to these agents (data not shown). The MCF-7TaxR cells 
tolerated tire déméthylation treatments and histone deacetylase inhibitor very well (data 
not shown). In addition, we included in the qPCR analysis the MDA-MB-231, T47D and 
paclitaxel resistant T47DTaxR breast cancer cell lines to check the gene expression levels 
of caspase-7 and -9. The qPCR method was performed as a two step analysis, as described 
in Chapter 2, Materials and Methods, using a reaction mixture ImProm-JF*^ Reverse 
Transcription System fiom Promega®, (following the manufacturer’s instructions) and 
SYBR Green reagent obtained fiom Stratagene®. Primers were obtained from 
Super Array® and reconstituted to give a 10 pM working solution. Act values were 
determined as fold change in gene expression; thus, the difference calculated between 
experimental genes and the housekeeping gene p-actin was equal to 2^ "'^
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Primers used were human CDKN2A (pl6), caspase-7 and caspase-9 obtained from the 
SuperArray Bioscience Corporation. The primers were designed for amplification of the 
NM_00007.3 fragment of the CDKN2A (pl6) gene, the NM_001227.3 fragment of the 
caspase-7 gene, and the NM_001229.2 fragment of the caspase-9 gene.
(pJ6) human gene sequence primer 5 ’-3': Forward CAGAGGATTTGAGGGACAGG 
Reverse CTCCTCTTTCTTCCTCCGGT
Caspase-7 human gene sequence primer 5'-3'\ Forward CCGTGGGAACGTAAGAAGAA 
Reverse GTCTTGATGGATCGCATGG
Caspase-9 human gene sequence primer 5 ’-3’: Forward CCTGCTTAGAGGACAC AGGC 
Reverse TTCGACAACTTTGCTGCTGCTTG
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Figure 7-2: qPCR analysis of p l6  gene expression in MCF-7DHcocktaiI and MCF- 
7TaxRDHcocktail cell lines.
(a) Levels of p i 6 expression were increased in MCF-7DHcocktail and MCF- 
7TaxRDHcocktail cells. The MCF-7DHcocktail and MCF-7TaxRDHcocktail cell cultures 
were treated at every passage with 100 pM zebularine, 2,5 pM 5-azacytidine and 150-300 
pM TSA and incubated for 72 h. Data are the means of 3 independent experiments 
(performed in duplicate), error bars indicate ±SD. (b) Table showing the Act values of 
p l6  expression in cells.
As seen in Figure 7-2, the qPCR analysis of p l6  shows the effectiveness of déméthylation 
and HDAC inhibitor treatments, which reversed pI6  gene silencing (Bachman et al. 
2003). The p l6  gene (tumour suppressor gene) was shown to be weakly expressed in 
MCF-7 and MCF-7TaxR cells, as previously described in the literature (Bachman et al. 
2003; D'Amico et al. 2004). The expression of p i6 increased in MCF-7DHcocktail and 
MCF-7TaxRDHcocktail cells.
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MCF-7 0.00033 0.00024
MCF-7TaxR 0.0 0.0
MCF-7TaxRREV 0.0 0.0
MCF-7DHcocktail 0.00047 0.00028
MCF-7TaxRDHcocktail 0.0010 0.0
T47D 0.00064 0.00016
T47DTaxR 0.00041 0.00027
MDA-MB-231 0.00030 0.00041
Figure 7-3: qPCR analysis of caspase-7 and caspase-9 genes in breast cancer cells and 
cells treated with DNMT and HDAC inhibitors.
(a) Levels of caspase-7 expression were increased in MCF-7DHcocktail and MCF- 
7TaxRDHcocktail cells. The MCF-7DHcocktail and MCF-7TaxRDHcocktail cells were 
treated every passage with 100 pM zebularine, 2.5 pM 5-azacytidine and 150-300 pM 
TSA and incubated for 72 h. Data are the means of 5 independent experiments 
(performed in duplicate), error bars indicate ±SD. (b) Table showing the Act values of 
caspase-7 and caspase-9 expression in cell lines.
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Figure 7-3 shows the analysis of caspase-7 and -9 gene expression in breast cancer cell 
lines. MCF-7 cells showed moderate expression of caspase- 7 -9, as expected. The MCF- 
7TaxR cells showed no expression of these caspases, as expected, consistent with other 
data obtained in various sections of this thesis. Also, MCF-7TaxRREV, a cell line that had 
been grown in the absence of paclitaxel treatment for several passages, showed a total 
absence of caspases -  indicative of a stable resistance phenotype. However, treatment with 
the DNMT and HDAC inhibitors elicited an increase in caspase-7 expression in MCF- 
7DHcocktail and MCF-7TaxRDHcocktail cells compared to their parent MCF-7 and 
MCF-7TaxR cells, respectively. The Act value for caspase-7 was particularly increased 
in MCF-7TaxRDHcocktail cells, compared to MCF-7DHcocktail cells, and to parent 
MCF-7 and MCF-7TaxR cells. These data are evidence for there being epigenetic 
modifications to the caspase-7 gene in the MCF-7TaxR line. However caspase-9 
expression remained undetectable in MCF-7TaxRDHcocktail cells. Caspase-7, -9 was 
detectable in T47D, T47DTaxR and MDA-MB-231 breast cancer cells, as expected, and 
consistent witli our previous findings (Western blotting data, Chapter 4).
7.5 Discussion
Epigenetic defects are frequently associated with the molecular pathology of cancer and 
its development, DNA hypermethylation being one of major changes that correlates with 
the severity and progression of disease (Feinberg and Tycko 2004). A small number of 
published studies have demonstrated that the development of a cancer-dmg resistance 
phenotype may also be associated with DNA méthylation (Nyce 1989).
In this study, we examined tlie possibility of epigenetic alterations in MCF-7 and
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paclitaxel resistant MCF-7TaxR cells by treatment with different demethylating agents 
and HDAC inhibitors, allowing for possible reversal of epigenetic alterations. Moreover, 
according to our findings, MCF-7 cells contain a moderate number of apoptotic gene 
defects, e.g. caspase-3 and FAS receptor deficiencies (Janicke et al. 1998; Yang et a l 
2001), whereas MCF-7TaxR cells are highly modified with regard to apoptosis (some 
caspases and some Bcl-2 family proteins being deleted). Therefore, we considered that 
potential hypermethylation of apoptotic genes might explain the reduction in caspase-7 
and caspase-9 proteins and that their expression might be upregulated by the 
administration of DNMT/HDAC inhibitors. We first tested the validation of the 
DNMT/HDAC treatment method in our study by testing the expression of p l6  (as an 
internal control, since this is known to be silenced in MCF-7 cells) following treatment 
with DNMT and HDAC inhibitors (Attri et a l  2005). The p l6  gene (CDKN2A) is a 
tumour suppressor gene and had been shown to be methylated in a wide range of 
malignancies (Bachman et a l 2003; Attri et a l 2005). The p i 6 qPCR test was successfiil, 
since p i 6 expression levels were shown to increase in MCF-7DHcocktail treated cells, 
and more so for MCF-7TaxRDHcocktail cells, consistent with earlier studies. This result 
confirmed that our protocol for reversing epigenetic gene silencing was effective.
Our successful qPCR analysis revealed a switch-on of caspase-7 expression in MCF- 
7TaxRDHcocktail cells compared to MCF-7TaxR cells. Also, in MCF-7DHcocktail cells, 
caspase-7 was increased compared to the MCF-7 parent cells. The level of caspase-7 was 
higher in MCF-7TaxRDHcocktail cells compared to MCF-7DHcocktail cells. In support 
of our findings, one study on MCF-7 cells that developed resistance to doxorubicin and 
cisplatin showed that DNA hypermethylation is associated with acquired resistance
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(Chekhun et al. 2007). The MCF-7 cells treated with doxorubicin developed resistance 
and the MDR phenotype; both MCF-7 cells resistant to doxorubicin and cisplatin showed 
hypermethylation of the Bad gene, which possibly confers resistance to apoptosis 
(Chekhun et al. 2007). Thus, our results indicate that MCF-7TaxR cells may be subjected 
to genetic hypermethylation (as a consequence of resistance acquisition) and that the 
DNMT/HDAC inhibitor protocol is able to reverse this méthylation, thereby increasing 
caspase-7 expression, hi addition, we have also run a Western blotting analysis to detect 
caspase-7 protein (data not shown). This analysis revealed that caspase-7 protein 
expression remained at an undetectable level in MCF-7TaxRDHcocktaill cells. However, 
the déméthylation protocol we used does not consistently lead to gene re-expression -  as 
we saw for the expression levels of caspase-9. Caspase-9 expression was not induced by 
DNMT/HDAC inhibitors in MCF-7DHcocktail or MCF-7TaxRDHcocktail cells and the 
reasons for this could be inefficiency of the drug cocktail -  or gene deletion. These data 
indicate that the DNA méthylation process can play an important role in cancer cell 
development and progression, but this may not be the entire reason for the marked down 
regulation of caspase genes in our cell line models. The technique of pyro-sequencing may 
be useful for future investigation of the apoptotic changes for MCF-7TaxR cell line. 
Moreover, our previous cytotoxicity assay on the MCF-7DHcocktail and MCF- 
7TaxRDHcocktail cells, testing their sensitivity to cisplatin (data not shown), showed that 
their sensitivities (ICsos) towards cisplatin were not changed compared to the respective 
parent cells. It is well established that hypermethylation is strongly associated with cancer 
resistance, suggesting that méthylation is critical in maintaining cancer cell growth 
(Segura-Pacheco et al. 2006). A study on a doxorubicin resistant MCF-7 cell line revealed 
that cells require DNA hypermethylation to generate the MDR phenotype leading to
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apoptosis resistance (Segura-Pacheco et al. 2006). In MCF-7 cells resistant to 
doxorubicin, treatment witli hydralazine (a demethylating agent) reversed tlie drug 
resistance (Segura-Pacheco etal. 2006).
MCF-7TaxR and MCF-7TaxRREV cells were shown to be devoid of caspase-7 and -9 as a 
consequence of paclitaxel resistance, as first indicated in our microarray analysis. Screening 
for caspase expression levels in other breast cancer cells that showed T47D, T47DTaxR and 
MDA-MB-231 cells showed detectable constitutive expression of caspase-7 and -9 genes, 
consistent with the Western blotting data (Chapter 4). These data are consistent with 
previous published findings showing that T47D and MDA-MB-231 cells showed activation 
of caspase-9 following treatment with the isothiocyanate compound sulforaphane (Pledgie- 
Tracy etal. 2007).
In conclusion, the data provided in the present chapter indicate tliat some epigenetic 
modifications are present in the MCF-7TaxR cell line but that otlier mechanisms of gene 
modification such as gene deletion may be implied, based on findings from other aspects 
of the work described throughout this thesis.
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8  Overall Conclusions and Future Work
According to the literature, there is more than one type of cell death that may be activated 
under specific conditions - particularly when the caspase-dependent apoptotic pathway is 
inactivated (Mathiasen and Jaattela 2002; Moretti et al. 2007). Defective apoptosis can 
occur following exposure to chemotherapeutic agents during development of the multiple 
dnig resistance (MDR) phenomena in tumours, leading to tumour cancer progression and 
proliferation (Jaattela 1999; Evan and Vousden 2001; Gottesman 2002).
Apoptosis and autophagy are both forms of programmed cell death (PCD I and II, 
respectively) and are potential mechanisms for the elimination of cancer cells in response 
to radiation or chemotherapy (Motyl et al. 2006). The apoptotic process is rapid and 
controlled by series of caspase cascades, Bcl-2 proteins, and other regulators (Lockshin et 
al. 2000; Cuervo 2004; Meijer and Codogno 2004). The autophagic mechanism is an 
ancient and conserwed process considered to be a catabolic mechanism for protein 
degradation (Lockshin et al. 2000; Cuer-vo 2004; Meijer and Codogno 2004). More 
importantly, autophagy functions in the elimination of cancer cells by triggering non- 
apoptotic cell death (PCD II) (Lockshin et al. 2000; Cuervo 2004; Meijer and Codogno
2004). The link between apoptosis and autophagy as part of the response to 
chemotherapeutic agents may depend on several factors such as mechanism of action of 
the dmg and the presence (or absence) and function of regulators mvolved in apoptotic 
mechanisms (Motyl et al. 2006). For example, it was observed in a study on MCF-7 cells 
treated with camptothecin (an inhibitor of DNA topoisomerase I) that both apoptosis and 
autophagy were induced (Lamparska-Przybysz et al. 2005). Apoptosis was induced in a
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subpopulation of cells that were set to initiate type I PCD. (Lamparska-Przybysz et al.
2005). Autophagy may be triggered in cells showing resistance to apoptotic cell death 
(Lamparska-Przybysz et al. 2005). These data agree with our finding that, in MCF-7 cells 
that showed a partial induction of apoptosis, a number of cells undergo autophagic cell 
death. Therefore, an autophagic response is a potential mechanism for cancer cells 
resistant to apoptosis to employ an alternative cell death process under conditions of 
persistent stress (Motyl et al. 2006). Thus, autophagic cell death is used by resistant cells 
incapable of undergoing apoptosis due to gene mutations and is an alternative to apoptotic 
cell death (Motyl et a l 2006). This hypotiiesis is consistent with our findings on the MCF- 
7TaxR paclitaxel resistant variant of MCF-7 cells which are sensitive to PCD II 
autophagic cell death due to apoptosis gene defects. In the present study, we showed that 
MCF-7 cells undergo both apoptosis and autophagic cell deatii whereas paclitaxel resistant 
MCF-7TaxR cells appeal' to exclusively commit to autophagic cell death under conditions 
involving chemotherapeutic drug induced stress.
The different apoptosis analysis methods cairied out in the present study have provided 
evidence that MCF-7 cells undergo moderate levels of apoptotic cell death via the intrinsic 
pathway, using caspase-7 as the executioner caspase instead of caspase-3. Previous studies 
demonstrated that caspase-7 and caspase-3 are almost identical in their substrate 
specificity, thus caspase-7 may compensate for a lack of caspase-3 function (Femandes- 
Alnemri et al. 1995). Our cell line characterisation studies indicated that caspase-7, 
caspase-9 and Apaf-1 were present in MCF-7 cells (apoptosis airay, western blotting and 
qPCR data). We confirmed that the extrinsic pathway is not functioning in MCF-7 cells, 
consistent with previous studies. Even though caspase-8 is available, it is unable to
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interact with tlie Fas receptor (Annexin V-FITC/PI and apoptosis array data) for inducing 
signalling leading to extrinsic pathway activation. Our data are consistent with those of 
Gorka et a\, (2005) who reported that, in MCF-7 cells treated with different analogues of 
paclitaxel, induction of autophagic cell death with a subpopulation of cells committing to 
intrinsic apoptotic cell death via the mitochondrial route was seen (Gorka et al. 2005).
On the other hand, our obsei'vations provided clear evidence of apoptosis resistance 
(Annexin V-FITC/PI data) in MCF-7TaxR cells in spite of their lack of cross-resistance to 
many cancer drugs apait from paclitaxel. Our Apoptotic Gene Microanay work revealed 
major and significant changes in apoptosis genes in MCF-7TaxR cells. A large number of 
apoptosis genes (caspase-3, -4, -5, -6, -7, -9, -10 and Apaf-1, Bid, Fas, TNF, FADD, 
TRADD) were shown to be absent from MCF-7TaxR cells during the development of 
paclitaxel resistance which would significantly confribute to apoptosis resistance in these 
cells. This result highlights the utility of microarray analysis as a potential tool for disease 
diagnosis and classification (Stears et al. 2003). Our Western blotting and qPCR data 
confirmed the absence of expression of caspase-7 and caspase-9 in MCF-7TaxR cells but 
not in MCF-7 parental cells. In addition, it has been reported that cells that possess a 
defect in the caspase-7 gene are more resistant to apoptotic cell death-inducing drugs with 
a delay in apoptotic cell death induction (Korfali et al. 2004). Another study showed that 
absence of expression or activity of Apaf-1 impaired tlie interaction of the apoptosome 
components (Apaf-1, pro-caspase-9, and cytochrome c) leading to inactivation of the 
intrinsic pathway, as obseiwed in many cancers including melanoma, leukaemia, 
glioblastoma, and gastric cancer (Pommier et al. 2004). This may be caused by promoter 
hypermethylation or chromosome deletion (Pommier et al. 2004).The lack of apoptotic
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genes in MCF-7TaxR is possibly only partially due to epigenetic silencing, as obtained via 
indirect evidence. The major mechanism underlying the absence of multiple apoptosis 
genes would appeal' to be via deletion.
In this present study, we demonstrated that the development of paclitaxel resistance is a 
multifactorial process. The characterisation of the MCF-7TaxR model was confirmed with 
our Western blotting data, which revealed overexpression of P-gp and the concomitant 
extraordinary alterations in the expression of apoptotic proteins, preventing apoptotic 
function which explains the apoptosis resistance developed in this cell line. Previous 
studies on paclitaxel in cancer cells have indicated that it may confer multifactorial 
resistance mechanisms which are still not fully understood (Hari et a l 2006). Mechanisms 
involved in paclitaxel resistance include overexpression of the P-gp transporter, mutations 
in tirbulin genes and alterations in expression of microtubule-associated proteins or 
apoptosis pr'oteins (Hari et al. 2006). In this part of the study wherein MCF-7TaxR 
developed resistance to paclitaxel, an approximately 18-fold increase in resistance 
resulting from the major genetic changes under discussion became apparent. By passage 
18, MCF-7TaxR cells had acquired genetic alterations producing resistance to apoptotic 
cell death and overexpression of P-gp/MDRl transporter. The beta III tubulin protein is 
not upregulated in our MCF-7TaxR cell line (data not shown. Dr. Helen Coley personal 
communication), but it is a commonly associated, albeit not universal, feature of paclitaxel 
resistance. Defects in apoptotic cell death mechanisms include alterations in the ratio of 
expression of pro-and anti-apoptotic proteins of the Bcl-2 family and this may also be 
associated with acquired paclitaxel resistance (Kutuk and Letai 2008). Our investigation 
of the expression of different anti-and pro-apoptotic proteins revealed a gradual loss in
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expression seen in MCF-7TaxR cells whilst developing paclitaxel resistance. The pro- 
apoptotic Bax, Bad and P-Bad proteins showed to be expressed in MCF-7TaxR cells at 
passages 18, 23 and 53. However, tlie BH-3 only domain factor Bimc was decreased in 
expression at passage 18 in MCF-7TaxR cells when tlie resistance to paclitaxel was 
becoming established. Subsequently, loss of BIibl expression was detected in MCF- 
7TaxR cells at passage 23. Bim is involved in mediating apoptosis induced by paclitaxel 
(Bouillet et al. 1999; Sunters et al. 2003). In addition, it was demonstrated in in vivo 
studies that apoptotic induction in paclitaxel treated cells is essentially dependent on the 
action of Bim (Tan et al. 2005), consistent with our findings showing deficient levels of 
Bim in our paclitaxel resistant MCF-7TaxR cells. It would be interesting to look at siRNA 
against Bim in MCF-7 parental cells and see how this modulates sensitivity to paclitaxel, 
in the light of our findings.
Our study using méthylation reversal agents on breast cancer cell lines provided indirect 
evidence for caspase-7 gene méthylation in MCF-7TaxR cells, based on modest 
unmasking of this genotype following several treatments with demethylating and HDAC 
inhibiting agents. Our various autophagy detection analyses have confirmed the induction 
of autophagic cell death in MCF-7TaxR cells at a higher level than MCF-7 cells. 
Autophagic cell death (PCD II) appears to be a major death system operative in MCF- 
7TaxR cells according to our data. In the present work, detection of autophagy associated 
protein expression, showed strong positive expression of LC-3II and Beclin 1 in MCF- 
7TaxR cells following staurosporine treatment. Different anticancer agents tliat induce 
autophagic cell death include tumour necrosis factor (TNF), staurosporine, and tamoxifen 
(Janicke et al. 1998; Scarlatti et al. 2004); in the present study we used staurosporine.
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Furüier, confocal microscopy for the localization of LC-3 activity provided evidence for 
autophagic cell death in response to staurosporine treatment in MCF-7TaxR and lesser so 
in MCF-7 cells. The inhibition caused by bafilomycin, a well Imown inhibitor of 
autophagy (Paglin et al. 2001), was used in this present work in conjunction with acridine 
orange staining. The results revealed a significant difference in autophagy inhibition in 
MCF-7TaxR and MCF-7 cells compared to MDA-MB-231 cells. MCF-7TaxR cells were 
sensitive to different inhibitors of PI3K (3-MA and LY294002) (Blommaart et al. 1997; 
Petiot et al. 2000; Aki et al. 2003). Moreover, investigations of the Akt/mTOR pathway, 
one of the main pathways involved in regulatmg autophagic cell death, were performed 
(Huang and Hung 2009). Western blotting analysis for Akt, inTOR and S6K expression 
showed an inhibition in expression in MCF-7TaxR cells following staurosporine or 
rapamycin treatment. Hence the inhibitory effects of these drugs contributed to the 
promotion of autophagic cell death in MCF-7TaxR cells (Figure 1-8).
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Figure 8-1: Summary of the cell death mechanisms induced in MCF-7 and MCF- 
7TaxR cells in response to chemotherapeutic drug treatment.
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Future work that could be cairied out on MCF-7 cells, such as knockdown experiments 
using siRNA silencing of the caspase-9 gene, would be interesting to provide an 
understanding of the mechanisms of cell death that might be used by MCF-7 cells. The 
mechanism of resistance requires further exploration to determine any mutations possible 
in the paclitaxel binding region of (3-tubulin. Since overexpression of tubulin has been 
shown to correlate with paclitaxel resistance (Kavallaris et a l 1997; He et a l 2001), it 
may be worthwhile to see if this influences the apoptotic pathway in any way. In addition, 
important further work can be performed on MCF-7TaxR cells using siRNA silencing of 
autophagic genes such as Beclin 1 and LC-3, in order to investigate different mechanisms 
of cell death in MCF-7TaxR cells when apoptosis and autophagic cell death are not 
functioning. Other possible experiments that might be carried out in MCF-7TaxR cells 
could involve more in depth use of PI3K inhibitors for treating cells and analysis of the 
expression of Akt and mTOR by Western blotting, hi addition, more in depth electron 
microscopy analysis should be cairied out on MCF-7TaxR cells for the detection of the 
autophagosomes and other morphological changes.
Our findings provided a significant insight into possible molecular pathways and effective 
biomarkers relevant to clinical responses to anticancer agents in breast cancer patients. 
Moreover, the MCF-7TaxR cells have been shown to be a good positive model for 
autophagic cell death, being more efficient in this process than MCF-7 cells. We have 
identified gene changes associated with resistance to paclitaxel in MCF-7 breast cancer 
cells. The present study, along with other previous studies, raises the possibility of using 
méthylation profiling to identify patients who may benefit from established treatments or 
for whom alternative therapies may be more appropriate, e.g. novel agents that target
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epigenetic mechanisms (Teodoridis et ah 2004). These advances may help to identify 
highly effective biomarkers for chemo-response in breast cancer patients and, indeed, for 
otlier types of tumours. Identification of altered apoptotic genes is useful in predicting the 
response to the chemotherapy agent paclitaxel in tumours of breast cancer patients. 
However, an analysis of autophagic cell deatli processes is equally important and, hence, 
apoptotic cell deaüi should not be considered in isolation, hi addition, caspase-dependent 
and non-caspase dependent pathways and genes play a major role in clinical dmg 
resistance and their changes in expression or activity may prove useful in determining 
patient prognosis post-treatment.
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